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Summary 
The stroma, which embeds epithelial cells, plays a major role in the shaping and 
physiological regulation of animal organs such as the breast. Aberrant functioning 
of the stroma was found to support tumorigenesis and cancer progression. 
Among many crucial aspects of breast cancer biology two issues focused our 
attention; (I) the impact of mutual interactions between the cancer cells and the 
stroma, specifically the endothelial cells and (II) the impact of insulin like growth 
factor one (IGF-I) on the gene expression profiles of stromal fibroblasts, as an 
example of the influence of a growth factor on the stroma. 
To address tumor-endothelial interaction we took advantage of an in vitro system 
mimicking the interaction of tumor and endothelial cells and explored gene 
expression changes using DNA microarrays. Our results suggest the interaction 
of endothelial cells and tumor cells that express the CD44+/CD24- signature 
indicative of stem cell-like cells, which are thought to have a low proliferative 
potential, might explain the unexpected and paradoxical association of the 
CD44+/CD24- signature with highly proliferative tumors that have an unfavorable 
prognosis. Furthermore, the gene expression signature induced in this system is 
of prognostic value in early stage and metastatic breast cancer.  
Since malignant epithelial cells and tumor-associated stromal cells are under the 
influence of hormones and growth factors, we examined the effects of IGF-I on 
cancer cells and primary fibroblasts in parallel to assess concordant and 
discordant gene expression changes. Our results show that primary breast 
fibroblasts, breast carcinoma associated fibroblasts and primary lung fibroblasts 
respond to IGF-I stimulation with increased expression of genes related with 
proliferation, which is phenotypically followed by an increased growth rate. 
Comparing in vitro gene expression data with available in vivo data, we have 
shown that the evoked gene expression signatures are able to stratify patients 
into groups with significantly different outcome. We propose that this prognostic 
gene expression signature might also serve as a predictor for the effectiveness of 
an anti-IGF-I therapy, a new therapeutic strategy that is currently in phase III 
development.  
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 Concluding, the data presented in this thesis underline the importance of the 
stroma, specifically the interaction between tumor and endothelial cells and the 
response of the stroma to stimulation with growth factors such as IGF-I. The 
gene expression changes in response to these interactions and stimulations 
carry prognostic information and might potentially be useful in clinical decision-
making.  
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 Introduction 
Cancer epidemiology 
Cancer is one of the major causes of death worldwide. The disease accounted 
for 7.9 million deaths (around 13% of all deaths) in 2007. This number is 
projected to continue rising, with an estimated 12 million deaths in 2030. Lung, 
stomach, colorectal, liver, and breast cancer cause most of cancer deaths each 
year [1]. Breast carcinoma, the most frequent type of cancer among women, was 
estimated to be responsible for 40,170 deaths in the United States in 2009 [2]. 
The high social impact of the disease implicates the need for more efficient 
treatments. In order to develop proficient treatments for the different forms of the 
disease, it is crucial to understand the biology of breast cancer, including role of 
stromal cells and tumor-stroma interactions in tumorigenesis and breast cancer 
progression. 
Cell types and microenvironmental factors affecting breast 
cancer development and progression 
Breast cancer is biologically and clinically a heterogeneous and multistage 
disease. It is mainly a malignancy of the mammary ductal or lobular epithelial 
cells (carcinomas), but can, rarely, affect the stromal tissue of the breast 
(sarcomas). At the initial stage hyperproliferative epithelial cells are contained 
entirely in situ, within the duct (ductal carcinoma in situ - DCIS) or lobule (lobular 
carcinoma in situ). Early breast DCIS lesions either do not evolve [3-4], or 
progress into invasive ductal carcinomas (IDC), when hyperproliferative cells 
break through the basement membrane surrounding the duct and invade into the 
stromal tissue of the breast. The process is schematically shown in figure 1. 
 
 
Figure 1. Schematic illustration of changes accompanying progression from healthy mammary 
duct to hyperplastic changes to ductal carcinoma in situ (DCIS) to invasive ductal carcinomas 
(IDC) (from the left to the right). 
Normal          Hyperplastic      DCIS      IDC 
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This stage is followed by multiple events including tumor vascularization and 
transition of epithelial cells into a mesenchymal state [5]. Vascularization 
facilitates tumor growth [6], and the epithelial to mesenchymal transition (EMT) 
allows cancer cells to spread. EMT is reversible and at the place of metastasis 
the cells shift back to the epithelial state and form tumors with the full 
characteristics of a primary tumor. As the changes (transition) are reversible they 
cannot be explained by genetic alterations, which suggests that there must be 
other regulatory components present, among them the tumor microenvironment 
[7]. In breast cancer, the population of malignant cells is heterogeneous as it 
consists of different cell clones and cell types (cancer stem cells and 
differentiated cancer cells) [8]. Moreover, the tumor bulk is comprised of cells of 
multiple origins, including fibroblasts, endothelial, myoepithelial, various immune 
cells and the extracellular matrix (ECM) [9]. All of the components intermingle 
and interact with many signaling loops implicated either through soluble factors 
[10-11] or involving direct interactions [12]. Additionally, the tumor is located 
inside the living organism and it is under constant, systemic influence of 
hormones, growth factors that actively modify the tumor microenvironment [13-
16]. The general idea is shown in figure 2. 
 
Figure 2. Schematic image illustrating the complexity of the breast cancer tumor bulk. Two 
populations of cancer cells (1) differentiated ancestors and (2) cancer stem cells are marked. 
Different cells building the tumor stroma like; (3) fibroblasts, (4) immune system cells e.g. 
macrophages (6) endothelial cells and (5) components of extra cellular matrix are visualized. 
Green arrows symbolize the systemic influence of hormones and growth factors acting on the 
cancer cells and on the carcinoma associated stroma. 
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 Different populations of cancer cells within tumor 
With the success of molecular in vitro studies, cancer research was focusing 
predominantly on the epithelial cells. Tumors have been understood as a 
homogenous population of highly proliferative malignant cells. Currently it is 
known that the malignant epithelial cell fraction contains a subset of cells with 
stem cell properties and their differentiated progenies.  
There are many reasons of malignant transformation and many cells are 
regarded to be cancer cell’s ancestors. Particular attention is given to somatic 
stem cells, as they are long living and therefore hypothesized to be able to 
accumulate multiple mutations since they are exposed to damaging agents or an 
unfavorable environment for a long time. The transition of a somatic stem cell into 
a cancer stem cell (CSC) is plausible because of the propensity of self-renewal 
and multiple divisions that might be the cause of fixation and propagation of 
alterations in their genome [17]. It was recently shown that tumor protein 53 
(p53), a well known tumor suppressor gene, regulates the polarity of cell division 
in mammary stem cells and that the loss of p53 favors symmetric divisions of 
stem cells, contributing to an increased amount of stem cells [18]. An increased 
number of symmetrically dividing stem cells increases the amount of target cells 
for transformation. After the transformation, cells with mutated p53 continue to 
divide symmetrically, increasing the amount of cancer stem cells within the 
tumor. The idea is schematically illustrated in figure 3. The concept of cancer 
stem cells, first proven in acute myeloid leukemia [19], is nowadays widely 
confirmed for numerous types of cancer including breast cancer [8, 20-22]. It is 
hypothesized that the cancer stem cell fraction is likely to be responsible for the 
resistance to chemotherapy [23] e.g. colon cancer stem cells were proven to 
produce and utilize IL-4 to protect themselves from apoptosis [24]. There are 
many markers that are suspected to define cancer stem cell including different 
combinations of CD24, CD29, epithelial specific antigen (ESA), CD44, CD49f, 
CD133, stem cell antigen one (Sca1), (reviewed in [25]) but the unambiguous 
marker constellations, characterizing a cancer stem cell, is unknown. Since the 
9
 markers are not yet precisely described detailed characterization of CSC, leading 
to effective targeting is still missing. 
 
Figure 3. Schema illustrating the impact of p53 mutation on the amount of mammary stem cells. 
Part A depicts physiological situation with symmetric division of the mammary stem cell (blue) into 
2 daughter cells: the renewed stem cell (blue) and its differentiated progeny (green). Part B 
depicts symmetric divisions of mammary stem cells with a lost of p53 (red). Increased amount of 
mammary stem cells increases the amount of target cells for transformation and later facilitates 
the amount of cancer stem cells within the tumor. 
Microenvironment affects tumorigenesis and cancer progression 
It has been shown in animal xenograft models that injection of purified malignant 
epithelial cells results in formation of histologically-complex tumors, with as many 
as 80% of the cells being stromal cells [26]. From developmental biology it is 
known that diverse types of cells building the mammary gland collaborate closely 
in its development, and the types of cells involved are highly conserved. All of 
them cooperate to establish the whole mammary gland and the mammary stem 
cell niche [27]. Similarly, during the neoplastic process, all cell types intermingle 
and interact. The cells building the tumor stroma are distinct from their normal 
counterparts [28], they have modified characteristics leading to active formation 
of the tumor microenvironment [29-32]. The fact that the microenvironment 
affects the efficiency of tumor formation, growth, invasiveness and metastatic 
potential was shown in many examples. A typical example of the 
A 
B 
p53 lost 
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 microenvironment leading to cancer is chronic inflammation, caused by 
Helicobacter pylori infection in stomach and leading to stomach cancer and 
hepatitis C infection of the liver, leading to chronic inflammation, proceeding to 
liver cirrhosis and, not infrequently, liver cancer [33]. In other experiments, 
injection of non-transformed mammary epithelial cells into irradiated mammary 
stromal fat pads resulted in increased tumor growth when compared to those 
injected into contralateral, non irradiated mammary fat pads [34]. The authors 
concluded that irradiated stromal cells alter the microenvironment and may lead 
to tumor promotion as illustrated in experiments with irradiated stroma. Moreover, 
malignant cells can exist within normal tissues but be restrained by normal milieu 
cues, what was concluded from experiments showing that similar patterns of 
mutations are found in both, normal epithelial tissue adjacent to tumor tissue and 
tumor tissue itself [35-36]. The authors concluded that, the mutation that initiates 
the carcinoma occurs in the epithelium, but events that promote tumor 
progression involve the stroma. In some cases, the trigger for neoplastic 
progression is speculated to come from signals within the stromal 
microenvironment [29]. In humans, early breast lesions are often present, 
however only a limited quantity of them progress towards malignancy. In the late 
eighties, Nielsen et al. analyzed 110 breast tissue autopsy samples and found 
that 32% of the patients displayed hyperplastic lesions, 27% had atypical ductal 
hyperplasia and 18% were DCIS positive [4]. Similar data were presented by 
Alpers et al. [3]. The high numbers of lesions not progressing into invasive 
carcinomas suggests that other mechanisms leading to malignancy must be 
involved including a “tumor prone” microenvironment as shown by Hu et al. [37]. 
Animal tumor models have shown that fibroblasts over expressing hepatocyte 
growth factor (HGF) or transforming growth factor beta (TGF-) are able to 
induce formation of tumors at diverse sites including stomach and prostate [38-
39]. Additionally, cancer-associated stromal cells are different from their 
corresponding normal analogues in terms of gene expression patterns already at 
a preinvasive (DCIS) tumor stage [28]. Summarizing, the described data suggest 
that microenvironment and stromal cells comprising for it are crucial not only in 
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 tumor invasion and metastasis, but also in the earlier steps of breast 
tumorigenesis. 
Fibroblasts in tumor progression 
One of the main pieces of evidence for the role of fibroblasts in tumor 
progression comes from mouse xenograft models. Co-injection of tumor cells 
with stromal cells (fibroblasts) induces a faster manifestation of bigger tumors 
[40-41]. It has been hypothesized that the delay in single-cell type xenografts is 
due to the time required for the cancer cells to recruit supportive cells to the 
tumor (e.g. from the bone marrow [42]), to form the complex structure and create 
signaling networks [43]. The instigating role of the stroma was extensively 
investigated and many factors taking part in the cross-talk between tumor and 
stroma cells were characterized. Fibroblast secreted protein-1 (FSP1; mts1) is a 
protein secreted by both fibroblasts and cancer cells making the environment 
more favorable for tumor progression as it regulates angiogenesis and 
inflammation and is responsible for metastatic cancer progression [44]. 
Moreover, tumors forming after co-injection of carcinoma cells with Fsp1-/- 
fibroblasts into Fsp1 -/- animals had significantly decreased numbers of 
infiltrating macrophages, smooth muscle actin-expressing myofibroblasts, and 
CD31-positive endothelial cells, compared to tumors developing after coinjection 
of tumor cells with Fsp1+/+ fibroblasts on the same mouse background [44]. Lack 
of CAFs expressing FSP1 in this system resulted in lower percentage of tumor 
formation and those formed did not metastasize at all. Other studies prove that 
CXCL12 (SDF-1, stromal cell-derived factor 1), expressed by fibroblasts, 
stimulates cancer cell proliferation by acting through C-X-C chemokine receptor 
type 4 (CXCR4) [11]. CXCL12 was proposed to stimulate metastasis to lung and 
lymph nodes through high expression of CXCL12 at these organs, resulting with 
homing of CXCR4 positive cancer cells to these organs. Additionally, CXCL12 
was shown to have an impact on angiogenesis as it is involved in recruitment of 
endothelial cell progenitors to the growing tumor [11]. Since CXCL12 is strongly 
chemotactic for lymphocytes [45] and all of the aforementioned data come from 
immuno-compromised mice, it was not possible to assess the effects of CXCL12 
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 mediated interactions between CAFs, leukocytes and tumor cells. Another 
molecule illustrating the role of the stroma in tumorgenesis and progression is 
type I collagen. Its increased amount is responsible for a high mammographic 
breast density, which correlates with an increased risk of sporadic breast cancer 
[46]. Carcinoma associated fibroblasts (CAF) are the cells responsible for the 
change of extracellular matrix composition to one with increased amounts of 
collagens (desmoplastic response) [26]. Therefore, fibroblasts producing 
increased collagen levels might be involved in sporadic breast cancer incidence 
[29]. Stromal fibroblasts also have an impact on tumor stroma composition by 
expression of different metalloproteinases, namely metalloproteinase 13 (MMP-
13), which is expressed by CAF-like cells in human breast cancer [47]. In vivo, 
breast cancer cells can stimulate fibroblasts to secrete MMP-13 [48]. MMP-13 
acts on the proteins building the ECM and modulates signaling pathways from 
the ECM and modulates the bioavailability of growth factors. Metalloproteinases 
are important in EMT transition and increased invasiveness of the breast cancer 
[49-50] as they help to break the basement membrane and release cancer cells, 
which is one of the most reliable signs of poor prognosis in most carcinoma 
systems.  
Concluding, fibroblasts, in particular the CAFs, actively support tumor cells and 
modify the tumor environment to make it more advantageous for tumor 
progression. 
Endothelial cells in tumor progression 
Endothelial cells, together with pericytes, form the tumor neovasculature, which 
supplies tumor cells with nutrients and oxygen, and removes waste and carbon 
dioxide. Primary tumors without vasculature are typically small, dormant nodules 
of tissue whose volume remains constant by a balance of cell proliferation and 
cell death [51]. Further growth of the tumor mass induces hypoxic conditions in 
the center of tumor bulk that induces expression of vascular endothelial growth 
factor-A (VEGF-A) and subsequently tumor vascularization [52]. Enhanced 
angiogenesis is associated with an increased risk of metastasis and poor 
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 prognosis [53]. Although highly important, vascularization is not the only role of 
endothelial cells, as they also serve as an important source of cancer growth 
regulation (e.g. for liver cancer cells in vitro [54]). Endothelial cells are also 
involved in the establishment of the cancer stem cell niche and metastatic spread 
of tumor cells into distant organs [55]. Tumor cell interaction with the endothelium 
during hematogenous dissemination, and the following interaction with 
endothelium and subendothelial matrix constitute the most crucial factors in 
determining the organ preference of metastasis. Cell surface adhesion molecules 
(i.e., integrins, cadherins, immunoglobulins and selectins) and many other 
unspecified molecules, mediate tumor-host endothelium interactions [31]. 
Selection of a place of metastasis is not the only process involving the 
attachment of tumor cells to the endothelium. The attachment as well provides 
the necessary anchorage that prevents anoikis and facilitates cancer cell 
proliferation [30]. Targeting tumor angiogenesis was shown to be an effective 
therapeutic option [52]. Nonetheless, both in preclinical and clinical settings, the 
benefits are of short duration and are followed by a restoration of tumor growth 
and progression, even with increased aggressiveness [56]. Pre-existing or 
acquired resistance to anti-angiogenic therapy might be mediated by factors that 
act through local paracrine loops between tumor cells and endothelial stromal 
cells in manner similar to CAFs that secrete platelet-derived growth factor C 
(PDGF-C), which in turn stimulates tumor angiogenesis [57] in answer to hypoxia 
induced by anti-VEGF therapy. 
Other stromal cells in tumor progression 
In addition to fibroblasts and endothelial cells, tumor stroma involves numerous 
cell types including immune cells, bone marrow derived cells and several factors 
constituting ECM.  
The host defense system comprises numerous types of cells and factors that, in 
the context of tumor biology, should concomitantly work to eradicate a tumor. 
Often the system is deformed, resulting in a benefit for the tumor i.e. as shown 
for inflammatory cells promoting tumor angiogenesis. Monocytes (at the tumor 
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site macrophages), lymphocytes and neutrophils are recruited to tumor stroma, 
where they release the variety of factors that alter cellular behavior. Classical 
examples are VEGF, HGF, metalloproteinase 2 (MMP-2) and interleukin 8 (IL-8) 
released by macrophages and neutorophils that affect endothelial cells 
contributing to tumor progression [32].  
Using in vivo experiments Karnoub et al. [10] demonstrated that mixing bone-
marrow-derived human mesenchymal stem cells (hMSCs) with weakly metastatic 
breast cancer cells and injecting them subcutaneously in the mouse resulted in 
tumors with an increased metastatic potential when compared to breast cancer 
cells injected alone. The presence of cancer cells stimulated bone-marrow-
derived hMSCs to secrete chemokine (C-C motif) ligand 5 (CCL5, RANTES), 
which acted back on cancer cells in a paracrine manner [10]. In other studies 
adult human mesenchymal stem cells enhanced breast tumorigenesis and 
promoted hormone independence. Co-injection of MCF-7 cells and hMSCs in 
mice induced hormone independence and increased proliferation and additionally 
sensitized tumors to estradiol. These tumors had probably as well increased 
estrogen signaling [58]. 
As a consequence of the studies focusing almost exclusively on cancer cells, 
nearly all of the currently used cancer therapeutic agents target the cancer cells 
themselves, which, due to their inherent genomic instability, frequently acquire 
therapeutic resistance [28, 59]. Due to the fact that stromal cells are thought to 
be genetically more stable and less heterogeneous than tumor cells, they seem 
to be an interesting drug target. If aiming to search for a target within the stroma 
we have to keep in mind that it mutually co-evolves together with the tumor [60]. 
Ma et al. recently confirmed this by conducting a comparative analysis of global 
gene expression changes in the stromal and epithelial compartments during 
breast cancer progression from normal to pre-invasive to invasive ductal 
carcinoma. They concluded that tumor-associated stroma undergoes extensive 
gene expression changes during cancer progression, to a level similar to the 
malignant epithelium [61]. From this point of view a solution might be targeting a 
specific interaction, signaling loop, between cancer cells and stroma cells that 
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 remains stable during cancer progression. A successful example of such an 
approach is VEGF blocking [52]. 
Despite these convincing data implicating a role of the tumor microenvironment 
and stromal cells in breast tumorigenesis, our understanding of the genes 
mediating cellular interactions and paracrine regulatory circuits among various 
cell types in normal and cancerous breast tissue and their role in breast 
tumorigenesis is limited [28]. In analogy to our work exploring tumor fibroblast 
interaction [12] we planned to take advantage of an in vitro system mimicking the 
tumor – endothelial interaction, to explore the effects of heterotypic interactions 
on global gene expression and describe the pathways involved in signaling 
between tumor cells and endothelium. 
Systemic influence of hormones and growth factors on cancer initiation 
and progression 
Another important factor regulating tumor progression is the involvement of 
hormones. The serum levels of some of them are positively correlated to breast 
cancer incidence [14, 62-63], e.g. sex hormones like estrogens. Tumor 
progression is also dependent on growth factors e.g. transforming growth factor 
beta (TGF-) signaling has multiple, context-dependent roles in human cancers 
ranging from arrest of cell growth to induction of migration, stimulation of 
epithelial to mesenchymal transition and tumor progression [13]. In addition to 
direct effects on tumor cells, hormones and growth factors might modulate tumor-
stroma interactions. Most carcinoma-associated fibroblasts, known to support 
cancer growth, express alpha smooth muscle actin (SMA) and have an 
increase in contractility, which indicates that the majority of these cells may be 
myofibroblasts. TGF- is capable of inducing the transformation of fibroblasts into 
myofibroblasts. Furthermore, genetic removal of TGF- receptor type two in 
stromal fibroblasts resulted in carcinoma of adjacent epithelial cell populations 
[13]. 
Estrogens are female sex hormones with a critical impact on reproduction and 
sexual functioning. A clear impact of estrogens on cancer development and 
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 progression was shown in numerous models including an observation from 1896, 
when G.T. Beatson described that bilateral oophorectomy resulted in the 
remission of breast cancer in premenopausal women [64]. Amongst many hazard 
factors, an excess of estrogens was proven to increase the risk of breast cancer. 
Case-control studies (New York University Women's Health Study and the 
Ormoni e Dieta nell'Eziologia dei Tumori study) indicated that increased levels of 
estrone, estradiol and bioavailable estradiol, as well as their androgenic 
precursors, may be associated with a 4- to 6-fold increase in the risk of 
postmenopausal breast cancer [63]. Moreover, estrogens administrated during 
hormone replacement therapy (estrogen plus progestin pills) increase the risk of 
invasive breast cancer. The Women's Health Initiative Estrogen-plus-Progestin 
Study showed that, after 5 years of follow-up, women receiving the hormones 
had a 24 percent increase in breast cancer risk compared with women in the 
placebo group [65]. From 51 to 82% of human breast cancers are estrogen 
receptor alpha (ER) positive and ER status is considered an important prognostic 
factor. The proportion of ER positive tumors increases with patient age [66]. 
Estrogens promote the development of mammary cancer in rodents and exert 
both direct and indirect proliferative effects on human breast-cancer in vitro. 
Direct tumor-initiating effects involve enzymes and proteins involved in nucleic 
acid synthesis and through the activation of oncogenes. Indirect effects may 
occur through the stimulation of prolactin secretion and the production of growth 
factors (e.g., transforming growth factor alpha and epidermal growth factor) and 
non–growth-factor peptides (e.g. plasminogen activators) [14]. Estrogen signaling 
in the tumor bulk is not only based on endocrine sources. Carcinoma-associated 
fibroblasts actively induce local estrogen synthesis, which contributes to 
carcinogenesis and progression [67]. The dependence of ER-positive cancer 
cells on estrogen provides a treatment option and drugs interfering with estrogen 
receptors are currently used in clinics. 
Prolactin (PRL) is a polypeptide hormone released from the anterior pituitary 
gland that stimulates milk production after childbirth. PRL can promote epithelial 
cells proliferation and survival, increase cell motility and support tumor cell 
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 vascularization [16]. In vitro, it increases the growth of normal and malignant 
breast cells [68-70]. In animal models, it is important for mammary epithelial 
development and its administration has been shown to increase the rate of 
mammary tumor formation [71]. Animal data suggest that PRL can induce 
estrogen ER negative (ER-) tumors or rarely estrogen receptor positive (ER+) 
tumors in mouse models [16]. Ingram et al. found that in human, prolactin levels 
higher than the median value in control subjects were associated with a more 
than two-fold increase in the risk of breast cancer [15], which was confirmed in a 
prospective study in postmenopausal women by Hankinson [62]. In addition, a 
modest positive association between prolactin and breast cancer risk was found 
among predominately premenopausal women [72]. 
Similar to the two aforementioned hormones, other hormones and growth factors 
influence development and progression of breast cancer. Insulin is a growth-
promoting hormone that is involved in the pathogenesis of various malignancies 
that may act as a growth hormone through regulation cell proliferation, 
differentiation and apoptosis. Insulin mediates its effects by binding to the 
transmembrane insulin receptor (IR) what leads to activation different mitogen-
activated protein (MAP) kinases (MAPK) and PI3K (Phosphoinositide 3-kinases) 
pathway [73-74]. Insulin enhances the production and mitogenic activity of growth 
factors such as epidermal growth factor and insulin-like growth factors what is 
suspected to lead to pathological cell proliferation [75]. Hyperinsulinemia (excess 
levels of circulating insulin in the blood) associated with insulin resistance, a 
typical feature of type II Diabetes mellitus, is one of the risk factors in the 
development of various malignancies, including breast, pancreas, liver, colon, 
bladder, and oral cavity cancer [74]. Furthermore, population studies have shown 
that women with a new diagnosis of type two diabetes have a significantly larger 
likelihood of a prior diagnosis with breast cancer. This association allows 
speculation that the elevated insulin levels during pre-diabetes phase are 
promoting breast cancer development and progression [76]. Most important, 
breast tumors over-express IR and increased IR expression correlates with poor 
survival [77]. Moreover, insulin is able to increase ER expression and insulin and 
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 estradiol synergistically accelerate breast cancer cell proliferation [77]. In 
addition, insulin has indirect effects on breast cancer progression including the 
ability to simulate aromatase activity thereby increasing the levels of bioavailable 
estradiol [78]. The similarity of IR signaling pathway with insulin-like growth factor 
one receptor (IGF-IR) signaling pathway allows speculation that the tumorigenic 
and tumor supporting actions of both are similar or somehow intermingled. The 
harmful impact of IGF-I in breast cancer development and progression is well 
documented and IGF-I-blocking strategies are currently under extensive 
investigation [79]. On the contrary to tumor cells, the impact of the IGF-I on the 
cells in vitro representing the stromal fraction of the tumor bulk, is an essentially 
unexplored area. Fibroblasts are the most abundant cells in the tumor stroma 
mass mediating large parts of the paracrine signaling between epithelial cells and 
stroma [26]. Stromal cells respond to IGF–I stimulation with increased 
proliferation, as shown for fibroblasts [80-81] and microvascular endothelial cells 
[82]. In the project presented in the second part of this thesis I sought to 
characterize gene expression changes induced by IGF-I stimulation on primary 
breast fibroblasts and tried to check if the gene expression changes 
accompanying IGF-I stimulation are of prognostic value. 
DNA Microarrays as a tool to profile gene expression changes 
DNA microarray technology has evolved from Southern blotting and enables the 
simultaneous measurement of expression levels of thousands of genes. The first 
microarray prototypes were used for gene expression profiling in 1987 [83] and 
the use of miniaturized microarrays for gene expression profiling was first 
reported in 1995 [84]. Since the first application, the technology evolved rapidly 
and currently various approaches (single or double color) and formats based on 
different concepts are in use. The most common format is a glass slide with 
many DNA fragments, known as probes, covalently attached. Since a single 
microarray slide contains thousands of probes, a microarray experiment can 
accomplish thousands of genetic tests in parallel. Presently, microarrays might 
be applied for various applications ranging from gene expression profiling, 
comparative genomic hybridization (CGH), alternative splicing detection to single 
19
 nucleotide polymorphism (SNP) detection. The performance of the microarrays is 
astonishing. An example is the Roche NimbleGen microarray that allows for 
simultaneous gene expression analysis of 12 patient samples on a single, high 
resolution slide (2um pixel resolution). Each patient sample is checked with 
135000 probes for complete coverage of the human transcriptome. In addition to 
the compact format, the high resolution provides better signal-to-noise 
performance. Furthermore, simultaneous processing of samples grants high level 
of inter-array reproducibility (r2=0.99). Although the technology seems expensive, 
as it requires a high resolution scanner and special hybridization chambers, the 
final cost per sample, especially for industrial purposes, is reasonable [85]. 
HEEBO-arrays 
In my work, I applied the two-color Human Exonic Evidence Based 
Oligonucleotide microarrays (HEEBO). The general experimental design of two 
color microarray format is visualized in figure 4. HEEBO microarrays consist of 
44,544 70mer probes, which include (a) constitutive exonic probes (30,718), (b) 
alternatively spliced / skipped exonic probes (8,441), (c) non-coding RNA probes 
(196), (d) BCR / TCR Genic / Regional Probes (372), (e) other Probes (843) and 
(f) controls. HEEBO microarrays were produced at the Stanford Functional 
Genomic Facility (Stanford, USA). Complete details regarding the clones on the 
arrays may be found at Stanford functional genomics facility website [86]. 
 
Figure 4. Schematic illustration of the experimental procedure of the two-color microarray 
approach. 
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Gene expression patterns as a tool to systematize cancer 
The progress of molecular profiling of solid tumors began in 2000 when Perou et 
al. proposed that phenotypic diversity of breast tumors might be mirrored by the 
diversity in gene expression patterns and that the systematic investigation of 
gene expression patterns might improve molecular taxonomy of breast cancers. 
The study, based on 42 patients and cell lines, had shown that breast tumors 
greatly differ in their gene expression patterns and the differences allow 
formulating a taxonomy of breast cancers. The division of the tumors based on 
expression levels of the so called “intrinsic” gene set allowed to formulate four 
groups: ER+/luminal-like; basal-like; Erb-B2 and normal breast [87]. The main 
caveat of this study is the limited amount of samples that did not allow 
distinguishing cancer subtypes with full resolution. Nonetheless, in addition to the 
first molecular breast cancers taxonomy, there were two striking conclusions 
gained from this work. First, so called “estrogen receptor negative” carcinomas 
covered at least two distinct tumor subtypes (basal-like and Erb-B2). Second, the 
molecular program of gene expression patterns of primary tumors was 
recapitulated in its metastases. In the follow-up study, Sorlie et al. increased the 
amount of specimens and provided a classification of 78 locally-advanced breast 
carcinomas [88]. The obtained classification confirmed the one previously 
proposed. The novel finding was that formerly defined ER+/luminal-like group 
could be divided into three subgroups: luminal A, luminal C and luminal B. In 
addition, the tumor gene expression characteristics were correlated with clinical 
outcome. Correlation of the five most distinctive groups with clinical data showed 
that all of them are unique in terms of overall-survival and relapse-free survival. 
The follow-up study, based on 115 samples, confirmed classification to five 
molecular subtypes of breast cancer and validated it within two independent 
datasets [89]. Additional inclusion of patients with mutations of BRCA1 (breast 
cancer 1, early onset) and BRCA2 (breast cancer type 2 susceptibility protein) 
genes revealed the similarity of this group of tumors to the basal subtype breast 
cancers that are ER negative and carry poor prognosis. 
Concluding, molecular profiling of breast carcinomas allowed a more detailed 
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 classification than classic pathological measurements and demonstrated that 
transcriptional programs in the tumor cells and the underlying genetic alternations 
are major determinants of the tumorgenic potential and ultimately the clinical 
outcome of the disease [89]. Molecular profiling of tumors was done also for 
other malignances including lung adenocarcinomas [90-91], lymphomas, liver 
cancer, ovarian cancers and soft tissue tumors [89, 92-94]. Since most of these 
analyses were performed using bulk tissue samples that are composed of 
multiple cell types or purified tumor epithelial cells, the specific contribution of 
epithelial and stromal cells to these tumor classifiers and prognostic signatures 
remained unknown [28]. 
Gene expression signatures as a tool to predict patients’ 
survival 
Parallel to the molecular profiling of tumors, an extensive work was conducted to 
assess if microarray derived gene expression patterns, called signatures, might 
be used as a tool to predict patients’ survival. The correlation of signatures with 
clinical characteristics was conducted by many researchers [87-88, 95-102] 
(reviewed in [103]). The best known, “70-genes” signature derived by Laura van t’ 
Veer et al. [104] in a supervised analysis of early stage breast cancers, is a 
potent gene expression pattern outperforming all known clinical predictors. It was 
created to distinguish genes strongly predictive of a short interval to distant 
metastasis for lymph-node positive and negative patients. The validity of the 
signature was confirmed in an independent study by Van de Vijer et al. within the 
dataset containing 295 samples [105]. Based on the signature, a small custom-
made microarray – “MammaPrint” was created. Results of the validation 
demonstrated that microarray technology could be used as a reliable diagnostic 
tool [106]. Further validation in an independent group of 307 patients (137 events 
after a median follow-up of 13.6 years, no systemic therapy) from five European 
cancer centers has shown that the “70-genes” signature is able to add 
independent information for clinicopathologic risk assessment for patients with 
early breast cancer [107]. In another prospectively conducted study, including 
427 patients in various cancer centers, the use of MammaPrint in combination 
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with standard clinical guidelines led to altered adjuvant treatment 
recommendations in 26% of patients [103]. Currently, the MINDACT (Microarray 
In Node-negative and 1 to 3 positive lymph node Disease may Avoid 
ChemoTherapy) trial is being conducted. The trial is a multicentre, prospective, 
phase III randomized study comparing the 70-gene expression signature with a 
common clinical-pathological prognostic tool (Adjuvant! Online) selecting patients 
for adjuvant chemotherapy in node-negative breast cancer. Up to 14th of October 
2009, 4114 patients entered the screening phase and 2264 were enrolled. The 
final goal is to enroll 6000 patients. The primary objective of the MINDACT trial is 
to confirm that patients with a “low risk” molecular prognosis and “high risk” 
clinical prognosis can be safely spared chemotherapy without affecting distant 
metastasis free survival (DMFS). MINDACT has several secondary objectives 
including the identification and validation of novel gene expression signatures 
predicting clinical response to therapies used (chemotherapy and endocrine 
therapy). Furthermore, an estimation of the efficacy of chemotherapy in terms of 
disease free survival, DMFS and overall survival in the two subgroups where the 
clinical-pathological prognosis and the molecular prognosis are discordant will 
also be performed. The project also aims to set up several tissue bank resources 
(RNA, tumor tissue, serum) for future translational research studies in both 
genomics and proteomics [108-109]. The results are still unknown but potentially, 
the signature might provide a method to tailor adjuvant systemic treatment and 
reduce the costs and side effects of unnecessary treatment. The limitation of the 
method is that MammaPrint test requires fresh tissue that has to be shipped to 
company producing MammaPrint for analysis. 
This limitation is overcome in an alternative prognostic test; OncoType DX 
created by Genomic Health [110] that might be processed from the formalin-
fixed, paraffin-embedded tissue sample. Also this test quantifies the likelihood of 
disease recurrence in women with early-stage breast cancer. It is based on 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) and 
assesses the expression of a panel of 21-genes to determine the probability of 
disease recurrence. It consists of 16 cancer genes and five reference genes used 
23
to normalize the expression of the cancer genes. Oncotype DX was evaluated in 
clinical trials involving over 3,300 patients with the conclusion that it not only 
quantifies the likelihood of breast cancer recurrence in women with node-
negative, estrogen receptor-positive breast cancer, but also predicts the 
magnitude of chemotherapy benefit [111-113].  
The possibility of connecting gene expression patterns with clinical data resulted 
in a large number of publications showing correlations between biological in vitro 
derived signatures and clinical characteristics of tumors sharing similar gene 
expression patterns. Some of them were able to stratify patients into groups with 
different survival [12, 87-89, 98, 100-107, 111-123]. Comparing all of those 
predictive signatures raised two questions; first, why is there nearly no gene 
overlap between the “70-genes” signature and other predictive signatures and 
the second; are the predictions derived from these gene signatures concordant 
for individual patient samples. The first topic was addressed by Ein-Dor et al. 
[124]. The authors focused at van’t Veer’s dataset [104] and repeated the 
methodology of the “70-genes” signature creation, changing only the initial step – 
the subset of patients used to create the predictor. The results showed that the 
set of predictive genes is not unique and it strongly depends on the subset of 
patients used to create the predictor. In other words, there are many prognostic 
signatures with similar predictive power even within one dataset. Furthermore 
results by Ein-Dor et al. showed that there are many genes correlated with 
survival and the differences between these correlations are small. This allows 
hypothesizing that every single gene caries a bit of information and microarrays, 
as a tool picturing a complex image of cells tested, have to be analyzed in a 
“context” manner in which the general deregulation of a pathway or a process 
must be an informative event and not a single gene expression fluctuation. The 
second question, if predictions derived from these gene sets are concordant for 
individual samples, was addressed by Fan et al. [125]. Within a single data set of 
295 samples [105] the authors applied five gene-expression-based models: 
intrinsic subtypes [89], 70-gene profile [104], wound signature [117], recurrence 
score [112], and the two-gene ratio [126] and compared the results for single 
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 patients and found that most models had high rates of concordance in their 
outcome predictions for the individual patients.  
Another important factor that has to be taken into account is that the majority of 
breast cancer patients today receive some form of postoperative treatment 
(radiation, endocrine and/or chemotherapy) that influences the clinical course 
and significance of prognostic factors. It is possible that creating the prognostic 
classifier (signature) from patients who are treated with different therapies with 
significant impact on survival might introduce a bias in prognostic capacities of 
the signature. Although the resulting predictive classifier may accurately describe 
the sample set used for its development, it may fail when applied to an 
independent test set containing patients which still differ in terms of outcome 
[127]. This issue was kept in mind when validation of the “70-genes” signature by 
Buyse et al. [107], was conducted. Similarly, another signature presented in a 
study by Wang et al. was created using gene expression of frozen tumor samples 
from 286 lymph-node-negative patients who had not received adjuvant systemic 
treatment. The authors identified a 76-gene signature that was highly informative 
in identifying patients who developed distant metastases within 5 years in pre- 
and postmenopausal women [122]. 
An exciting possibility that might be achieved with microarray-based technology 
is creating a single microarray test covering prognosis, ER and HER2 status and 
sensibility to various treatment approaches. Invention and application of such 
custom microarray would provide clinicians with all required information for 
individual future treatment options shortly after tumor resection.  
Stroma and tumor-stroma interaction derived gene expression 
signatures as a tool to predict patients’ survival 
Gene expression profiling of tumors is a field that developed with similar trends to 
those in cancer biology. Gene expression profiling studies started with a focus on 
epithelial cells that widen to tumor stroma, finally to notice the importance of 
single tumor stromal cell types that are now extensively studied.  
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One of the first gene expression signatures that might be named "stromal” was a 
signature obtained by West et al. [123] from soft tissue sarcomas that 
recapitulate features of normal connective tissue; solitary fibrous tumors – STF 
(derived from fibroblasts) and desmoid-type fibromatosis – DTF (derived from 
deep soft tissue fibroblasts). These two sarcoma types have very distinct gene 
expression profiles including differential expression of extracellular matrix and 
growth factors genes. By immunochemistry, cells positive for gene markers 
specific for DTF were found in reactive tissues like scar and inflammatory 
granulation tissue and cells positive for STF markers were found in normal tissue. 
A signature of 786 genes that was able to distinguish the STF from DTF was 
defined. These patterns of expression were also present in breast cancer and 
were able to stratify breast cancer patients into two groups with significantly 
different outcomes. The data obtained by West et al. were evaluated in a follow-
up study, involving four more independent datasets [114]. In these four datasets, 
the authors identified a core set of 66 DTF-associated genes that were 
coordinately expressed in a subset of 25-35% of breast cancer patients. Patients 
with tumors representing high levels of this signature tend to have a better 
prognosis. In addition, the authors evaluated the protein expression of a single 
DTF core protein - secreted protein, acidic, cysteine-rich (SPARC), and showed it 
to be frequently expressed in the tumor stroma and absent in non-neoplastic 
tissue. Furthermore, breast cancer patients with strong stromal expression of 
SPARC showed a trend to increased survival. Concluding, the signature 
representing genetic alterations in tumors originating from fibroblasts was a valid 
prognosticator for breast cancer patients. Yet, one has to remember that the 
signature was not derived from stroma cells itself but malignant mesenchymal 
cells and thus may represent specific sarcoma cells gene expression profile and 
not solely a cancer stroma gene imprint. 
The first signature derived from stromal cells, namely fibroblasts, was created by 
Chang et al. [117], based on the observation of histological similarities between a 
healing wound and the tumor microenvironment resembling “normal wound 
healing gone awry” [128]. In the study, fibroblasts from ten anatomical sites were 
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 stimulated with serum and evoked gene expression patterns were analyzed. The 
“wound signature”, containing 512 stereotype genes up-regulated in fibroblasts 
upon serum stimulation was postulated to reflect the role of fibroblasts in wound 
healing and was hypothesized to provide a molecular estimate for the presence 
of the wound-healing process in human cancers. The signature was able to 
distinguish between patients with significantly different outcome for different 
types of human cancers such as locally advance breast carcinoma, lung 
adenocarcinomas (two datasets) and gastric carcinomas. However, it failed to 
distinguish patients with diffuse large B-cell lymphoma, medulloblastoma, and 
glioblastoma multiforme. Immunochemical staining revealed that LOXL2 (lysyl 
oxidase-like 2), an extracellular matrix remodeling enzyme present in the 
signature, was exclusively expressed by peritumoral fibroblasts around invasive 
carcinomas (45 of 106 tumors examined). LOXL2 primarily produced by 
fibroblasts may act on endothelial cells during tissue remodeling. Collectively, the 
data presented in this study show that the gene expression profile of fibroblasts 
stimulated by serum in human cancers represents a multicellular program in 
which all of the cells building the “tumor-bulk” actively participate, and the gene 
expression signature evoked in fibroblasts might be a valid predictor in breast 
cancer. In a follow-up study [116], the authors proved that the “wound signature” 
is able to stratify breast cancer patients in an independent early breast cancer 
dataset into two groups with significantly different prognoses. Moreover the 
signature was able to split breast cancer patients into groups that do or do not 
require adjuvant chemotherapy more efficient than National Institutes of Health 
[129] or St. Gallen [130] criteria, suggesting that treatment decision based on 
“wound signature” might be beneficial for patients [116], sparing some women 
the toxic chemotherapy.  
It is worth noting that the “wound signature” [117], the molecular classification of 
breast cancers [89] and “70-genes” signature [104] proved that gene expression 
patterns are a tool to classify the tumors and predict their course either by direct 
survival fitting (“70-genes” signature) or by in vitro modeling (“wound signature”). 
Both of the signatures classified tumors into coherent and internally consistent 
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groups, and where the signatures diverged, the combined information gave 
improved risk stratification compared to individual signatures [116]. 
An important contribution to gene expression profiling of tumor stroma was done 
by Allinen et al. [28] who used cell-type specific markers to isolate epithelial and 
stromal cell populations from normal breast tissue, DCIS and invasive breast 
carcinomas and analyzed the gene expression of single cell types with serial 
analysis of gene expression (SAGE). The gene expression data showed that not 
only epithelial cells, but also stromal cells are different from corresponding 
counterparts already at the pre-invasive DCIS stage. The study revealed high 
expression levels of genes coding CXCL12 and chemokine (C-X-C motif) ligand 
14 (CXCL14) at both DCIS and invasive stages by myoepithelial cells and 
myofibroblasts. Both chemokines are known to stimulate cancer cell growth 
through CXCR4 [131]. In addition, array comparative genomic hybridization 
(aCGH) analysis revealed that genetic changes like chromosomal gains or losses 
are limited only to tumor epithelial cells. This study provided a comprehensive 
analysis of gene expression of normal breast, DCIS and invasive breast 
carcinomas and showed that stromal cells associated with tumors are different 
from corresponding normal cells. Since CXCL12 and 14 produced by 
myoepithelial cells are able to stimulate cancer growth, they represent interesting 
drug targets. 
Gene expression profiling of the breast cancer derived fibroblasts in invasive 
breast cancer was conducted by Singer et al. [132]. They compared gene 
expression patterns of cultured stromal fibroblasts obtained from malignant tissue 
of 10 women with gene expression patterns of cultured normal breast tissue 
fibroblasts of 10 women with benign breast disorders. Out of 2400 genes 
examined with DNA microarrays, 135 were more than two fold up-regulated and 
105 more than 0.5 fold down-regulated in fibroblasts from malignant tissue. The 
majority of genes with increased expression levels were encoding tumor-
promoting cytokines (e.g. colony stimulating factor 1), transcription factors (HYL) 
and cell-matrix associated proteins (cadhepsin L). Osteopontin, recently shown to 
be involved in mobilizing stromal cell precursors from the bone marrow into the 
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circulation, thereby making them available for tumors [42], was significantly up-
regulated in breast cancer derived fibroblasts. An important observation taken 
from this study is that fibroblasts retain their distinctive gene expression pattern in 
the absence of tumor epithelial cells in cell culture. These authors hypothesized 
that the carcinoma-associated fibroblasts represent a specific fibroblast 
subpopulation which favors tumor growth [132].  
Recent findings by Casey et al. [133] confirmed that cancer-associated stroma 
(fibroblasts) differs from the normal mammary stroma in gene expression of 
genes mostly involved in ECM remodeling (MMP-1, MMP-13, FAP, TLL2), as 
well as SPARC, POSTN (periostin) and TGF-. Moreover, using microarrays, the 
author profiled all laser capture microdissected (LCM) stromal components of 
tumor and compared it to corresponding parts of normal breast, concluding that 
breast cancer invasion proceeds through the acquisition of a motile phenotype in 
tumor epithelial cells and a reactive phenotype in cancer associated fibroblasts. 
Gene expression profiling of the endothelial cells in invasive breast cancer was 
conducted by Parker et al. [53]. Purified endothelial cells from either normal 
mammoplasty or primary breast tumors were used to generate a SAGE database 
of gene expression changes accompanying vascular proliferation in invasive 
breast cancer. Invasive breast cancer vasculature, in contrast to normal 
endothelium, expressed ECM and surface proteins characteristic of proliferating 
and migrating vasculature cells. Furthermore, compared to other types of cancer 
(colon cancer), invasive breast cancer endothelial cells induced high expression 
levels of two transcription factors SNAIL1 (Snail 1 Drosophila homolog) and 
HEYL (hairy/enhancer-of-split). HEYL was shown to induce proliferation and 
attenuate apoptosis of primary endothelial cells in vitro. In addition, PRL3 
(Protein-tyrosine phosphatase type IVa, member 3), another intracellular protein, 
was shown to be predominantly expressed by endothelial cells of invasive breast 
cancer and being able to enhance the migration of endothelial cells in vitro [53]. 
The data presented by Parker et al. confirmed that tumor-associated endothelial 
cells differ from corresponding normal counterparts in terms of gene expression 
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and some of the dissimilarities are specific only for breast cancer.  
These studies, as well as a tumor microenvironment characterization provided by 
Allinen [28], give an insight in carcinoma-associated stroma biology and proves 
that they are co-conspirators, rather than innocent bystanders, of cancer 
progression. Although the authors did not check the prognostic capacities of the 
signatures in human cancer gene expression databases, I speculate that some of 
them would be valid predictors as they cover genes involved in processes crucial 
in instigating tumor growth. Entirely tumor stroma-derived microarray gene 
expression pattern used as a prognostic marker for clinical outcome was 
published by Finak et al. [120]. Laser microdissected stromal compartments from 
53 primary breast tumors were gene expression profiled together with matching 
normal tissue. Genes differentially expressed between tumor stroma and normal 
stromal tissue were used to create a stroma derived prognostic predictor (SDPP). 
SDPP has shown increased accuracy with respect to previously published 
predictors [89, 106, 116, 119, 123], especially for HER-2 positive tumors. The 
efficiency of the signature in independent, whole-tumor derived gene expression 
datasets suggests that changes in breast tumor stroma have an essential role in 
disease progression and outcome and the information that it carries might be 
found in whole tumor bulk gene expression profiles. Moreover, the prognostic 
capacity independent of ER and HER-2 status allows speculation that the 
information carried by the SDPP identifies processes different from those 
associated with tumor clinical subtype, like specific receptor status. As mentioned 
above, the signature was created based on the entire tumor stroma. This has 
some advantages, such as including genes involved in immunological responses, 
angiogenesis and hypoxia. The disadvantage is as that using a mixture of the 
cells does not allow distinguishing the cells responsible for gene overexpression. 
Furthermore it does not reveal any signaling loops that may take place between 
the cells. However a plus of this predictive signature is its size (26 genes). It is 
smaller than the complementary SFT/DTF signature what makes it more 
applicable for diagnostic practice. The small size also allows speculation that the 
most important actions of the stroma are pictured without blurring the image with 
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redundant information. In addition, it reduces the chance of distribution of the 
patients to groups with different outcome based on genes that carry only little 
information. The strong predictive power suggests that all of the genes included 
in the signature are important. SDPP was derived from the whole stroma of 53 
primary breast tumors, 50 of them represented invasive ductal carcinoma (IDC). 
As it is known that tumor-associated stroma undergoes extensive gene 
expression changes during cancer progression, to an extent similar to the 
malignant epithelium [61], it is possible that SDPP represents alterations of tumor 
stroma only at the IDC stage. This allows speculation that the signature 
composition could differ if other stages of tumor progression were included e.g. 
the stroma surrounding DICS when the basement membrane is intact. 
A subtype of gene signatures derived from stromal components are gene 
expression profiles derived from co-culture studies. An example is the interferon 
response signature [12]. In experiments involving ex-vivo co-culture models, 
simulating tumor stroma interaction, the authors found that in the proximity to 
cancer cells the fibroblasts secreted type I interferons, which induced expression 
of the interferon response genes (IRG) in the tumor cells. Paralleling this model, 
immunohistochemical analysis of human breast cancer tissues showed that 
STAT1, the key transcriptional activator of the IRGs, and itself an IRG, was 
expressed in a subset of the cancers, with a striking pattern of elevated 
expression in the cancer cells in close proximity to the stroma [12]. The 
signature, induced by co-culture, was able to segregate 295 early-stage breast 
cancers into two groups with significantly different outcomes. Since fibroblasts 
from different body sites have different gene expression programs [134-135], a 
chance for differential interaction of primary CAFs with breast tumor cells exists. 
This limitation was partially overcome in a similar work conducted by Sato and 
colleagues for co-culture of pancreatic cancer cells and primary pancreatic 
fibroblasts. This analysis identified multiple genes as differentially expressed in 
co-culture as a consequence of mutual interaction, including genes associated 
with tumor invasion, metastasis and angiogenesis. In vitro the invasive potential 
of pancreatic cancer cells (CFPAC1) was increased when they were co-cultured 
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with primary pancreatic fibroblasts. Selective inhibition of cyclooxygenase 2, a 
gene found to be up-regulated in both cell types during co-culture, partially 
decreased the invasive properties of cancer cells [136]. Unfortunately, the 
authors did not correlate the obtained gene expression signature to clinical data 
so one cannot conclude if using site-matching fibroblasts influences the 
prognostic capacity. 
When one is thinking about tumor expression profiling, it is important to 
remember that gene expression studies of tumors are based on samples 
containing a variety of cells [88-89, 104-105, 122]. In general, for cancer 
microarray profiling, biopsy samples containing less than 50% of cancer cells are 
excluded from the studies [137]. This reduces the amount of the samples that are 
profiled, thereby reducing the number of patients that can benefit from the gene 
expression profiling. It is crucial to consider the degree to which inclusion of 
stromal cells influences the outcome of tumor profiling studies. This issue was 
addressed by Roepman et al. [137]. The prognostic capacity of a previously 
formulated gene expression signature [138] varied depending on the cancer cell 
content in the biopsy. Interestingly not only low (<50%) but also too high (>90%) 
cancer cell content in gene expression profiled biopsy decreased the capacity to 
foresee metastasis in head and neck squamous cell carcinoma (HNSCCs) based 
on the signature. To analyze the problem, they created artificial samples with 
different percentages of LCM dissected stromal and tumor cells admixed and 
determined the gene expression profiles. With this approach it was possible to 
assess which of the genes were stroma and which were tumor specific. The 
results showed that 12% of genes in the previously established predictive 
signature are predominantly expressed in the stroma, 25% are specific for tumor 
cells and the rest of genes are equally expressed in the tumor and the stroma. In 
other words, the strength of the signature to foresee presence of metastasis in 
HNSCCs is associated with up-regulation of a set of genes specific for the stroma 
in the tumor bulk. This data underlines both the importance of the stromal 
component in gene expression profiles and in metastatic process, and shows that 
profiling of cancer cells only may introduce a bias and decrease the predictive 
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power of the gene expression signatures. Another important observation was 
made by Bryant et al. who quantified the proportion of lipopolysaccharide-
induced differentially-expressed monocyte genes that could be measured in 
peripheral blood mononuclear cells, and determined the extent to which gene 
expression in the non-monocyte cell fraction diluted or obscured fold changes 
that could be detected in the cell mixture. They concluded that the effect of non-
responding cells in a mixture obscures the detection of subtle changes in gene 
expression in an individual cell type. However, for studies in which only the most 
highly differentially expressed genes are of interest, separating and analyzing 
individual cells might be unnecessary as the mixture does not hide those genes 
[139]. Concluding, in the search for highly differentially-expressed genes, the 
screen done with microarray technology does not require purification to single 
cell type, as most deregulated genes aren’t going to be hidden. On the other 
hand if one searches for subtle differences between normal and cancer-
associated stroma, purification of the cells to a single cell type suspension seems 
to be crucial. 
Tumor-stroma derived gene expression patterns as prognosticators 
in breast cancer 
Concluding, tumor gene expression signatures are valid predictors in cancers 
including breast cancer. Signatures derived from carcinoma-associated cells, 
fibroblasts under the conditions mimicking wound healing, or tumor-stroma 
interactions are also valid predictors. Since the stroma plays a crucial role in 
cancer progression, new drugs targeting different aspects of tumor-stroma 
interactions or stroma itself are needed. To describe alterations taking place in 
either primary breast fibroblasts under the influence of growth factors or in tumor 
stroma interactions we sought to characterize global gene expression changes in 
both systems using microarray technology. Gene expression signatures derived 
from both in vitro systems will be validated in publically available gene expression 
datasets. 
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Tumor-endothelial interaction links the CD44(+)/CD24(-) 
phenotype with poor prognosis in early-stage breast cancer 
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MATERIALS ANDMETHODS: The genomic effects of tumor-endothelial interactions in cancer are not yet well char-
acterized. To study this interaction in breast cancer, we set up an ex vivo coculture model with human benign and
malignant breast epithelial cells with endothelial cells to determine the associated gene expression changes using
DNA microarrays. RESULTS: The most prominent response to coculture was the induction of the M-phase cell
cycle genes in a subset of breast cancer cocultures that were absent in cocultures with normal breast epithelial
cells. In monoculture, tumor cells that contained the stem cell–like CD44+/CD24− signature had a lower expres-
sion of the M-phase cell cycle genes than the CD44−/CD24+ cells, and in the CD44+/CD24− cocultures, these
genes were induced. Pretreatment gene expression profiles of early-stage breast cancers allowed evaluating
in vitro effects in vivo. The expression of the gene set derived from the coculture provided a basis for the segre-
gation of the tumors into two groups. In a univariate analysis, early-stage tumors with high expression levels (n =
137) of the M-phase cell cycle genes had a significantly lower metastasis-free survival rate (P = 1.8e − 5, 50%
at 10 years) and overall survival rate (P = 5e − 9, 52% at 10 years) than tumors with low expression (n = 158;
metastasis-free survival, 73%; overall survival, 84%). CONCLUSIONS: Our results suggest that the interaction of
endothelial cells with tumor cells that express the CD44+/CD24− signature, which indicates a low proliferative
potential, might explain the unexpected and paradoxical association of the CD44+/CD24− signature with highly
proliferative tumors that have an unfavorable prognosis.
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Tumor angiogenesis is a prerequisite for tumor progression and metasta-
sis. It is a complex process that requires cooperative reciprocal interaction
of tumor cells and endothelial cells [1–4] and, thereby, offers an attractive
therapeutic target [5]. Clinical trials with antiangiogenic agents, such as
bevacizumab, which is an antibody against vascular endothelial growth
factor (VEGF), introduced these agents into clinical practice [6]. During
the last several years, antiangiogenic therapies, in combination with con-
ventional chemotherapeutic agents, have been established for different
tumor types, such as colorectal cancer [7], non–small cell lung cancer
[8], renal cell cancer [9], and breast cancer [10]. The average clinical
benefit of these drugs, however, is relatively modest, and it is unclear
which patients benefit the most. Improvements are likely to come from
a more thorough understanding of the molecular and cellular mecha-
nisms that govern tumor-endothelial cell interactions. Tumor angiogene-sis involves a plethora of soluble and cellular components that interact
in a process of mutual signaling [11]. This requires a coordinated expres-
sion of proangiogenic factors [12] and suppression of antiangiogenic
factors [13], which leads to endothelial cell proliferation and migration
and vessel formation. Although multiple single genes have been de-
scribed in numerous reports to be involved in angiogenesis, such as
988 Tumor-Endothelial Interaction Buess et al. Neoplasia Vol. 11, No. 10, 2009growth factors [12,14], membrane-bound molecules [15], and extra-
cellular matrix components [16], there are likely others that have
remained unidentified. The interplay between the various factors and
their combined effects in tumor angiogenesis, however, remains to be
further characterized.
Carcinomas are not merely aggregates of malignant epithelial cells
but are, in many respects, organlike structures that include host
stromal cells, such as fibroblasts, adipocytes, inflammatory cells, and
the cells that form the tumor vasculature, and the malignant cells
themselves that intermingle and interact with all of these cell types
[17]. During the last few years, there has been growing evidence that,
besides the cellular processes within the tumor cells, a relevant con-
tribution to tumor progression is provided by the cells of the tumor
microenvironment [18]. On the molecular level, genome-scale gene
expression studies of many different carcinomas have illustrated in de-
tail the complexity of the tumors and the diversity of the associated
non–epithelial cell types [19]. Inductive interactions between these dif-
ferent cell types can play not only a morphogenetic role but also an
important mechanistic role in the pathogenesis and progression of
malignancy. The endothelial cells have so far been mainly viewed in
the context of vessel formation to improve the blood supply of the
tumor. However, relatively little is known about the paracrine effects
of these tumor-endothelial cell interactions. It was commonly thought
that the formation of new vessels would mainly be important for the
transport of nutrients and oxygen to the tumor cells and that inter-
rupting this support is the key mechanism of antiangiogenic therapies.
If we assume that, by the interruption of the vascular support, the
tumor gets more hypoxic, it seems paradoxical that antiangiogenic
therapies enhance the effects of chemotherapy and radiation. In the
hypoxic environment, these therapies have usually been shown to be
less effective [20]. However, the effects of these agents could be due,
in good part, to the disruption of the paracrine tumor-promoting sig-
naling that occurs as a result of the interaction of the cancer and endo-
thelial cells. Such reciprocal inductive signaling has been well known
from developmental biology and has again attracted special attention
with the concept of cancer stem cells and their stem cell niche [21].
Therefore, characterizing heterotypic cell-cell interaction effects on
a global gene expression scale might help to better understand the
currently used antiangiogenic agents and eventually lead to the iden-
tification of novel targets that could be used to interrupt these paracrine
stimulatory signaling pathways. This study specifically focuses on the
interaction between breast cancer cells and endothelial cells to identify
their reciprocal signaling effects.
Breast cancer is a heterogeneous disease, which implies that the tumor-
endothelial cell interactions might also be diverse. Tumor-endothelial
cell interactions are not yet well characterized on a genome-wide scale,
and they have not been compared between different tumor subtypes.
Toward this aim, we performed a systematic analysis of the interactions
between well-characterized breast cancer cell lines and primary endo-
thelial cells in coculture.
We have recently used the approach of in vitro coculture experiments
to characterize heterotypic interaction effects with DNA microarrays to
systematically describe the global-scale effects that the tumor-fibroblastic
stroma interaction has on gene expression. We identified a strong induc-
tion of an interferon response by specific tumor cells in coculture with a
diverse set of fibroblasts, which corresponded to a subset of breast cancers
with an unfavorable prognosis in vivo [22].
In this study, we used breast cancer cell lines and endothelial cells
for systematic coculture experiments, which allowed the interactioneffects to be characterized on a global gene expression scale. Using this
system, we investigated the following hypotheses:
1. The interaction of tumor and endothelial cells leads to changes
in gene expression, which are important for angiogenesis and tu-
mor progression. The gene expression programs that are involved
provide hints for the signaling mechanisms that are involved.
2. The interaction of tumor and endothelial cells leads to the in-
duction of gene expression signatures that are clinically rele-
vant. These interaction effects might account for a significant
proportion of the unexplained information in the gene ex-
pression data from tissue specimens. Given the evidence that
interactions between cells can play critical roles in tumor pro-
gression, these data might be even more meaningful than
prominent expression patterns, which are driven by the propor-
tional representation of a given cell type in a tissue.
We have performed a systematic overview of heterotypic interaction
effects of breast cancer and endothelial cells. The picture we obtained is
complex, but our results suggest that the interaction of endothelial cells
with a subset of CD44+/CD24− breast cancer cell lines induces a sig-
nature of “tumor-endothelial cell–induced M-phase cell cycle” genes,
which is associated with a worse outcome in human breast cancer.
Materials and Methods
Cell Culture
Human mammary epithelial cells (HMECs; Cambrex Bio Science
Walkersville, Walkersville, MD) were expanded in mammary epithelial
basal medium that was supplemented with bovine pituitary extract,
human epidermal growth factor, insulin, and antibiotics (Clonetics,
Cambrex Bio Science Walkersville). MCF-7, T47D, MDA-MB-231,
SKBR-3, Hs578T, and BT549 (ATCC, Atlanta, GA) were propagated
in Dulbecco’s modified Eagle medium that was supplemented with
10% FBS (HyClone, Logan, UT), glutamine, 100 U/ml penicillin,
and 100 μg/ml streptomycin (Gibco, Grand Island, NY). Human
umbilical vein endothelial cells (HUVECs; ATCC) and human der-
mal microvascular endothelial cells (HDMECs; Cambrex Bio Science
Walkersville) were expanded in endothelial basal medium 2 (EBM2;
Cambrex Bio Science Rockland, Rockland, ME) that was supplemented
with human epidermal growth factor, hydrocortisone, GA-1000 (genta-
micin, amphotericin-B), 5% FBS, VEGF, human fibroblast growth
factor-B (with heparin), R3-IGF, and ascorbic acid. For the coculture
experiments, the cells were cultivated for 48 hours at an equal density
of 50,000 cells/cm2 (25,000 tumor cells/cm2 and 25,000 endothelial
cells/cm2) in endothelial basal medium (Cambrex Bio Science Rockland)
supplemented with 0.2% FBS. This medium served as a good universal
medium for all the cells in the study.
Proliferation Assays
Direct cell counting. For cell counting, prestarved cells were plated
in quadruplicate in 24-well plates at a density of 50,000 cells/cm2.
After 24 and 48 hours, the cells were trypsinized and resuspended in
0.2 ml of FACS buffer that contained 0.5% BSA and 2 mM EDTA
in PBS. The total cell number was determined using a cell counter.
WST-1 assay. The proliferation reagent 4-[3-(4-iodophenyl)-2-(4-
nitro-phenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1; Roche
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used according to the manufacturer’s instructions. WST-1 is changed
by mitochondrial enzymes of metabolically active cells to a colorful
formazan that can be measured at a wavelength of 450 nm. The cell
number was determined by comparison of the absorbance values to a
standard cell dilution curve.
Comparison of HUVECs Proliferation in Response to
Different Conditioned Medium
To obtain the conditioned medium, 10e6, Hs578T,MDA-MB-231,
MCF-7, or HUVECs were extensively washed to avoid transfer of any
stimuli from the regular cell growth medium. The cells were kept in
10 ml of EBM2 that contained 0.2% FBS for 24 hours. The medium
was then aspirated and filtered through a 0.2-nm pore filter. In paral-
lel, 3000 HUVECs per well were plated in a 96-well plate and starved
for 24 hours in EBM2 that contained 0.2% FBS. For the stimulation
experiments, HUVECs were washed once with PBS and incubated for
48 hours in 1:2 diluted conditioned medium in EBM2 that contained
0.2% FBS. EBM2 that contained 0.2% FBS was used as a negative
control (vehicle medium), HUVEC culture supernatant that was di-
luted 1:2 in vehicle medium was used as an autologous medium con-
trol, and the full endothelial cell growth medium 2 that contained 5%
FBS and all the supplements that were described above was used as a
positive control. To determine the cell growth in response to stimula-
tion with conditioned medium, the cells were stained with 7% WST-1
in low-serumDulbecco’s modified Eagle medium (0.2% FBS) for 1 hour
at 37°C in 5% CO2. The absorbance was measured with an ELISA
reader at a wavelength of 450 nm. Values for each experimental condi-
tion were obtained by calculating the average of at least eight indepen-
dent replicates.
Inhibition with the Blocking Antibody Bevacizumab
To block the stimulatory effects of tumor cell conditioned media, the
medium was supplemented with 100 ng/ml bevacizumab (Avastin;
Genentech/Roche). To control the effect of bevacizumab, an additional
HUVEC culture was set up with a medium that was enriched with re-
combinant VEGF-A (5 ng/ml) and 5% FBS. The cell growth was de-
termined as above, and the absolute absorbance values were compared.
To check if blocking is specific for bevacizumab, trastuzumab
(Herceptin; Genentech/Roche) was included at equal concentrations
(0, 360, 720 ng/ml) in the analysis. As a negative control, HUVECs
that were treated with Hs578T cell culture supernatant were used.
The cell growth was determined as described before, and the absolute
absorbance values were compared.
RNA Isolation and Amplification
After discarding the culture medium and washing the cell layer once
with PBS, total RNA was isolated by lysing the cells in the culture
dish with RLT buffer (Qiagen, Valencia, CA) and extracting with the
RNeasy Mini Kit (Qiagen). Five hundred nanograms of total RNAwas
amplified using the Message Amp II aRNA Kit (Ambion, Austin, TX).
The amplification product was checked for integrity by electrophoresis
in a 1% agarose gel in MOPS buffer.
Complementary DNA Microarrays and Hybridization
The human complementary DNA (cDNA) microarrays contained
40,700 elements, which represented 24,472 unique genes that were
based on Unique Clusters. The arrays were produced at the Stan-ford Functional Genomic Facility. Complete details regarding the clones
on the arrays may be found at: http://www.microarray.org/sfgf/jsp/
servicesFrame.jsp#productionArrays.
cDNA produced from 6 μg of amplified RNA were hybridized to
the array in a two-color comparative format, with the experimental
samples labeled with one fluorophore (Cy5) and a reference pool of
messenger RNA (Universal Human Reference mRNA; Stratagene,
La Jolla, CA) labeled with a second fluorophore (Cy3). The fluo-
rescent dyes were purchased from Amersham Pharmacia Biotech
(Piscataway, NJ). Hybridizations were carried out using the standard
protocol that was described previously [19].Data Analysis and Clustering
Array images were scanned using an Axon Scanner 4000B (Axon
Instruments, Union City, CA), and image analysis was performed
using GenePix Pro version 5.0 3.0.6.89 (Axon Instruments). The raw
data files were stored in the Stanford Microarray Database [23], and the
data that were used for the article are available at: http://microarray-
pubs.stanford.edu/tumor-endothelial interaction. Data were expressed
as the log2 ratio of fluorescence intensities of the sample and the refer-
ence for each element on the array.
The (Cy5/Cy3) ratio is defined in the Stanford Microarray Database
[23] as the normalized ratio of the background-corrected intensities.
Spots with aberrant measurements that were due to obvious array arti-
facts or poor technical quality were manually flagged and removed
from further analysis. A filter was applied to omit measurements where
the fluorescent signal from the DNA spot was less than 50% above the
measured background fluorescence that surrounded the printed DNA
spot in either the Cy3 or the Cy5 channel. Genes that did not meet
these criteria for at least 80% of the measurements across the experi-
mental samples were excluded from further analysis. Valid data were
filtered to exclude elements that did not have at least a three-fold de-
viation from the mean in at least two samples. Data were evaluated by
unsupervised hierarchical clustering [24] and significance analysis of
microarray [25] and were displayed using TreeView (http://rana.lbl.
gov/EisenSoftware.htm).GO::Termfinder
GO::TermFinder comprises a set of object-oriented Perl modules for
accessing Gene Ontology (GO) information and evaluating and visu-
alizing the collective annotation of a list of genes to GO terms [26]. It
can be used to draw conclusions from microarray and other biologic
data by calculating the statistical significance of each annotation.Determination of the Heterotypic Interaction Effect on
Gene Expression
To facilitate the identification of heterotypic interaction effects on
global gene expression in a mixed coculture experiment, the gene ex-
pression data were normalized based on the proportional contribution
of each cell type to transcript abundance. Given that the average gene
does not change because of the heterotypic interaction and that there
are simple additive effects to account for, a linear regression fit was used
for normalization. To determine the contribution of each cell type to
the combined gene expression pattern in the linear regression model,
the expression levels of the monocultures were the predictors, and the
expression levels of the coculture were the response.
Specifically, a set of equations (1 − n) was established (one per gene):
en
coculture = ((a × en
monoculture1) + ((1 − a) × enmonoculture2)) × In, where e
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portional contribution of mRNA from the respective monoculture,
n represented the number of genes measured on the microarray, and
I represented the interaction coefficient. We assume that the average
gene is not influenced by the heterotypic interaction in the mixed co-
culture, which is represented as I = 1. Because the data set over e1 − n
is skewed, a linear regression fit was empirically identified based on
Gamma errors and identity link as a good model to calculate a. The
equation 1 − n can then be solved for I1 − n, which results in a pro-
file of interaction effects for the genes1 − n. These interaction effects
can be analyzed in much the same way as conventional gene expres-
sion measurements.Human Breast Cancer Data Set
The data set for breast cancer contained 295 tumors that were
analyzed on a 25,000-spot oligonucleotide array [27]. In brief, pa-
tients were diagnosed and treated at the Netherlands Cancer Institute
(NKI) for early-stage breast cancer (stages I and II) between 1984 and
1995. The clinical data were updated in January 2005. The median
follow-up for patients who are still alive is 12.3 years.
The “tumor-endothelial cell–induced M-phase cell cycle” gene list
consists of 98 genes that are represented by 95 image clones on the cDNA
Stanford Array. Clones having the same Unigene locus were removed.
The gene sequences were mapped to spots on the NKI array using
Unigene build no. 184 (released on June 9, 2005) to give 36 unique spots.
To overcome possible overweighting of clones from Unigene clusters
that were matched to more than one probe on the NKI array, expression
values that were derived from probes that were not matched to the
same Unigene cluster were averaged. Expression measurements for each
gene were mean centered. The resulting data set was subjected to hierar-
chical clustering with average linkage clustering [24] and displayed with
TreeView (http://rana.lbl.gov/EisenSoftware.htm).
Distant metastasis was analyzed as first event only (distant metastasis-
free probability). If a patient developed a local recurrence, an axillary
recurrence, a contralateral breast cancer, or a second primary cancer
(except for nonmelanoma skin cancer), he/she is censored at that time
and the subsequent distant metastases are not analyzed. This is based on
the theoretical possibility that the locally recurrent or second primary
cancers could be a source for distant metastases. An ipsilateral supra-
clavicular recurrence was soon followed by a distant metastasis in all
but one patient. An ipsilateral supraclavicular recurrence was thus con-
sidered to be the first clinical evidence for metastatic disease for this
analysis, and patients were not censored at the time of ipsilateral supra-
clavicular recurrence. Overall survival was analyzed based on death from
any cause, and patients were censored at last follow-up. Kaplan-Meier
survival curves were compared by the Cox-Mantel log-rank test using
Winstat for Microsoft Excel (R Fitch Software, Staufen, Germany).
A data set of gene expression patterns from advanced breast cancers
was described by Sorlie et al. [28]. Expression data from 53 image
clones that represented the “tumor-endothelial cell–induced M-phase
cell cycle” gene list were included in this data set. Genes and samples
were organized by hierarchical clustering. Relapse-free and overall sur-
vivals were calculated as described above.Centroid Correlation
The method of calculating the centroid for each patient was pre-
viously described by Sorlie et al. [28]. The centroids were profiles
that consisted of the average gene expression value for each of thepatients. Briefly, the centroids for the genes that represented the
“tumor-endothelial cell–induced M-phase cell cycle” signature as well
as the other signatures were calculated based on the NKI data set. To
test a similarity between the signatures, the correlation between values
of different centroids was checked for each patient. The correlation
was calculated using the Pearson correlation coefficient with R soft-
ware [29].Results
Setup of a Tumor-Endothelial Coculture Model
As a model for investigating the gene expression program in re-
sponse to epithelial-endothelial interactions in the normal breast
and in breast cancer, cells that represented either benign or malig-
nant epithelial cell compartments and cells that represented endothe-
lial cell compartments were examined in an in vitro mixed coculture
setting. The cells were cocultivated for 48 hours in low-serum me-
dium (0.2% FBS) to allow reciprocal signal exchange with minimal
background from the influence of undefined molecular signals that
are inherent in fetal bovine serum. We examined the effects of co-
cultivation for each cell pair in two independent biologic replicates.
The gene expression profiles of the cocultures were compared with
the expression profiles of the corresponding cells that were kept in
monoculture using cDNA microarrays that contained approximately
40,700 elements representing 24,472 unique Unigene clusters (build
no. 173, released on July 28, 2004). To establish this experimental
approach, we first focused our experiments on the breast cancer cell
line, Hs578T, the dermal microvascular endothelial cell, HDMEC,
and the coculture of these two cell types. The data passing our data
quality filter, a filter for data distribution and a filter selecting genes
that are more consistent within replicate samples than between ex-
perimental samples, were organized using unsupervised hierarchical
clustering of the replicate experiments to provide an overview of the
effects on global gene expression (Figure 1A). In the coculture, most
genes displayed intermediate expression levels, which closely approxi-
mated the proportionally weighted average of their expression levels
in the two cell types in monoculture. Despite setting up the cocul-
ture with equal cell numbers of Hs578T and HDMEC, the gene
expression pattern after cocultivation is dominated by the pattern of
Hs578T. However, one set of genes showed a consistent increase in
transcript abundance in the coculture when compared with either
monoculture, which suggested that the induction of these genes was
an effect of cocultivation.
Interestingly, 11% of the 44 genes within this gene set are involved
in DNA replication as determined by GO terms, and they are RRM2,
Cdc45L, MCM4, KIAA1212, and MCM8 [26] (Appendix Figure 1).
The frequency of the genes that were involved in this function is
significantly enriched (P = .006) compared with the background of
1140 genes passing the data quality and data distribution filters as
shown in the heat map of Figure 1. Furthermore, several genes are
involved in the cell cycle, and they are CCNA2, RAD54B, AURKA,
and CENPN. STC1, which is an extracellular matrix protein found
in breast cancer [30] and known to be involved in angiogenesis [31],
was also detected in this set of genes. Taken together, these gene sets
suggest proliferation of the tumor-endothelial cell coculture.
Because breast cancer is a clinically and molecularly heterogeneous
disease, we selected a broad spectrum of different breast cancer cell lines
to sample this heterogeneity and explore the effects of a heterotypic
Figure 1. Effect of heterotypic interaction between an endothelial cell and a breast cancer cell line. (A) Biologically independent repli-
cates of the monocultured HDMEC, the breast cancer cell line Hs578T, and the mixed coculture of HDMEC and Hs578T were grown for
48 hours at low serum conditions and characterized by DNA microarray hybridization. Hierarchical clustering of a total of 1140 elements
that display a greater than three-fold variance in expression in more than two different experimental samples. Data from individual ele-
ments or genes are represented as single rows, and different experiments are shown as columns. Red and green denote the expres-
sion levels of the samples. The intensity of the color reflects the magnitude of the deviation from baseline. Unsupervised hierarchical
clustering of the experiments grouped the biologic replicates together. Gene expression varied considerably between HDMEC and
Hs578T cultures as expected for cells of mesenchymal or epithelial origin, respectively. The coculture profile showed mainly inter-
mediate expression levels. However, the vertical black bar marks a cluster of genes that were induced in all cocultures when compared
with both monocultures, which indicated that they were induced by the heterotypic interaction. Zooming in on the genes that were
upregulated in coculture revealed that they were specific for proliferation and mitosis. (B) Correlation of the measured coculture gene
expression levels and their estimated expression levels based on the proportional contribution of each cell type as determined by a linear
regression fit of the monoculture to the coculture data. (C) Fold change of each gene that was associated with coculturing of HDMEC and
Hs578T. Genes of the “proliferation and mitosis” cluster are indicated in red. Dashed lines indicate 95% confidence limits.
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The focus was on epithelial-endothelial cell interactions, which were
studied by cocultivating endothelial cells of different origins (HUVEC
and HDMEC) in combination with HMECs or six widely used breast
cancer cell lines. HDMECs, which are a commercially available dermal
microvascular endothelial cell line, were selected to resemble the tumor
vasculature endothelial cells of breast cancer as accurately as possible.
HUVECs were selected to represent venous cells, despite the fact that
the umbilical and breast environments are different. However, the
changes that were observed suggest the system works well.
The changes in gene expression that are due to heterotypic inter-
actions were subtle when compared with the large intrinsic variation in
expression patterns among the involved cell types, as illustrated in
Figure 1A for the cell pair of Hs578T and HDMEC. To identify thegene expression changes that resulted from cell-cell interactions, it was
necessary to control for the simple additive effects that reflect the pro-
portional contribution of the two cell types to the total population of
each gene’s transcript in coculture. Elimination of these proportionally
weighted additive contributions allowed the isolation of supra-additive
interaction effects. The fact that the transcript levels of most genes did
not change in response to coculture allowed a linear regression model
that was based on the transcription profiles of each monoculture be
fitted to the coculture data for normalization. An example of this type
of analysis is shown in Figure 1B. For each gene, the ratio of the mea-
sured transcript level and the level that was estimated by the linear
model provides a measure of the heterotypic interaction effect. This
is illustrated in Figure 1C , which shows the distribution of the gene
expression changes of the Hs578T/HDMEC coculture. The genes that
992 Tumor-Endothelial Interaction Buess et al. Neoplasia Vol. 11, No. 10, 2009were identified by hierarchical clustering as differentially expressed in
coculture when compared with monoculture are highlighted to illus-
trate the performance of this approach. Interaction effects, which are
represented as gene expression changes, are converted to quantitative
values that can be analyzed for similarities and disparities over multiple
different pairwise interactions between cells with the same tools that
are used to analyze conventional gene expression data.
There was an obvious heterogeneity in the responses of different
pairs of cells to cocultivation (Figure 2). A striking feature was a cluster
of genes that was induced in MDA-MB-231 and Hs578T cocultures
with either HUVEC or HDMEC but not in the cocultures with the
HMECs. To test for enrichment in a specific functional gene ontology,
we applied again the GO::Termfinder tool and found that this set of
104 genes was highly enriched for genes associated with the M-phase
of the cell cycle compared with the background of 8140 genes (P =
1.87e − 16). This set of “tumor-endothelial cell–induced M-phase cell
cycle” genes included TOP2A, CDC2A, CCNB2, DHFR, CIT, TK1,
CCNA, RRM2,NUSAP1,TPX2,CDC25C,CENPA,CENPE, AURKA,
DTL, DICER, WHSC1, PSIP1, and MTPN. Interestingly, WHSC1
plays a role in tumorigenicity, adhesion, and clonogenic growth in mul-
tiple myeloma [32]; PSIP1 [33], which is a transcriptional coactivator
that is involved in different processes, plays a protective role in stress
induced apoptosis; and MTPN [34] is a gene that belongs to the myo-
trophin family.Figure 2. Gene expression changes in multiple cocultures of breast
cancer cell lines with endothelial cells. Overview of collapsed data
from repeat coculture experiments of eight benign and malignant
epithelial cells with two different endothelial cells (HUVEC and
HDMEC). The 9 monocultures and the 14 cocultures were analyzed
independently in duplicates on 46 HEEBO arrays. Raw data were fil-
tered for technical quality as described in Materials and Methods
section, leaving 37,773 spots. A data distribution filter eliminating
spots with a log2-based red-green normalized ratio of less than 1 in
at least two arrays removed 10,183 suid(s), leaving 27,590. Genes
with missing data in more than 20% of the arrays were removed,
leaving 14,565. On the basis of this data set, the calculation of the
interaction factors was performed for all 14 cocultures separately
as described in Materials and Methods section. The interaction fac-
torswere then further analyzed for their distribution, and factors with
an SD of less than 0.5 were eliminated, leaving interaction factors
for 8140 genes, which are shown as a heat map after unsupervised
hierarchical clustering. Red and green denote relative changes in
expression that were associated with heterotypic interaction. The
magnitude of the relative change is given by color intensity. Zooming
in on a cluster of genes that was consistently upregulated in more
than two of the cocultures revealed that they were specific for the
M-phase of the cell cycle.Differential Induction of Proliferation with Conditioned
Medium from Different Tumor Types
As implied by the higher expression of the “tumor-endothelial cell–
induced M-phase cell cycle” gene signature, the proliferation rate, as
determined by direct cell counting over time, was significantly higher
in the coculture of Hs578T and HUVEC than in isolated Hs578T
or HUVEC cultures (Figure 3A). Also, by flow cytometric cell cycle
analysis using propidium iodine staining, we observed a higher propor-
tion of cells leaving the G1 phase in the coculture than in the mono-
cultures indicative of a higher proportion of cells cycling and passing the
M-phase (data not shown).
We speculated that specific factors secreted by the tumors might
increase the growth of the endothelial cells or vice versa. Toward this
aim, we reciprocally incubated one cell type in conditioned medium
from the other cell type. In fact, when the conditioned medium from
the HUVECs is applied to the tumor cells, the tumor cells show a
significantly higher proliferation rate than when kept in autologous
medium as measured by the increase in relative cell numbers using
the WST-1 proliferation assay (P = 1.3e − 12 [MCF-7], P = 4.6e −
06 [Hs578T], P = 4.3e − 07 [MDA-MB-231], unpaired 2-sided
t test; Figure 3B). This explains the enhanced proliferation, but it
does not explain the differences in proliferation between cocultures
of the distinct tumor subtypes. Of note, the conditioned medium from
HUVECs induced a higher level of proliferation in MCF-7 cells than
in either MDA-MB-231 or Hs578T cells. However, when the condi-
tioned media that are derived from the different tumor types are applied
to HUVECs, there is an increase in proliferation on stimulation with
conditioned medium from Hs578T cells, which is not seen in the
response to the supernatant from MCF-7 cells (Figure 3C). This pat-
tern of differential induction is consistent with the differences in the
expression of the “tumor-endothelial cell–induced M-phase cell cycle”
gene signature, which was observed in the cocultures of Hs578T or
MCF-7 in combination with HUVECs.
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We speculated that the induction of the “tumor-endothelial cell–
induced M-phase cell cycle” genes in cocultures of Hs578T and
MDA-MB-231 is due to cell-cell signaling of factors that are specifi-
cally expressed at higher levels in these cells. To systematically identify
these molecules, a two-class significance analysis of microarray data was
performed [25], with one class formed by Hs578T and MDA-MB-
231 and the other by HMEC, HDMEC, HUVEC, BT549, SKBR3,
T47D, and MCF-7. Among the genes that were expressed at signifi-
cantly higher levels in these two cell types were several inducers of
angiogenesis, which included VEGFC, FGF12, PTN, and NF1. There
were also several transcription factors that were coexpressed with theseFigure 3. Proliferation of tumor and endothelial cells is due to recip-
rocal stimulation. (A) Proliferation of HUVECs and Hs578T monocul-
tures and their 1:1 coculture as determined by measuring the
increase in cell number by direct cell counting after 36 hours. (B)
Box-and-whisker diagrams of relative cell numbers of MCF-7,
Hs578T, and MDA-MB-231 after incubation with conditioned me-
dium from HUVECs compared with a normalized negative control
of the same cells incubated with autologous medium as measured
by the colorimetric cell proliferation assay with the WST-1 com-
pound. (C) Proliferation of HUVECs that was induced by conditioned
medium from Hs578T and MCF-7 cells as measured by WST-1. Rel-
ative absorbance values of colorful formazan, which has been con-
verted by HUVECs, correspond to relative cell numbers. A single
column represents average absorbance values for a minimum of
eight independent replicates. y Axis error bars correspond to SD.
The HUVECs that were treated with the Hs578T supernatant grew
significantly faster than the same cells that were treated with the
MCF-7 supernatant, the fresh vehicle medium, or the autologous
(HUVEC-derived) medium.genes, such as SNAI2 and ZFHx1B, which are known to be involved
in the epithelial-mesenchymal transition. Interestingly, the PDGFB re-
ceptor, which responds to PDGFB that is secreted by endothelial cells,
was found in these cells (Figure 4A). The full list of genes is given in
Appendix Table 1.Expression of CD44/CD24 in the Diverse Cells
Because breast cancer cells that have the potential to influence the
cells within their microenvironment in a way that enhances prolifera-
tion might have stem cell characteristics, we speculated that the tumor
cells that expressed these angiogenic factors might carry the CD44+/
CD24− stem cell–like signature, as previously described [35]. Figure 4B
shows the relative expression of the mRNA of these two antigens in
the breast cancer cell lines as measured on the cDNA microarray.
CD44 is consistently upregulated in the breast cancer cells that induced
the M-phase cell cycle genes in the coculture with endothelial cells,
whereas CD24 is consistently downregulated.
This led us to the following working model: Tumor cells first se-
crete endothelial stimulatory signals, such as VEGF, FGF12, PTN, and
NF1 (Figure 4C). On stimulation, the endothelial cells start to express
PDGFB, which then signals back to the tumor cells through the up-
regulated PDGFB-R. This feedback loop is facilitated by matching pairs
of receptors and ligands, and the coculture starts proliferating.Blocking Hs578T-Induced Proliferation of HUVEC
with Bevacizumab
One of the best described signaling pathways of endothelial cell pro-
liferation is the VEGF pathway [12]. This pathway can be specifically
blocked by bevacizumab, which is amonoclonal antibody against VEGF
[36]. Whereas Hs578T induces the “tumor-endothelial cell–induced
M-phase cell cycle” gene signature in cocultivation with HDMEC,
the expression level of this signature in the coculture of MCF-7 and
HDMEC represents just the average of the two cells in monoculture
(Figure 5A). In accordance with these observations, bevacizumab is
able to specifically block the stimulatory effect of Hs578T conditioned
medium on HUVECs, whereas there was no significant effect on
HUVECs that were incubated with conditioned medium that was de-
rived fromMCF-7 (Figure 5B). Bevacizumab, in contrast to trastuzumab,
which served as a negative control, was able to block the conditioned
medium that was derived fromHs578T cells and resulted in a reduction
in proliferation of HUVECs by approximately 50% to 80%, depending
on the antibody concentration (Figure 5C). This supports the VEGF
pathway as an important factor that enhances tumor-endothelial cell
proliferation. However, it is not sufficient alone to explain the full effect.
Other factors that were identified by differential expression analysis in
our coculture model might also be involved and, therefore, represent
valuable targets for therapeutic intervention.In Vivo Effects of the “Tumor-Endothelial Cell–Induced
M-Phase Cell Cycle” Gene Signature
We investigated the effect on global gene expression in response to
heterotypic cell-cell interaction as a simple, controlled, ex vivo model
of tumor-endothelial cell interaction. We reasoned that identifying and
characterizing gene expression programs that were characteristically in-
duced by the interaction between specific pairs of cells in culture might
enable us to recognize and interpret specific features in the expression
profiles of human cancers that represent similar interactions between
Figure 4. Genes associated with the tumor-endothelial induced M-phase cell cycle gene signature. (A) Significance analysis of micro-
array data to identify genes that show the largest expression differences between tumor cells that were inducing a proliferation re-
sponse in coculture with the cells and those that were not inducing proliferation. The expression levels of the top 63 genes are shown
on a heat map after unidimensional hierarchical clustering of the genes. (B) Relative expression of CD44 and CD24 in diverse breast cancer
cell lines. The average expression of their mRNA over the cell lines corresponds to 0. (C) Working model of reciprocal tumor-endothelial
signaling based on the higher expression in the cocultures that induced proliferation.
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ex vivo cocultivation of breast cancer and endothelial cells was the
induction of “tumor-endothelial cell–induced M-phase cell cycle”
genes. We, therefore, looked for this response in the expression patterns
in the published data from 295 early-stage (stages I and II) breast can-
cer samples from the NKI [27]. The “tumor-endothelial cell–induced
M-phase cell cycle” genes showed a strikingly coherent variation in
expression among these cancers, which enabled these cancers to be di-
vided into two groups. One group had a relatively high expression and
the other had a relatively low expression of the “tumor-endothelial cell–
induced M-phase cell cycle” genes. Clustering the breast carcinomas
based only on the expression of the “tumor-endothelial cell–inducedM-phase cell cycle” genes separated them into two main clusters, with
one cluster having a high-level expression of most of the “tumor-
endothelial cell–inducedM-phase cell cycle” genes and the other having
a lower expression of these genes (Figure 6A). The same coordi-
nated behavior and segregation of tumors could be observed in a dif-
ferent set of advanced breast cancer samples [28,37], which suggested
that variation in this “tumor-endothelial cell–induced cell M-phase
cell cycle” program is a general feature in breast cancer (Appen-
dix Figure 2).
As a first assessment of its potential biologic relevance, distant
metastasis-free survival and overall disease-specific survival were com-
pared between the two groups. Early-stage tumors with high expression
Figure 5. Stimulatory effect of Hs578T conditioned medium on en-
dothelial cells can be partially blocked by bevacizumab. (A) Rela-
tive expression of the “tumor-endothelial cell–induced M-phase
cell cycle” genes in different monocultures of breast cancer cell
lines and endothelial cells and in their respective cocultures. (B)
Blocking of the stimulatory effect of Hs578T conditioned medium
by bevacizumab. Absolute absorbance values of formazan dye that
was converted by HUVECs, which corresponds to cell numbers,
are shown in columns, with the y axis bars corresponding to SD.
Bevacizumab (100 ng/ml) depleted the stimulatory effect of Hs578T
cell culture supernatant in a significant manner, whereas it had no
effect on the MCF-7 cell culture supernatant. Recombinant VEGF-A
(5 ng/ml) and 5% FBS served as positive and negative controls,
respectively. (C) Dose-dependent blocking of HUVEC proliferation
by bevacizumab and trastuzumab. Absolute absorbance values of
formazan dye that was converted by HUVECs are shown. HUVECs
that were treated with the Hs578T cell culture supernatant repre-
sent the baseline stimulatory effect. Bevacizumab depleted the
stimulatory effect of the Hs578T conditioned medium in a signifi-
cant, dose-dependent manner. Trastuzumab, which is a monoclonal
antibody against HER2, did not influence HUVEC stimulation by the
Hs578T conditioned medium.
Figure 6. “Tumor-endothelial cell–inducedM-phase cell cycle”genes
in early-stage breast cancer. (A) The expression values of genes in
the “tumor-endothelial cell–induced M-phase cell cycle” gene signa-
ture were extracted from a published expression study of 295 early-
stage breast cancers from the Netherlands Cancer Institute [35].
Genes and samples are organized by hierarchical clustering. The
tumors were segregated into two groups that were defined by
high (red) or low (blue) expression levels of the 30 genes matching
the M-phase cell cycle gene cluster. (B) Correlation of the “tumor-
endothelial cell–induced M-phase cell cycle” gene signature status
with distant metastasis-free and overall survival. Kaplan-Meier
curves for the clinical outcomes of the indicated tumors that exhibit
high (red curve) and low (blue curve) “tumor-endothelial cell–induced
M-phase cell cycle” gene signature expression are shown.
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tant metastasis-free survival (P = 1.8e − 5; 50% at 10 years) and overall
survival rate (P = 5e − 9; 52% at 10 years) than tumors with low ex-
pression levels (n = 158; metastasis-free survival, 73% at 10 years; over-
all survival, 84% at 10 years; Figure 6B).
The same trend toward unfavorable outcome in patients with
cancers that showed high levels of “tumor-endothelial cell–induced
M-phase cell cycle” gene transcripts (P = .17) could be seen in theanalysis of the data set from advanced-stage breast cancers [28] (data
not shown) from Norway/Stanford.Correlation to Other Prognostic Gene Expression Signatures
The relationship between the “tumor-endothelial cell–induced
M-phase cell cycle” gene signature and three previously identified gene
expression signatures, which were useful prognosticators in this data set,
were also investigated (Figure 7). The first signature is a set of 70 genes
[38], which was identified in a supervised analysis of a subset of the
NKI early-stage breast cancer data set [27], that could predict freedom
from metastasis at 5 years. The second signature was identified in vitro
by exposing fibroblasts to serum to mimic a wound response, and it
has been shown to predict a risk of progression [39]. The “tumor-
endothelial cell–induced M-phase cell cycle” gene signature seems to
be highly correlated with the poor prognosticator wound (0.605) sig-
nature and to be the reciprocal of the good prognosticator 70-gene
signature (−0.708), which indicated that our hypothesis that was based
996 Tumor-Endothelial Interaction Buess et al. Neoplasia Vol. 11, No. 10, 2009on an in vitro model is of in vivo clinical relevance. Interestingly, the
“tumor-endothelial cell–induced M-phase cell cycle” gene signature
has even a higher correlation to the 70-gene profile, which was derived
as a prognosticator by a top down analysis of this exact data set, than the
wound signature. The invasiveness gene signature, which was derived
from a comparison of CD44+/CD24− stem cell–like cells with normal
breast epithelial cells, predicted poor prognosis in breast cancer [40].
This signature, despite having similar prognostic power as the wound
signature, did not correlate well with the 70-gene signature, with the
wound signature, or with the “tumor-endothelial cell–inducedM-phase
cell cycle” gene signature (−0.21).Figure 7. Correlation to other prognostic gene signatures in early-stage
signature [49], the invasiveness gene signature [40], and the “tumor-en
data set. Pairwise scatter plot matrix of the three gene signatures. PeDiscussion
The main objective of this study was to examine and characterize the
effects of heterotypic cellular interaction to gain insight into the under-
lying biology of these effects in normal mammary tissue and in breast
cancer, with a specific focus on the interaction between epithelial tumor
cells and endothelial cells. To isolate specific, direct interactions from
more complex interactions that involve multiple cell types in a whole
tissue or organism, we used a simple ex vivo coculture model. Because
some important heterotypic interactions might require direct cell-cell
contact, we focused on a coculture model where the two cell types were
mixed [22]. In this report, we describe the systematic genomic analysisbreast cancer. Correlation of the 70-gene signature [50], the wound
dothelial cell–induced M-phase cell cycle” signature score in the NKI
arson correlations are shown in the lower part of each plot.
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actions between benign and malignant epithelial cells and endothelial
cells in normal breast tissue and in breast cancer.
Common Gene Set Induced by Tumor-Endothelial Coculture
As expected, based on our experience with the tumor-fibroblast inter-
action [22], the picture of heterotypic interaction effects from the survey
of diverse tumor cells with two different types of endothelial cells is
complex and reflects the different abilities of normal and malignant cells
to send and respond to extrinsic signals. Our data show that the effects
of the tumor-endothelial cell interaction differ between different breast
cancer cell lines that each represents a different breast cancer subtype.
A prominent theme in our coculture experiments was a set of genes that
were characteristic of the mitotic phase of the cell cycle, which we called
the “tumor-endothelial cell–induced M-phase cell cycle” gene expres-
sion signature. This observation on the gene expression level is consis-
tent with the phenotypic features that show a higher proliferation rate
in the respective cocultures. In our setting, the mere coexistence of two
cell types of different origin, such as the Hs578T breast cancer cells and
endothelial cells, seems to be sufficient to induce proliferation. Co-
operate induction between cells of different lineages is well known from
developmental biology, where stem cells cooperate with their environ-
mental cells to form the stem cell niche. The stem cell concept has also
been introduced in cancer [41]. Cells with stem cell characteristics have
been prospectively isolated from breast cancer using CD44 and CD24
as markers [35]. From these cells, which are characterized as CD44+/
CD24−, a prognostic gene expression signature has been determined,
which has been called the invasiveness signature [40]. This signature
has been associated with an unfavorable prognosis in breast cancer.
However, it was unclear how that small fraction of stem cells could lead
to such a prominent gene expression pattern in the genomic profile of
breast cancer, and it was unexpected that a signature that was derived
from stem cells, which are known for their low proliferative potential,
was linked to the highly proliferative, poor prognostic tumors.
Hs578T and MDA-MB-231 both exhibit the CD44+/CD24−
phenotype. Whereas in monoculture under low serum conditions, they
proliferated slowly in a manner that was similar to stem cells [42,43],
in coculture with endothelial cells, they had a high proliferation rate
along with associated changes in gene expression. This induction of
proliferation markers is absent in the cocultures with CD44−/CD24+
cells. Therefore, cocultivation of endothelial cells with breast cancer
cells links the CD44+/CD24− signature with high proliferation, which
is then associated with the overexpression of the “tumor-endothelial
cell–induced M-phase cell cycle” gene signature and predicts a poor
prognosis in breast cancer. We are well aware that the CD44+/CD24−
signature is preferentially associated with basal type carcinomas, in
contrast to the CD44−/CD24+ signature, which is associated with the
luminal-type breast cancer cells [44]. In this context, the cocultivation
with endothelial cells explains the worse prognosis of basal type breast
cancer despite the lower proliferation rate of the isolated basal-type
breast cancer cells in monoculture. This exemplifies that this simple
in vitro coculture model is more similar to the in vivo situation than
the monoculture. The stem cell–like cells with highly potent tumor-
initiating properties, as they were described by Al-Hajj et al. [35], clearly
exhibited the CD44+/CD24− signature but were also characterized by
additional markers. It has been shown that CD44+/CD24−–expressing
cell lines contain these tumor-initiating cells [42,45], but, of note, we
did neither specifically focus on nor explicitly select for these stem
cell–like cells.Differences Are Due to Differential Endothelial
Cell Proliferation
A comparison of the gene expression program between the CD44+/
CD24− tumor cells that upregulate the “tumor-endothelial cell–
induced M-phase cell cycle” genes and the CD44−/CD24+ tumor
cells that do not reveals multiple genes that seem to be involved in
angiogenesis. This gene subset includes VEGF, FGF, and other endo-
thelial stimulatory factors. Many genes in this cluster are functionally
less well described, although they might be involved in tumor cell
proliferation or in the induction of tumor angiogenesis. To demon-
strate their functional impact, we blocked VEGF with bevacizumab,
which is a specific antibody against VEGF. A good part of the stimu-
latory effect of Hs578T conditioned medium on HUVECs was abro-
gated with bevacizumab. This demonstrates that these genes play a
considerable functional role and are not just surrogate markers that
are associated with faster tumor growth. Whereas VEGF partially
blocks the effects of the tumor cell supernatant, other factors might
also contribute to endothelial proliferation and thereby represent pos-
sible additional new therapeutic targets. Most notably, these additional
factors could be responsible for drug resistance to anti-VEGF mono-
therapy if tumors start using these alternative angiogenic factors to grow
blood vessels.
With consideration to the cancer stem cell concept, the stem cell
niche has been proposed to play an important role in carcinogenesis
and progression, although it remains largely uncharacterized at the cel-
lular and molecular levels. It is possible to speculate that endothelial
cells participate in the breast cancer stem cell niche. In a mouse model,
VEGFR+ bone marrow–derived cells have been shown to form a stem
cell niche for cancer cells, and such cells have been identified in human
breast cancer biopsies [46]. In brain cancer, stem cells were demon-
strated to live in a vascular niche that secretes factors that promote their
long-term growth and self-renewal [47]. The factors that we have
described to enhance the proliferation of Hs578T, a CD44+/CD24−–
expressing cell line, which contains at least in part stem cell–like cells
[42] and endothelial cells, might also be involved in a breast cancer stem
cell niche. We are well aware that the endothelial cells of the vascular
system are diverse [48] and that the tumor vasculature consists of spe-
cifically altered endothelial cells. The endothelial cells that we selected,
which were the HUVECs and HDMECs, do not represent the autolo-
gous tumor vasculature endothelial cells of breast carcinomas. We can,
therefore, not exclude the possibility that endothelial cells that are
isolated from within a tumor might show additional specific interaction
effects. Nevertheless, it would be surprising if carcinoma-associated
endothelial cells failed to show the strong effects that we consistently
observed in cocultures with HUVECs and HDMECs. Because these
experiments might be insufficient to detect subtle differences between
cocultures that involve different types of tumor-endothelial cells, a
more specific selection of primary tumor-associated endothelial cells
would be needed in the optimal case in cocultivation with primary
tumor cells.Predictive Marker for Antiangiogenic Drugs
We have shown that the “tumor-endothelial cell–induced M-phase
cell cycle” signature is a strong prognostic signature that strongly cor-
relates with other prognostic signatures such as the wound signature [49]
and the 70-gene signature [27]. A subset of the genes that are found
in our signature overlaps with a subset of the genes that are found in
the “wound signature,” which was characterized by the stimulation of
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ing. Our situation also resembles the situation of wounding, where
new vessels have to spread to the wound area to nourish the new wound
fibroblasts. The 70-gene signature is currently studied in prospective
clinical trials to spare some women chemotherapy without risking their
chance of cure [50]. For clinical decisionmaking, it is important to define
biomarkers that could serve as predictive factors about the benefit of
certain therapies, especially in the case of new therapeutic options, such
as antiangiogenic drugs. So far, there is no valid biomarker for this pur-
pose. Although there is evidence from preclinical studies, we have to
be cautious when extrapolating preclinical data to the human disease.
Preclinical experiments are often designed to look at the influence of
well-defined biologic phenomena on drug efficacy. By contrast, human
disease ismore complex andmight requiremultiplemarkers to accurately
predict efficacy. For this purpose, a set of in vitro–designed biomarkers,
which are already independently tested for their prognostic power, such
as our “tumor-endothelial cell–induced M-phase cell cycle” gene signa-
ture or the associated set of angiogenesis-inducing factors, could serve as
potential predictors that are worth further evaluation.Our in vitromodel,46which involves the mere coculture of two cell types, seems to allow the
identification of a strongly prognostic gene signature. Whereas the genes
from the 70-gene signature have not yet been associated with a single
functional ontology, our signature is linked to a mechanistic in vitro
model that allows for further experimentation.
In our previous work, we have modeled the interaction of tumor cells
with fibroblasts, which allowed us to define an interferon response gene
set [22]. In this work, we have characterized a tumor-endothelial cell
interaction. It would be interesting to see how different carcinoma-
associated fibroblasts and endothelial cells interact and how the addition
of tumor cells would reprogram the system. Our coculture technique
may allow us to further explore these more complex interactions among
the multiple molecules that operate in these cells to orchestrate the pro-
cess of cancer progression and metastasis. Our experience suggests that
in vitro modeling of specific processes and features of the tumor micro-
environment can provide a valuable interpretive framework for the
analysis of associated gene expression patterns in more heterogeneous
in vivo samples and the identification of the effects of heterotypic cel-
lular interactions.
Appendix
Appendix Figure 1. GO terms. Graphical visualization of the output from GO::Termfinder for process ontology: GOgraph layout that
includes the significant GO nodes annotated by DNA replication, derived from 44 clones from a background of 1140. The color of the nodes
is an indication of their Bonferroni corrected P value (orange ≤ 1e− 10; yellow = 1e − 10 to 1e−8; green = 1e−8 to 1e−6; cyan = 1e−6
to 1e−4; blue = 1e−4 to 1e−2; tan > 0.01).
Neoplasia Vol. 11, No. 10, 2009 Tumor-Endothelial Interaction Buess et al. 999
47
1000 Tumor-Endothelial Interaction Buess et al. Neoplasia Vol. 11, No. 10, 2009Appendix Table 1. List of Genes Expressed in Breast Cancer Cell Lines Inducing Proliferation in Coculture.CLID UniGene Cluster ID ∣∣ Symbol ∣∣ Gene NameIMAGE:754582 ∣∣ Hs.567266 ∣∣ NF1 ∣∣ Neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease)
IMAGE:280699 ∣∣ Hs.563491 ∣∣ EPDR1 ∣∣ Ependymin related protein 1 (zebrafish)
IMAGE:138991 ∣∣ Hs.233240 ∣∣ COL6A3 ∣∣ Collagen, type VI, alpha 3
IMAGE:878836 ∣∣ ∣∣ ∣∣ ∣∣ AA670429 ∣∣ ∣∣ ∣∣ IMAGE:878836 ∣∣ 110839
IMAGE:45138 ∣∣ Hs.435215 ∣∣ VEGFC ∣∣ Vascular endothelial growth factor C
IMAGE:1031532 ∣∣ Hs.226780 ∣∣ OSTM1 ∣∣ Osteopetrosis associated transmembrane protein 1
IMAGE:460002 ∣∣ Hs.269027 ∣∣ GALNT5 ∣∣ UDP-N -acetyl-alpha-D-galactosamine:polypeptide N -acetylgalactosaminyltransferase 5 (GalNAc-T5)
IMAGE:204737 ∣∣ Hs.360174 ∣∣ SNAI2 ∣∣ Snail homolog 2 (Drosophila)
IMAGE:1913366 ∣∣ Hs.128013 ∣∣ PRSS3 ∣∣ Protease, serine, 3 (mesotrypsin)
IMAGE:898218 ∣∣ Hs.450230 ∣∣ IGFBP3 ∣∣ Insulin-like growth factor binding protein 3
IMAGE:489519 ∣∣ Hs.297324 ∣∣ TIMP3 ∣∣ TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory)
IMAGE:489089 ∣∣ Hs.474053 ∣∣ COL6A1 ∣∣ Collagen, type VI, alpha 1
IMAGE:488404 ∣∣ Hs.27621 ∣∣ ∣∣ Clone TUA8 Cri-du-chat region mRNA
IMAGE:753587 ∣∣ Hs.167741 ∣∣ BTN3A3 ∣∣ Butyrophilin, subfamily 3, member A3
IMAGE:857640 ∣∣ Hs.420269 ∣∣ COL6A2 ∣∣ Collagen, type VI, alpha 2
IMAGE:1030805 ∣∣ Hs.458623 ∣∣ ∣∣ Transcribed locus, moderately similar to XP_509196.1 PREDICTED: similar to FTO protein [Pan troglodytes]
IMAGE:868212 ∣∣ Hs.369397 ∣∣ TGFBI ∣∣ Transforming growth factor, beta-induced, 68 kDa
IMAGE:2545711 ∣∣ Hs.592971 ∣∣ ∣∣ Transcribed locus
IMAGE:1470128 ∣∣ Hs.411391 ∣∣ LOC399959 ∣∣ Hypothetical gene supported by BX647608
IMAGE:121981 ∣∣ Hs.419240 ∣∣ SLC2A14 ∣∣ Solute carrier family 2 (facilitated glucose transporter), member 14
IMAGE:1893136 ∣∣ Hs.596112 ∣∣ ∣∣ Transcribed locus ∣∣ AI278518 ∣∣ ∣∣ ∣∣ IMAGE:1893136 ∣∣ 313617
IMAGE:753467 ∣∣ Hs.419240 ∣∣ SLC2A14 ∣∣ Solute carrier family 2 (facilitated glucose transporter), member 14
IMAGE:789147 ∣∣ Hs.511915 ∣∣ ENO2 ∣∣ Enolase 2 (gamma, neuronal)
IMAGE:299539 ∣∣ Hs.584758 ∣∣ FGF12 ∣∣ Fibroblast growth factor 12
IMAGE:471196 ∣∣ Hs.111577 ∣∣ ITM2C ∣∣ Integral membrane protein 2C
IMAGE:504761 ∣∣ Hs.374774 ∣∣ ANKRD29 ∣∣ Ankyrin repeat domain 29
IMAGE:811000 ∣∣ Hs.514535 ∣∣ LGALS3BP ∣∣ Lectin, galactoside-binding, soluble, 3 binding protein
IMAGE:153646 ∣∣ Hs.172928 ∣∣ COL1A1 ∣∣ Collagen, type I, alpha 1
IMAGE:897768 ∣∣ Hs.476218 ∣∣ COL7A1 ∣∣ Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)
IMAGE:263716 ∣∣ Hs.474053 ∣∣ COL6A1 ∣∣ Collagen, type VI, alpha 1
IMAGE:269425 ∣∣ Hs.34871 ∣∣ ZFHX1B ∣∣ Zinc finger homeobox 1b
IMAGE:754106 ∣∣ Hs.297324 ∣∣ TIMP3 ∣∣ TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory)
IMAGE:809719 ∣∣ Hs.477128 ∣∣ CCDC80 ∣∣ Coiled-coil domain containing 80
IMAGE:1558164 ∣∣ Hs.89901 ∣∣ PDE4A ∣∣ Phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce homolog, Drosophila)
IMAGE:293339 ∣∣ Hs.360174 ∣∣ SNAI2 ∣∣ Snail homolog 2 (Drosophila)
IMAGE:291290 ∣∣ Hs.558402 ∣∣ SSX4 ∣∣ Synovial sarcoma, X breakpoint 4
IMAGE:609332 ∣∣ Hs.409662 ∣∣ COL14A1 ∣∣ Collagen, type XIV, alpha 1 (undulin)
IMAGE:239256 ∣∣ Hs.173859 ∣∣ FZD7 ∣∣ Frizzled homolog 7 (Drosophila)
IMAGE:210717 ∣∣ Hs.1501 ∣∣ SDC2 ∣∣ Syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan)
IMAGE:415122 ∣∣ Hs.48384 ∣∣ HS3ST3B1 ∣∣ Heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1
IMAGE:625234 ∣∣ Hs.642759 ∣∣ KDELR3 ∣∣ KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3
IMAGE:843222 ∣∣ Hs.210283 ∣∣ COL5A1 ∣∣ Collagen, type V, alpha 1
IMAGE:234736 ∣∣ Hs.514746 ∣∣ GATA6 ∣∣ GATA binding protein 6
IMAGE:80643 ∣∣ Hs.482730 ∣∣ EDIL3 ∣∣ EGF-like repeats and discoidin I-like domains 3
IMAGE:502689 ∣∣ Hs.632387 ∣∣ NEXN ∣∣ Nexilin (F actin binding protein)
IMAGE:109424 ∣∣ Hs.103110 ∣∣ PPARA ∣∣ Peroxisome proliferative activated receptor, alpha
IMAGE:813823 ∣∣ Hs.406475 ∣∣ LUM ∣∣ Lumican
IMAGE:110503 ∣∣ Hs.480712 ∣∣ LARP2 ∣∣ La ribonucleoprotein domain family, member 2
IMAGE:1475595 ∣∣ Hs.75431 ∣∣ ALPL ∣∣ Alkaline phosphatase, liver/bone/kidney
IMAGE:742125 ∣∣ Hs.65436 ∣∣ LOXL1 ∣∣ Lysyl oxidase-like 1
IMAGE:510729 ∣∣ Hs.437040 ∣∣ PTPN21 ∣∣ Protein tyrosine phosphatase, non-receptor type 21
IMAGE:769686 ∣∣ Hs.643513 ∣∣ THY1 ∣∣ Thy-1 cell surface antigen
IMAGE:144916 ∣∣ Hs.62661 ∣∣ GBP1 ∣∣ Guanylate binding protein 1, interferon-inducible, 67 kDa
IMAGE:345849 ∣∣ Hs.102267 ∣∣ LOX ∣∣ Lysyl oxidase
IMAGE:502664 ∣∣ Hs.35861 ∣∣ TMEM158 ∣∣ Ras-induced senescence 1
IMAGE:786265 ∣∣ Hs.501928 ∣∣ MICAL2 ∣∣ Microtubule associated monoxygenase, calponin and LIM domain containing 2
IMAGE:590759 ∣∣ Hs.105269 ∣∣ SC4MOL ∣∣ Sterol-C4-methyl oxidase-like
IMAGE:854678 ∣∣ Hs.567598 ∣∣ LBH ∣∣ Hypothetical protein DKFZp566J091
IMAGE:344272 ∣∣ Hs.9999 ∣∣ EMP3 ∣∣ Epithelial membrane protein 3
IMAGE:361974 ∣∣ Hs.371249 ∣∣ PTN ∣∣ Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1)
IMAGE:1593317 ∣∣ Hs.509067 ∣∣ PDGFRB ∣∣ Platelet-derived growth factor receptor, beta polypeptide
IMAGE:756372 ∣∣ Hs.438823 ∣∣ KCNH2 ∣∣ Potassium voltage-gated channel, subfamily H (eag-related), member 2
IMAGE:415134 ∣∣ Hs.632256 ∣∣ STAT5B ∣∣ Signal transducer and activator of transcription 5BGenes that are differentially expressed between breast cancer cell lines inducing the “tumor-endothelial cell–induced M-phase cell cycle” gene signature contain multiple endothelial growth factors.48
Appendix Figure 2. “Tumor-endothelial cell–induced M-phase cell cycle” genes in advanced-stage breast cancer. The expression values
of genes in the “tumor-endothelial cell–induced M-phase cell cycle” gene signature were extracted from a published expression study of
advanced-stage breast cancers from Norway/Stanford [33]. Genes and samples are organized by hierarchical clustering. The tumors seg-
regated into two groups defined by high (red) or low (blue) expression levels of 29 genes matching the “tumor-endothelial cell–induced
M-phase cell cycle” gene signature.
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Abstract
Background: Insulin-like growth factor-1 (IGF-I) signalling is important for cancer initiation and progression. Given
the emerging evidence for the role of the stroma in these processes, we aimed to characterize the effects of IGF-I
on cancer cells and stromal cells separately.
Methods: We used an ex vivo culture model and measured gene expression changes after IGF-I stimulation with
cDNA microarrays. In vitro data were correlated with in vivo findings by comparing the results with published
expression datasets on human cancer biopsies.
Results: Upon stimulation with IGF-I, breast cancer cells and stromal fibroblasts show some common and other
distinct response patterns. Among the up-regulated genes in the stromal fibroblasts we observed a significant
enrichment in proliferation associated genes. The expression of the IGF-I induced genes was coherent and it
provided a basis for the segregation of the patients into two groups. Patients with tumours with highly expressed
IGF-I induced genes had a significantly lower survival rate than patients whose tumours showed lower levels of
IGF-I induced gene expression (P = 0.029 - Norway/Stanford and P = 7.96e-09 - NKI dataset). Furthermore, based
on an IGF-I induced gene expression signature derived from primary lung fibroblasts, a separation of prognostically
different lung cancers was possible (P = 0.007 - Bhattacharjee and P = 0.008 - Garber dataset).
Conclusion: Expression patterns of genes induced by IGF-I in primary breast and lung fibroblasts accurately predict
outcomes in breast and lung cancer patients. Furthermore, these IGF-I induced gene signatures derived from
stromal fibroblasts might be promising predictors for the response to IGF-I targeted therapies.
See the related commentary by Werner and Bruchim: http://www.biomedcentral.com/1741-7015/8/2
Background
There is a considerable amount of evidence that the
insulin-like growth factor (IGF) family is important for
cancer development and progression and IGF signalling
is known to involve complex regulatory networks with
numerous interacting ligands, receptors and binding
proteins [1,2]. IGF-I, the first ligand of the family, may
act as a tissue growth factor in an autocrine or paracrine
manner or as a circulating hormone [3]. An elevated
IGF-I level in the plasma is linked to an increased risk
of developing ductal carcinoma in situ of the breast,
invasive breast cancer, colorectal cancer, prostate cancer
and lung cancer [4-9].
IGF-I signalling is crucial for tumour progression
because it is involved in cell proliferation, differentiation,
migration and survival [2,3,10-13]. On the molecular
level, IGF-I is one of the factors that enables cells to
pass the G1-S checkpoint in the cell cycle [14]. Normal
mammary epithelial cells can be maintained and will
proliferate with IGF-I in serum free cell culture media,
underscoring the IGF-I’s importance for the growth of
breast epithelial cells [15,16]. In combination with mam-
mogenic hormones, IGF induces ductal growth in mam-
mary gland explant cultures [17]. Furthermore, IGF-I
and IGF-II can suppress apoptosis of mammary
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epithelial cells induced by serum withdrawal [12]. In
vivo, the involution of mammary glands is delayed in
mice over-expressing human IGF-I due to reduced
alveolar apoptosis [18]. During mammary gland develop-
ment, IGF-I synergizes with estrogen in terminal end
bud formation [19]. Finally, both IGF-I and IGF-II pro-
vide cancer cells with radioprotection and resistance to
chemotherapeutic agents [20,21].
Further highlighting the importance of the IGF-I axis,
the IGF-I receptor (IGF-IR) is crucial in cancer develop-
ment and progression. The IGF-IR was found to be
over-expressed and highly activated in malignant breast
tumours compared with normal breast tissue [22,23].
Patients bearing an oestrogen receptor negative breast
tumour have a worse prognosis when their tumour is
positive for IGF-IR [24]. The functional importance of
IGF-IR has been shown in vitro by inhibiting the recep-
tor signalling which results in cancer cell apoptosis. In
vivo, the inhibition of IGF-IR signalling prevents tumour
formation in nude mice [1,25]. Moreover, IGF-IR-defi-
cient fibroblasts cannot be transformed by viral or cellu-
lar oncogenes [26], supporting the importance of IGF-IR
signalling in tumourigenesis.
That IGFs are involved in breast cancer migration and
invasion has been demonstrated using dominant-nega-
tive IGF-IR constructs in MDA-435 breast cancer cells
in vitro and in vivo [27]. Another experiment revealed
that IGF-I stimulates cell motility, but not proliferation,
in MDA-231BO cells in which the predominant adaptor
protein for IGF-IR is the insulin receptor substrate 2
(IRS2) instead of the insulin receptor substrate 1 (IRS1).
Further evidence supporting the involvement of IGF-IR
and IRS2 axis in motility and metastasis comes from in
vivo data. The mating of mice expressing the PyV-MT
(polyomavirus middle T) oncogene, which induces
breast cancer, with IRS2 null animals instead of wild-
type animals results in their offspring showing a
decrease in the formation of metastasis [28]. Thus, IGF-
I is emerging as an important factor in tumourigenesis
as a cell death inhibitor and a proliferation enhancer. Its
involvement in tumour progression, metastasis and
resistance to anti-neoplastic therapies makes it a pro-
mising drug target which is currently being examined in
numerous clinical trials [29].
So far, the attention on IGF-I has focused on mito-
genic and tumourigenic signalling in cancer cells
[9,29,30]. With the increasing knowledge of the role of
the tumour stroma in cancer initiation and progression,
the role of IGF-I signalling in the stroma is of equal
interest. In tumours, most of the IGF-I mRNA is loca-
lized in the stromal cells [31], especially fibroblasts [32],
whereas most of the IGF-IR mRNA is in the tumour
cells [33] which indicates that IGF-I produced in the
stroma influences the tumour cells. However, there is
evidence that IGF-I also influences the stroma. Stromal
cells respond to IGF-I stimulation with increased prolif-
eration, as do fibroblasts [34,35] and microvascular
endothelial cells [36].
In addition to the response of the tumour cells to
IGF-I, we specifically focused on the response of the
stromal cells to this growth factor. Bendall et al. recently
showed that the IGF-IR axis is involved in the establish-
ment of the stem cell niche [37]. Blocking IGF-II/IGF-
IR reduces the survival and clonogenicity of human
embryonic stem cells (ES). Similarly, IGF-II alone is suf-
ficient to maintain human ES cells in culture. In this
system, IGF-II was expressed by autologously human-
ES-cell-derived fibroblast-like cells.
In our study, we explore the role that IGF-I stimula-
tion plays in cancer and stroma cells. We study the
molecular changes that occur in primary normal and
cancer-associated fibroblasts when they are stimulated
with IGF-I. Furthermore, we hypothesized that gene
expression changes in this system might be of prognos-
tic significance in human cancer.
In this report, we show that primary normal and car-
cinoma-associated breast fibroblasts are sensitive to
IGF-I. In addition, fibroblasts of different origin show a
unified response to IGF-I. We also demonstrate that
genes up-regulated in primary breast and lung fibro-
blasts may have prognostic significance in human breast
cancer and lung adenocarcinomas.
Results
Effects of IGF-I on gene expression in breast cancer cells
and stromal fibroblasts
In order to characterize the effects of IGF-I on tumour
and stromal cells, we stimulated pre-starved MCF-7
cells and CCL-171 fibroblasts with 50 ng/ml IGF-I (a
concentration within the physiological range) for 24 h.
We then profiled gene expression changes using human
exonic evidence-based oligonucleotide (HEEBO) micro-
arrays. After stimulation, total RNA was extracted and
amplified using a modified Eberwine procedure. The
amplified RNA was labelled with the fluorescent dye
Cy5 and pooled with Cy3 labelled reference RNA [38]
and then the pooled RNA was hybridized onto HEEBO
microarrays. After hybridization and washing, the arrays
were scanned on a fluorescent microscope scanner and
the raw data files were stored in the Stanford Microar-
ray Database [39].
In order to establish the system, we characterized the
response of both cell types to IGF-I separately. In both
cell types, we observed a remarkable change in the gene
expression profile following IGF-I stimulation (Figure 1).
As the interaction between IGF-I and stromal cells in
the tumour microenvironment has not yet been studied,
we first characterized the IGF-I-induced genes in
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CCL-171 cells. The most prominent change after stimu-
lation was a greater than 1.5-fold induction (mean: 2.35,
standard deviation: 0.45) in the expression level of 370
genes (Additional file 1). The fibroblast derived IGF-I
signature contains TTK, NEK2, PBK, SPBC24, RAC-
GAP1, CLASP1, HECTD3, RCC2, MAD2L1, CDCA8,
PTTG1, BIRC5, PKMYT1, HCAP-G, CCNB1, CENPF,
CDC20, CKS2, SPAG5, PLK1, BUB1B, CCNF, KIF11,
CDC25C, DLG7, BRRN1 and CDCA5, genes that are
known to be involved in proliferation, cell cycle and
mitotic cell division.
In order to check, in an unbiased way, what features the
members of the IGF-I induced signature share and to
verify the significance of enrichment of a specific gene
ontology, we used the GO TermFinder tool [40]. The
analysis revealed that the fibroblast derived IGF-I signa-
ture is significantly enriched for genes involved in biolo-
gical processes such as M phase, mitotic cell cycle,
mitosis and cell cycle, with a P value equal to ≈ 1.03e-
10 and cell division with P ≈ 1.03e-8 (Table 1 and Addi-
tional file 2). In addition, among the 370 unique genes
up-regulated by IGF-I we found genes that are involved
in angiogenesis, the p53 pathway and integrin and Wnt
signalling. The mRNA expression level of six soluble
factors already recognized in cancer biology (POSTN,
TNC, CSPG2, LOXL1, ATRN, FBS1) increases in
response to IGF-I stimulation, suggesting that these fac-
tors play some role in stimulating tumour cell prolifera-
tion and metastasis.
We selected the MCF-7 cell line, the well-known repre-
sentative of the luminal type breast cancer, to assess the
global gene expression effects of IGF-I stimulation. IGF-
I stimulation increased the mRNA expression level of
numerous genes (such as BMP7, ID1, ID3, SRF and
VEGF) that play a role in tumour biology as well as
genes with ontologies assigned to protein metabolism
(RPS6KA4, PSMC4, MAPK6, LMAN2L, RPL8, EIF5 and
CEBPB), responses to a protein stimulus and to
unfolded protein (HSP90AA1, HSPE1, HSPA1A,
DNAJA1, HSPA4, HSP90AB1, HSPH1, and DNAJB1).
In contrast to the upregulation of genes involved in the
proliferation that we found in CCL-171 cells, the gene
expression pattern in MCF-7 cells stimulated with IGF-I
is not significantly associated with the cell cycle or
proliferation.
After comparing these gene expression patterns, we
hypothesized that the mesenchymal stromal cells and
malignant epithelial cells exhibit distinct gene expression
changes in response to IGF-I stimulation. In order to
test this hypothesis, we compared the gene expression
profiles of CCL-171 and MCF-7 cells with, and without,
IGF-I stimulation. Within each cell type, we subtracted
the expression profile of unstimulated cells from IGF-I
stimulated cells and then filtered and merged the pro-
files and performed a hierarchical clustering of the
genes. The results were visualized with a heat map
using TreeView software [41], which showed that the
IGF-I stimulus induced some common and some dis-
tinct effects on gene expression in the two cell types
(Figure 1). This is easily explained when we consider the
differences in the distinct default gene expression pro-
files of the two cell types, including the well-known
markers for epithelial and mesenchymal cells
Figure 1 The effects of insulin-like growth factor-1 (IGF-I) on
gene expression in CCL-171 fibroblasts and MCF-7 tumour
cells. Unsupervised hierarchical clustering of genes deregulated in
CCL-171 and MCF-7 cells upon IGF-I stimulation. The gene
expression levels were normalized to the non-stimulated specimens
as described. Genes are presented in rows and experiments in
columns. The red and green colours provide information about up-
or down-regulation, respectively. The intensity of the colour renders
quantitative information about the change in expression level. IGF-I
stimulation induces some common and some distinct effects on the
gene expression profiles in different cell types. (A) Genes specifically
up-regulated in MCF-7 cells involved in: epidermal growth factor
and fibroblast growth factor signalling; protein metabolism and
modification; nucleoside, nucleotide and nucleic acid metabolism.
(B) Genes specifically up-regulated in CCL-171 cells include
transcription factors and transferases, in addition to genes involved
in Wnt and TGF-b signalling.
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(Additional file 3). The two gene clusters with discor-
dant gene expression changes (Figure 1) were examined
with the GO TermFinder tool. Genes that are up-regu-
lated in CCL-171 and down-regulated in MCF-7 cells
belong to the following ontologies: Wnt and TGF-b sig-
nalling and nucleic acid binding (transcription factors
and transferases). Genes that are up-regulated in MCF-7
and down-regulated in CCL-171 cells are involved in
protein metabolism and modification, as well as nucleo-
side, nucleotide and nucleic acid metabolism. This list
also contains genes involved in epidermal growth factor
and fibroblast growth factor signalling.
Thus, we concluded that, when epithelial and
mesenchymal cells are exposed to IGF-I, they show
some concordant and some discordant gene expression
changes. Based on these observations, and given that the
role of IGF-I in the stromal compartment is not yet well
characterized, we further focused on the IGF-I response
in stromal cells.
In order to characterize the gene expression pro-
gramme induced in fibroblasts upon IGF-I stimulation,
we extended our survey to primary breast fibroblasts.
Rinn et al. [42] reported that fibroblasts from different
body sites have unique default gene expression profiles,
which led us to believe that distinct fibroblasts may
respond differently to stimulation with IGF-I. Therefore,
we felt that it would be important to analyse primary
breast fibroblasts from breast cancer patients in order to
examine the role that these stromal cells play in breast
cancer.
After obtaining informed consent from three patients
with oestrogen and progesterone receptor positive and
HER-2/neu negative invasive ductal adenocarcinoma of
the breast, tissue specimens were obtained during breast
tumour excision. An experienced breast pathologist dis-
tinguished tumour tissue from adjacent normal tissue.
Carcinoma associated fibroblasts (CAF) and normal
fibroblasts obtained from normal breast tissue of the
same patient were cultured separately. The desired pur-
ity of the cell culture was obtained by serial passaging
and separation with magnetic beads targeting fibroblast-
specific antigens. Both cell types, CAF and normal fibro-
blasts, were stimulated with IGF-I and gene expression
profiles were observed. We confirmed that the profiled
cells were, indeed, mesenchymal fibroblasts because they
showed an elevated expression of fibroblast markers,
such as fibronectin 1 (FN1) and cadherin 2 (CDH2), and
lacked E-cadherin (CDH1) expression (Additional file 4).
The expression level of these specific markers did not
change upon IGF-I stimulation (data not shown). All of
the primary fibroblasts had a slightly higher IGF-IR
mRNA expression level (mean: 1.6-fold; standard
Table 1 Gene ontology terms for genes up-regulated in CCL-171 cells by insulin-like growth factor (IGF-I).
Gene ontology term Cluster frequency Gene frequency in background Corrected
P-value
FDR False positives
M phase 42 out of 325 genes, 12.9% 67 out of 2133 genes, 3.1% 1.84E-16 0.0% 0.0
Cell cycle phase 45 out of 325 genes, 13.8% 82 out of 2133 genes, 3.8% 1.46E-14 0.0% 0.0
Cell division 38 out of 325 genes, 11.7% 69 out of 2133 genes, 3.2% 5.07E-12 0.0% 0.0
M phase of mitotic cell cycle 32 out of 325 genes, 9.8% 52 out of 2133 genes, 2.4% 1.06E-11 0.0% 0.0
Cell cycle process 50 out of 325 genes, 15.4% 113 out of 2133 genes, 5.3% 2.13E-11 0.0% 0.0
Nuclear division 31 out of 325 genes, 9.5% 51 out of 2133 genes, 2.4% 4.65E-11 0.0% 0.0
Mitosis 31 out of 325 genes, 9.5% 51 out of 2133 genes, 2.4% 4.65E-11 0.0% 0.0
Cell cycle 57 out of 325 genes, 17.5% 143 out of 2133 genes, 6.7% 7.11E-11 0.0% 0.0
Organelle fission 31 out of 325 genes, 9.5% 52 out of 2133 genes, 2.4% 9.95E-11 0.0% 0.0
Mitotic cell cycle 39 out of 325 genes, 12.0% 86 out of 2133 genes, 4.0% 7.94E-09 0.0% 0.0
Organelle organization 67 out of 325 genes, 20.6% 217 out of 2133 genes, 10.2% 4.21E-07 0.0% 0.0
Cellular component organization 91 out of 325 genes, 28.0% 358 out of 2133 genes, 16.8% 1.78E-05 0.0% 0.0
Microtubule-based process 21 out of 325 genes, 6.5% 40 out of 2133 genes, 1.9% 2.56E-05 0.0% 0.0
Regulation of mitotic cell cycle 17 out of 325 genes, 5.2% 31 out of 2133 genes, 1.5% 2.40E-04 0.0% 0.0
Spindle organization 10 out of 325 genes, 3.1% 14 out of 2133 genes, 0.7% 2.70E-03 0.4% 0.1
Microtubule-based Movement 10 out of 325 genes, 3.1% 15 out of 2133 genes, 0.7% 0.01 0.6% 0.1
Mitotic cell cycle checkpoint 9 out of 325 genes, 2.8% 13 out of 2133 genes, 0.6% 0.01 0.6% 0.1
Regulation of cell cycle 27 out of 325 genes, 8.3% 79 out of 2133 genes, 3.7% 0.01 0.6% 0.1
Biological regulation 152 out of 325 genes, 46.8% 785 out of 2133 genes, 36.8% 0.04 0.6% 0.1
Microtubule cytoskeleton organization 12 out of 325 genes, 3.7% 24 out of 2133 genes, 1.1% 0.05 0.7% 0.1
Detailed list of gene ontology terms specifically up-regulated in CCL-171 fibroblasts upon IGF-I stimulation in comparison to background file including all genes
deregulated by IGF-I. Bonferroni corrected p values for of the output from GO::Termfinder for process ontology are listed.
FDR, false discovery rate.
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deviation: 0.24) compared to reference mRNA isolated
from a pool of 11 cell lines [38], indicating that they
might be responsive to IGF-I stimulation. The IGF-IR
mRNA expression level decreased after IGF-I stimula-
tion (mean: 0.6-fold; standard deviation: 0.09). In order
to systematically identify significant gene expression
changes upon IGF-I stimulation in primary cells, we
applied a two-class significance analysis of microarray
(SAM) data [43]. One class was formed by fibroblasts
starved in low serum medium and the other class con-
sisted of the same cells stimulated with IGF-I. SAM ana-
lysis revealed 208 gene IDs up-regulated and 300 gene
IDs significantly repressed in stimulated cells (false dis-
covery rate [FDR] ≤ 0.05%, Additional file 5). The 208
up-regulated genes were used to create the breast fibro-
blast derived IGF-I signature (Figure 2A). By comparing
the gene function with the GO Termfinder, we observed
that the genes up-regulated by IGF-I in primary breast
fibroblasts (Additional file 5) share similar features to
those up-regulated in IGF-I-stimulated CCL-171 cells
(Additional file 1), suggesting that they are involved in
the same processes (proliferation, cell cycle and mitosis
- Additional file 6, Table 2). Contrary to our expecta-
tions, we did not find any significant differences in the
response to IGF-I between CAF and normal fibroblasts.
Taken together, primary fibroblasts coming from breast
cancer and the normal breast, as well as CCL-171 fibro-
blasts, respond to IGF-I stimulation and display up-reg-
ulation of similar gene signatures involved in cell
proliferation and mitotic cell division.
In order to verify that the gene expression profile is
reflected by a phenotypic alteration upon IGF-I stimula-
tion, we examined the proliferation rate of the fibro-
blasts. The cells were seeded and starved in low serum
medium for 48 h in order to exclude any effects of fetal
bovine serum (FBS) from regular cell growth culture
conditions. The cells were then stimulated with IGF-I,
and the cell proliferation was assessed with a colouri-
metric method using WST-1. Primary breast fibroblasts
(Figure 2C), both normal and CAF, grew significantly
faster when stimulated with IGF-I rather than unstimu-
lated cells (P < 0.0001 for 24, 48 and 72 h, t-test, two-
sided; P < 0.0001, analysis of variance [ANOVA]). A
similar response to IGF-I stimulation was observed in
CCL-171 fibroblasts as presented in Figure 2B (P <
0.0001 for 24, 48 and 72 h, t-test, two-sided; P < 0.001,
ANOVA).
Taken together, these suggest that primary fibroblasts
stimulated with IGF-I induce expression of genes
involved in cell proliferation and mitotic cell division.
Relevance of the fibroblast derived IGF-I induced gene
signature in vivo
In order to verify the relevance of our in vitro experi-
ments, we checked the expression of the breast
fibroblast derived IGF-I signature in microarray data of
early stage breast cancer biopsies from 295 patients
from the Netherlands Cancer Institute (NKI), which are
publicly available [44]. In the NKI dataset, the expres-
sion of the genes belonging to breast fibroblast derived
IGF-I signature was coherent, providing a basis for seg-
regation of the tumours into two groups. In one group
the signature was up-regulated and in the other group
the signature was down-regulated (left and right side of
Figure 3A, respectively). As visualized with Kaplan-
Meier plots (Figure 3B), the patients with early stage
breast cancers with a high expression level of the breast
fibroblast derived IGF-I signature had a significantly
higher risk of developing metastasis than the patients
with a low expression level (P = 6.75e-05, 52% versus
73% after 10 years, hazard ratio (HR): 2.24, 95% confi-
dence interval [CI]: 1.5-3.4; top panel). In parallel, the
overall survival rate was significantly lower for patients
with up-regulation of the breast fibroblast derived IGF-I
signature (P = 7.96e-09, 55% versus 86% after 10 years,
HR: 4.03, CI: 2.4-6.8; middle panel). The same coordi-
nated behaviour and segregation of tumours could also
be observed in a set of advanced breast cancers from
Norway/Stanford [45,46]. In a univariate analysis,
patients with high expression levels of IGF-I induced
genes had a significantly shorter disease-specific survival
than patients with low expression levels (P = 0.0219,
HR: 2.6, CI: 1.1-6.2, data not shown). In addition, as the
classification of data based on hierarchical clustering
was suggested to be unstable and codependent on many
factors like presence of missing values [47], we validated
the results using continuous scoring and stratified the
patients of the NKI dataset based on a score derived
from the average expression level of breast fibroblast
derived IGF-I signature. In agreement with the results
obtained by hierarchical clustering, the continuous scor-
ing divided the early breast cancer patients (NKI data-
set) [44] into two groups with significantly different
outcomes (distant metastasis-free survival: P = 3.6e-07
and overall survival: P = 3.5e-09; Additional file 7).
On the molecular level, an interaction of IGF-I with the
oestrogen receptor (ER) has been described. Therefore,
we performed a multivariable analysis corrected for ER
status (positive versus negative) in the early and
advanced breast cancer datasets. The breast fibroblast
derived IGF-I signature was able to stratify breast cancer
patients into groups with significantly different out-
comes even when corrected for ER status. The results of
the multivariable analysis were significant (overall survi-
val: P = 1.6e-09, time to metastasis: P = 2.2e-4 in the
NKI dataset and disease specific survival in the Norway/
Stanford dataset P = 8.6e-5, respectively). In both data-
sets, the combination of ER negative receptor status and
up-regulation of the breast fibroblast derived IGF-I
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Table 2 Gene ontology terms for genes up-regulated in breast fibroblasts by insulin-like growth factor-1 (IGF-I).
Gene Ontology term Cluster frequency Gene frequency in
background
Corrected
P-value
FDR False
positives
M phase 36 out of 186 genes, 19.4% 175 out of 8918 genes, 2.0% 2.00E-23 0% 0.00
Cell cycle phase 37 out of 186 genes, 19.9% 223 out of 8918 genes, 2.5% 1.18E-20 0% 0.00
Cell cycle process 41 out of 186 genes, 22.0% 314 out of 8918 genes, 3.5% 4.69E-19 0% 0.00
Nuclear division 28 out of 186 genes, 15.1% 128 out of 8918 genes, 1.4% 1.64E-18 0% 0.00
Mitosis 28 out of 186 genes, 15.1% 128 out of 8918 genes, 1.4% 1.64E-18 0% 0.00
Cell cycle 46 out of 186 genes, 24.7% 425 out of 8918 genes, 4.8% 2.85E-18 0% 0.00
M phase of mitotic cell cycle 28 out of 186 genes, 15.1% 131 out of 8918 genes, 1.5% 3.21E-18 0% 0.00
Organelle fission 28 out of 186 genes, 15.1% 133 out of 8918 genes, 1.5% 4.99E-18 0% 0.00
Mitotic cell cycle 33 out of 186 genes, 17.7% 229 out of 8918 genes, 2.6% 3.30E-16 0% 0.00
Cell division 28 out of 186 genes, 15.1% 164 out of 8918 genes, 1.8% 1.88E-15 0% 0.00
Microtubule-based process 24 out of 186 genes, 12.9% 130 out of 8918 genes, 1.5% 8.42E-14 0% 0.00
Microtubule-based movement 13 out of 186 genes, 7.0% 47 out of 8918 genes, 0.5% 3.61E-09 0% 0.00
Spindle organization 10 out of 186 genes, 5.4% 27 out of 8918 genes, 0.3% 3.73E-08 0% 0.00
Cytoskeleton-dependent intracellular
transport
13 out of 186 genes, 7.0% 56 out of 8918 genes, 0.6% 4.11E-08 0% 0.00
Organelle organization 44 out of 186 genes, 23.7% 737 out of 8918 genes, 8.3% 6.24E-08 0% 0.00
Chromosome segregation 10 out of 186 genes, 5.4% 41 out of 8918 genes, 0.5% 3.83E-06 0% 0.00
Microtubule cytoskeleton organization 12 out of 186 genes, 6.5% 70 out of 8918 genes, 0.8% 8.84E-06 0% 0.00
Phosphoinositide-mediated signalling 8 out of 186 genes, 4.3% 27 out of 8918 genes, 0.3% 2.32E-05 0% 0.00
Mmitotic sister chromatid segregation 7 out of 186 genes, 3.8% 22 out of 8918 genes, 0.2% 9.41E-05 0% 0.00
Sister chromatid segregation 7 out of 186 genes, 3.8% 22 out of 8918 genes, 0.2% 9.41E-05 0% 0.00
Cellular component organization 50 out of 186 genes, 26.9% 1187 out of 8918 genes, 13.3% 3.40E-04 0% 0.00
Regulation of mitotic cell cycle 10 out of 186 genes, 5.4% 72 out of 8918 genes, 0.8% 1.03E-03 0% 0.00
Second-messenger-mediated signalling 8 out of 186 genes, 4.3% 44 out of 8918 genes, 0.5% 1.36E-03 0% 0.00
Regulation of cell cycle 16 out of 186 genes, 8.6% 197 out of 8918 genes, 2.2% 1.68E-03 0% 0.00
Cytoskeleton organization 16 out of 186 genes, 8.6% 198 out of 8918 genes, 2.2% 1.80E-03 0% 0.00
Protein polymerization 6 out of 186 genes, 3.2% 23 out of 8918 genes, 0.3% 2.63E-03 0% 0.00
Positive regulation of mitosis 4 out of 186 genes, 2.2% 7 out of 8918 genes, 0.1% 2.73E-03 0% 0.00
Amino acid biosynthetic process 6 out of 186 genes, 3.2% 25 out of 8918 genes, 0.3% 4.45E-03 0% 0.00
Chromosome localization 4 out of 186 genes, 2.2% 8 out of 8918 genes, 0.1% 0.01 0% 0.00
Establishment of chromosome localization 4 out of 186 genes, 2.2% 8 out of 8918 genes, 0.1% 0.01 0% 0.00
Cell cycle checkpoint 7 out of 186 genes, 3.8% 47 out of 8918 genes, 0.5% 0.02 0% 0.04
Establishment of localization in cell 24 out of 186 genes, 12.9% 472 out of 8918 genes, 5.3% 0.02 0% 0.04
Cellular localization 25 out of 186 genes, 13.4% 507 out of 8918 genes, 5.7% 0.03 0% 0.04
DNA metabolic process 17 out of 186 genes, 9.1% 275 out of 8918 genes, 3.1% 0.03 0% 0.06
Amine biosynthetic process 6 out of 186 genes, 3.2% 35 out of 8918 genes, 0.4% 0.03 0% 0.08
Serine family amino acid biosynthetic
process
3 out of 186 genes, 1.6% 5 out of 8918 genes, 0.1% 0.04 0% 0.08
Detailed information and P values for single biological processes up-regulated by IGF-I in primary breast fibroblasts in comparison to background file including all
genes used for significant analysis of mcroarray analysis as revealed by gene ontology term finder tool with a Bonferoni corrected P value higher than 0.05.
FDR, false discovery rate.
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signature had the worst outcome. Additionally, in early
stage breast cancer, the breast fibroblast derived IGF-I
signature was able to segregate ER positive breast cancer
patients into two groups with significantly different out-
comes (P = 1.6e-5, Figure 3B, lowest panel). In sum-
mary, we found that genes induced in primary breast
fibroblasts upon IGF-I stimulation predict the outcome
of breast cancer patients. Furthermore, the expression
signature distinguishes between patients with ER posi-
tive cancer who have significantly different prognoses.
Correlation of the IGF-I induced gene signature with
previously published prognostic gene expression
signatures
As the breast fibroblast derived IGF-I signature is a
prognostic marker in human breast cancer, we next
sought to see if the signature might be related to other
previously published gene-expression signatures, which
were useful prognosticators in the NKI dataset. To this
aim, we correlated the signatures based on their cen-
troids, which represent the average expression values of
all genes building the signature in a single tumour speci-
men, using the Pearson correlation test. First, we
checked the correlation of the breast fibroblast derived
IGF-I signature centroid to the wound signature cen-
troid [48], which was created based on the response of
fibroblasts to serum stimulation. The breast fibroblast
derived IGF-I signature, as presented in Figure 4, was
highly correlated to the wound signature (0.76). It was
also moderately correlated (0.69) to basal type breast
cancer [46]. Furthermore, the breast fibroblast derived
IGF-I signature was highly reverse-correlated to the
good-risk 70-genes signature (-0.74) [49]. The good-
risk70-genes signature was created n order to predict
freedom from metastasis in this same dataset. The
Figure 2 Effects of insulin-like growth-1 (IGF-I) stimulation on primary breast fibroblasts and CCL-171 fibroblasts. (A) Unsupervised
hierarchical clustering of genes differentially expressed in fibroblasts upon IGF-stimulation. Unsupervised hierarchical clustering of genes
differentially expressed between IGF-I stimulated and non-stimulated primary breast fibroblasts as discovered by SAM (genes with a false
discovery rate ≤ 0.05% are represented). Grey fields indicate missing expression values. The colour of dendrogram branches renders information
about sample stimulation; yellow = not stimulated and blue = stimulated with IGF-I (50 ng/mL). (B) IGF-I induced proliferation of CCL-171 cells.
Cell proliferation assay based on absorbance measurement of WST-1. Formazan absorbance correlates to the cell number. Average absolute
absorbance of replicates of CCL-171 cells stimulated with 50 ng/mL IGF-I in comparison to non-stimulated cells at different time points. Points
represent the average of six replicates per condition and correspond to the cell number. The vertical error bars denote the standard deviation.
Stimulation of CCL-171 cells with IGF-I induces significant, constant cell growth after 24, 48 and 72 h. (C) IGF-I induced proliferation of primary
breast fibroblasts. Cell proliferation assay based on absorbance measurement of WST-1. Points represent the average absolute absorbance of a
minimum of eight replicates of six primary fibroblasts (carcinoma associated fibroblasts and normal fibroblasts) after 24, 48 and 72 h. Error bars
correspond to the magnitude of the standard deviation. Stimulation of primary breast fibroblasts with IGF-I induces significant, constant cell
growth.
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detailed list of correlation values for all of the signatures
may be found in Additional file 8.
IGF induced genes are prognostic in lung cancer
Knowing that the gene expression signature derived
from primary breast fibroblasts in response to IGF-I sti-
mulation is relevant in vivo, and is a strong prognostic
factor in human breast cancer, we investigated this find-
ing to see if it could be generalized to other types of
human cancer. We felt that this was likely because of
the similarity between the IGF-I responses of primary
breast fibroblasts and CCL-171 lung fibroblasts. We
decided to check our hypothesis using the IGF-I derived
signature from CCL-171 in vitro in lung cancer datasets.
Global gene expression profiles of 67 human lung can-
cers were derived from 56 patients; 24 had survival data
published by Garber et al. [50] (GEO: GSE3398). As
shown in Figure 5A, in this dataset the expression of
the lung fibroblast derived IGF-I gene signature was
clear, even though the expression data for many genes
was missing. This provided a basis for segregation of the
tumours into two groups. The two groups were described
as having the core part (proliferation associated genes) of
the signature up-regulated or down-regulated (left and
right side of Figure 5A, respectively). As visualized by
Kaplan-Meier plots (Figure 5B), the patients with high
expression levels of IGF-I induced genes had a signifi-
cantly shorter overall survival (P = 0.008; n = 24, 60% ver-
sus 0% after 2 years, HR: 7.74, CI: 1.9-31.6). Thus, we
concluded that the lung fibroblast derived IGF-I signature
is a prognostic marker in lung cancer.
We then decided to validate our findings in a larger
and better-annotated dataset published by Bhattacharjee
[51], which contains microarray profiles of 203 tumours
with clinical annotation for 125 of them. In line with
our hypothesis, the expression of the lung fibroblast
derived IGF-I signature was coherent, providing a basis
Figure 3 Breast fibroblast derived IGF-I signature in early stage breast cancer. (A) Unsupervised hierarchical clustering of breast fibroblast
derived IGF-I signature in Netherlands Cancer institute dataset. The expression values of genes in the breast fibroblast derived IGF-I signature
revealed by signficant analysis of microarray were extracted from a published expression study of 295 early stage breast cancers from the
Netherlands Cancer Institute (NKI). Genes are presented in rows and experiments in columns. Breast fibroblast derived IGF-I signature stratifies
early breast cancer patients (NKI) into two groups with high (blue) or low (yellow) expression levels of genes representing the signature.
Horizontal bar below the figure represents positive (purple) or negative (orange) ER status. (B) Relationship of expression level of genes building
breast fibroblast derived IGF-I signature with distant metastasis free and overall survival. Kaplan-Meier curves representing the clinical outcomes
of tumors exhibiting high (blue curve) and low (yellow curve) expression levels of the IGF-I induced signature. The upper two figures represent
all patients and the bottom figure shows only patients with oestrogen receptor positive breast tumours.
Rajski et al. BMC Medicine 2010, 8:1
http://www.biomedcentral.com/1741-7015/8/1
Page 8 of 18
59
for segregation of the tumours into two groups. The
patients with a high expression level of the signature
(right side of Figure 5C) had a significantly shorter dis-
ease-free survival (P = 0.001; 45% versus 82% after 5
years, HR: 3.7, CI: 1.5-9.4) and overall survival (P =
0.007; 38% versus 66% after 5 years, HR: 2.1, CI: 1.2-3.8)
than the patients with low expression of the signature
(left side of Figure 5C). Both Kaplan-Meier curves are
shown in Figure 5D.
Taken together, these findings indicate that genes
induced by IGF-I in human lung fibroblasts are helpful
in predicting outcomes in human lung cancer. As the
signature derived from breast and lung fibroblasts upon
IGF-I stimulation is a prognostic marker for lung can-
cer, we suggest that the response of stromal fibroblasts
to IGF-I might be a universal feature of cancer.
In order to further validate the general effect of IGF-I
on fibroblasts, the ability of the breast and the lung
Figure 4 Correlation of the breast fibroblast derived insulin-like growth factor-I (IGF-I) signature with previously reported
prognosticators in breast cancer. Correlation of the good-risk 70-genes signature centroid [49], the wound signature centroid [60], the basal
type of breast cancer created by Soerlie [46] and the breast fibroblast IGF-I induced signature score in the Netherlands Cancer Institute dataset.
Pairwise scatterplot-matrix of four gene signatures. Pearson correlations for the signature are shown in the corners of the plots.
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fibroblast derived IGF-I signatures to be a prognostic
factor in a non-site matching dataset was crosschecked.
The breast fibroblast derived IGF-I signature was able to
stratify patients with lung cancer (Bhattacharjee dataset)
into two groups with significantly different rates of sur-
vival (overall survival with P = 0.043 and disease free
survival with P = 0.022, data not shown). Also in this
dataset, we validated the results obtained by hierarchical
clustering using a continuous score and found a
significant correlation (overall survival P = 0.005 and
disease specific survival P = 0.001; Additional file 9).
The lung fibroblast derived IGF-I signature was also
able to arrange breast carcinoma patients from the NKI
dataset into two groups with significantly different times
for metastasis free survival and overall survival (P =
7.9e-9 and P = 9.8e-6, respectively, data not shown).
N order to further cross validate the IGF-I signatures
derived from fibroblasts of different origins, the
Figure 5 Fibroblast derived insulin-like growth factor-I (IGF-I) signature divides lung cancer patients into two groups with significantly
different outcome. (A) Unsupervised hierarchical clustering of fibroblast derived IGF-I signature in Garber lung cancer dataset. The expression
values of genes in the fibroblast derived IGF-I signature were extracted from a published expression study by Garber [50]. Genes are presented
as rows and the experiments are presented as columns. Although some gene expression data are missing, the fibroblast derived IGF-I signature
stratifies lung cancer patients into two groups with high (blue) or low (yellow) expression levels of genes representing the signature. (B)
Relationship of expression level of genes building fibroblast derived IGF-I signature with overall survival in Garber data. Kaplan-Meier curves
denoting the clinical outcomes of the indicated tumours exhibiting high (blue curve) and low (yellow curve) expression levels of the signature.
(C) Unsupervised hierarchical clustering of fibroblast derived IGF-I signature in Bhattacharjee lung cancer dataset. The expression values of genes
in the fibroblast derived IGF-I signature were extracted from a published expression study by Bhattacharjee [51]. Genes are presented as rows
and the experiments are presented as columns. Fibroblast derived IGF-I signature stratifies adenocarcinoma patients into two groups with high
(blue) or low (yellow) expression levels of genes representing the signature. (D) Relationship of expression level of genes building fibroblast
derived IGF-I signature with overall survival and disease specific survival in Bhattacharjee dataset. Kaplan-Meier curves illustrating the clinical
outcomes of the indicated tumours exhibiting high (blue curve) and low (yellow curve) expression levels of the signature.
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correlation of the centroids for the signature obtained
from lung fibroblasts were correlated to the signature
derived from human primary breast fibroblasts (0.77; P -
value < 2.2e-16, Additional file 10) in the NKI breast
cancer dataset. The strong and significant correlation
supports their similarity.
Discussion
IGF-I has multiple effects on tumour initiation, develop-
ment and progression and its effects on the cancer cells
have been well described [13]. However, solid tumours
do not consist only of malignant epithelial cells; rather,
they form organ-like structures with a stroma consisting
of fibroblasts, inflammatory cells and endothelial cells.
Therefore, an endocrine or paracrine stimulus such as
IGF-I might influence both the tumour cells and the
stromal cells. The goal of this study was to characterize
the effects of IGF-I on the cancer cells and the stromal
fibroblasts in parallel. On the molecular level, cancer
cells and fibroblasts show distinct response patterns to
stimulation with IGF-I (Figure 1), including differential
expression of genes involved in proliferation, protein
metabolism and Wnt and TGF-b signalling. Focusing on
the effect of IGF-I on MCF-7 cells, we observed altera-
tions in protein metabolism. Similar changes in protein
metabolism, including up-regulation of genes involved
in transport and biosynthesis of amino acids, had
already been reported previously in a global gene
expression study of MCF-7 cells endogenously over-
expressing IGF-I [52]. Additionally, we noted an up-reg-
ulation of VEGF in MCF-7 cells treated with IGF-I.
VEGF is a known target gene for IGF signalling [52],
with well-described implications in tumour progression
and dissemination. Similar to our results, up-regulation
of genes involved in metabolism and biosynthesis have
been described in a comparable system of MCF-7 cells
stimulated with exogenous IGF-I [53]. Apart from the
similarities to the study by Creighton et al. [53], we also
found discrepancies in the gene expression profile of
proliferation-associated genes. The main reason might
be because of the gene-wise standardization of the unsti-
mulated samples applied in our setup which eliminated
the inherent pattern of proliferation in MCF-7 cells.
With a focus on the stroma, there are studies showing
that human dermal fibroblasts [35] and IMR90 fibro-
blasts [34] respond to IGF-I stimulation. Furthermore, it
has been shown that primary breast fibroblasts over-
express IGF-I and IGF-II (normal and malignant derived
fibroblasts, respectively) [31,54] but none of these stu-
dies focused on the effects of IGF-I signalling on global
gene expression. There was only one small study with
first generation microarrays profiling the global gene
expression effects of IGF-I stimulation in NIH-3T3
mouse fibroblasts, which showed an up-regulation of
proliferation-associated genes [55]. To the best of our
knowledge, we are the first to show microarray gene
expression profiles of primary human breast fibroblasts
in response to IGF-I. The gene expression changes
induced by IGF-I in fibroblasts contained several soluble
factors, such as POSTN, which was reported to be
involved in bone metastasis formation and angiogenesis
[56,57], TNC, which enhances tumour cell proliferation
[58], as well as LOXL1, a member of lysyl oxidase
family, similar to LOXL2, that might act on or in the
vicinity of epithelial cells during tissue remodelling.
LOXL2 has previously been reported to be involved in
an invasiveness process [59] and specifically expressed
by fibroblasts in tumour tissue [60]. The presence of
these factors indicates that the IGF-I activated stroma
enhances proliferation and the metastatic potential of
the cancer cells.
That one single stimulus has both common and dis-
tinct effects on cells of different origins has been shown
previously on the global gene expression scale for the
response to oxygen deprivation under hypoxic condi-
tions [61]. To the best of our knowledge, our experi-
ments are the first to make a direct comparison of the
effects of IGF-I on different cell types. Most interest-
ingly, among the genes that were upregulated only in
CCL-171 cells, and not in MCF-7 cells on IGF-I stimu-
lation, did we observe many transcription factors
(FUBP3, TEAD2, KLF16, SP3 and PIK3R3 involved in
insulin receptor signalling pathway, MKNK2, SH3BP2
and CIT) all taking part in cell surface receptor linked
signal transduction. Stromal cell specific genes among
the IGF-I induced genes were of interest when we corre-
lated this signature with in vivo data derived from whole
tissue biopsies consisting of cancer cells and stromal
cells. Signatures obtained from fibroblasts upon serum
stimulation [60], as well as growth factor derived signa-
tures, such as a TGF-b gene expression signature in
mouse hepatocytes [62], are well-described prognostica-
tors in human breast cancer. In our study, we confirmed
the validity and robustness of IGF-I derived signatures
from primary breast and lung fibroblasts in four differ-
ent human solid cancer datasets. Genes induced in pri-
mary breast fibroblasts upon IGF-I stimulation are
predictive of outcome in breast cancer patients. N addi-
tion, the signature allows for the stratification of ER
positive breast cancer patients into two groups with sig-
nificantly different prognoses. Prognostication in this
heterogeneous patient population is important for clini-
cal decisions about adjuvant therapies in patients with
ER positive breast cancer.
The ability to derive prognostic information from can-
cer stroma has already been shown by Finak et al. [63].
The gene expression signature of stromal cells obtained
by laser capture microdissection (LCM), the stroma
Rajski et al. BMC Medicine 2010, 8:1
http://www.biomedcentral.com/1741-7015/8/1
Page 11 of 18
62
derived prognostic predictor (SDPP), has been shown to
be a prognostic marker in breast cancer. However, Finak
et al. did not separate the different stromal components
and, therefore, could not associate this signature to a
specific cell type. In our study, we were able to specifi-
cally observe the effects of IGF-I on fibroblasts, which
might be advantageous as targeted therapies are
designed to specifically inhibit a signal at a particular
cell type. Using laser capture microdissection, Roepman
et al. managed to show that the genes expressed in the
stroma are highly correlated with metastasis formation
[64]. Specifically, they showed that 12% of the genes
associated with lymph node metastasis in head-neck
squamous cell carcinoma (HNSCC) are predominantly
expressed in the stroma, 25% are tumour cell specific
and the other genes are equally expressed in the tumour
and the stroma. We speculate that the involvement of
stroma-derived information might also be of importance
in breast and in lung cancer. In our signatures, we
found several of the genes that have been identified by
Roepman et al. as being predominantly expressed in the
stroma (ACTA1, TPM2, CDH2, COL5A1, COL5A2,
HNRPL, TCF3). These segregated the patients into two
groups with significantly different prognosis.
The IGF-I induced signatures in primary breast and in
lung fibroblasts are similar to each other (Additional file
10) and to important, previously published signatures
(Figure 4). The high reverse correlation of the IGF-I sig-
nature and the good-risk 70-genes signature supports
the power of the IGF-I derived signature as a negative
prognosticator in breast cancer. While the ‘good-risk
70-genes signature’ [49] was developed to predict free-
dom from metastasis in a top-down manner and vali-
dated in the same dataset of breast cancer patients from
the NKI, the IGF-I induced signature is a marker for
poor prognosis and is well connected to a defined in
vitro biological system.
The IGF-I induced signature is also highly correlated
to the wound signature [60], another strong prognostic
signature in NKI dataset outperforming all known prog-
nostic parameters so far. This is interesting, since a sin-
gle growth factor, such as IGF-I, is able to induce a
gene expression programme similar to the mix of unde-
fined factors inherent in FBS. Using a fully defined sti-
mulus in a concentration within the physiological range
provides a simple and well-controlled in vitro model
that enables specific experimental interventions to be
made. Its effects can then be tested in vivo. Considering
the notion by Sotirou [65] that proliferation is a main
driver of the strong prognostic signatures such as the
good-risk 70-genes signature and the wound signature
facilitates speculation that IGF-I is one of the important
factors responsible for the induction of proliferation.
This does not exclude other, equally or more important,
growth factors from inducing proliferation and up-regu-
lation of proliferation associated genes.
We observed that both IGF-I signatures derived from
lung and breast fibroblasts are exchangeable prognostic
factors for the other cancer type, which allowed us to
speculate that we could generalize this finding to other
types of human solid cancer. The consistent response of
fibroblasts (our data and [34,35,55]) to IGF-I might also
help to explain the worse outcome of patients with ele-
vated IGF-I levels in different cancer types [4-8], a find-
ing that is not necessarily explained by the cancer cells
themselves based on their IGF-receptor expression sta-
tus on the cell surface. Specifically, since the correlation
of the IGF-IR expression and patient outcome in human
breast cancer is conflicting [66], the IGF-I induced gene
expression signature showing the functional effects of
IGF-I axis stimulation, which is correlated with the
patients’ clinical outcome, might be of interest when
selecting patients who might benefit best from IGF-I
blocking therapies.
IGF-I signalling is an emerging cancer drug target. In
vivo, in mouse models, confirms that block IGF-I signal-
ling demonstrate efficacy in inducing tumour regression
and growth arrest [29] and sensitized cancer cells to
conventional chemotherapeutic treatment and irradia-
tion [67]. Exogenously added IGF binding protein I
(IGFBP-1) inhibits IGF-I mediated growth of breast can-
cer cells [68,69]. Many other inhibitors of IGF signalling,
applying different approaches [67], are currently under
clinical investigation in phase I and II trials (reviewed in
[29,70]). Some have already shown promising results,
such as the phase II study on CP- 751, 851. This anti-
insulin-like growth factor I receptor antibody, together
with paclitaxel and carboplatin, was suggested to be safe
and showed promising effectiveness in patients with
non-small-cell lung cancer (NSCLC) showing the high-
est overall response rate of 78% in squamous cell carci-
noma and 58% in adenocarcinomas [71]. Besides the
monoclonal antibodies, there are small molecule inhibi-
tors, such as XL228, that have blocking activity in the
IGF1-R pathway and also in Src, fibroblast growth factor
receptors (FGFR) and BCR-Abl pathways [72]. Although
compounds that block IGF-I signalling demonstrate effi-
cacy in inducing tumour regression and growth arrest in
vivo, there is an emerging need to develop markers that
predict a response to these therapies. We have tested
the prognostic significance of our signature in patients
with adenocarcinomas. In this group of patients, show-
ing the lower response rate to IGF-I targeting therapies
than squamous cell carcinomas [71], a better selection
using a marker with predictive power would be espe-
cially beneficial. It might, therefore, be worthwhile to
test whether or not the gene expression signatures
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developed and described here are useful predictive mar-
kers for IGF-I signalling blockade.
Conclusions
The consistent and similar gene expression changes in
human primary breast and lung fibroblasts suggest that
the proliferative response to IGF-I is a general feature of
stromal fibroblasts. Expression patterns of genes induced
by IGF-I in primary breast and lung fibroblasts accu-
rately predict outcomes in breast and in lung cancer
patients. As IGF-I signalling is an emerging cancer drug
target there is an emerging need to develop markers
that predict a response to these therapies. Our IGF-I
induced gene signatures derived from stromal fibroblasts
might be promising predictors for the response to IGF-I
targeted therapies.
Methods
Cell culture
Human primary fibroblasts CCL-171 and the human
breast cancer cell line MCF-7 were obtained from
American Type Culture Collection (ATTC, Atlanta,
USA). Cells were propagated in Dulbecco’s modified
Eagle’s medium (D-MEM, Invitrogen, Carlsbad, USA)
supplemented with 10% heat inactivated FBS (Invitro-
gen), 4.5 g/lglucose, 4 mM L-glutamine and 100 U/ml
penicillin and 100 μg/ml streptomycin (Gibco, Carlsbad,
USA). Cells were maintained by regular passages when
confluent. The study was approved by the Ethikkommis-
sion beider Basel, Switzerland (approval No. 271/05).
Tumour and healthy tissue were obtained with consent
from the patients who underwent surgery in University
Hospital of Basel. For each patient, a sample of malig-
nant tissue and a sample of side-matched healthy tissue
were extracted by an experienced pathologist. The tissue
was digested in a collagenase and RNase mix for 1 h
and pressed through a 230 μm pore diameter sieve
(Sigma Aldrich, St Louis, USA). The cells were cultured
in a 1:1 v/v mixture of RPMI 1640 (Sigma Aldrich) and
F12 Hamm (Gibco) medium supplemented with 12.5%
FBS (Invitrogen), 2 mM Puryvat (Gibco), 4 mM L-gluta-
min (Gibco), 1 × Minimal Non-Essential Amino Acids
(Gibco), 1 × RPMI 1640 Vitamins Solution (Sigma
Aldrich), 100 U/ml penicillin and 100 μg/ml streptomy-
cin (Gibco) and propagated until confluent. At this
stage, cells were selected with anti-Fibroblast MicroBe-
ads (Miltenyi Biotec, Gladbach, Germany) according to
the manufacturer’s instructions. All cells used in the
experiments were kept in culture up to a maximum of
10 passages.
IGF-I stimulation
For the experiment, 30,000 cells/cm2 were seeded in 3
mL of 5% FBS D-MEM for CCL-171 cells and 5% FBS
RPMI 1640/F12 mix for primary cells for 6 h, so that
they would attach. The cells were extensively washed
with phosphate buffered saline and starved for 48 h in
fresh low-serum medium (0.2% FBS), D-MEM and
RPMI 1640/F12 mix for CCL-171 and primary cells,
respectively. The cells were starved n order to reduce
the effects of any stimulation from regular cell culture
medium. The medium was subsequently replaced by
fresh low-serum D-MEM with or without 50 ng/ml of
IGF-I (human recombinant in Escherichia coli; Sigma
Aldrich). The cells were stimulated for 24 h and the
RNA was harvested to test the effects of IGF-I on
mRNA expression patterns.
WST-1 proliferation assay
The proliferation reagent (Roche Diagnostics GmbH,
Roche Applied Science, Basel, Switzerland) was used
according to the manufacturer’s instructions. In our
setup, cells were plated in 96 well plates and starved for
48 h in low serum conditions. After, the cells were incu-
bated in low-serum D-MEM with 50 ng/ml IGF-I over
24 h. n order to determine the cell numbers, the cells
were stained with 10% WST-1 in low-serum D-MEM at
37°C, 5%CO2 for 2 h. The absorbance was measured
with an ELISA reader at a wavelength of 450 nm. The
proliferation rate of IGF-I stimulated primary breast
fibroblasts and CCL-171 cells was compared to a respec-
tive reference samples not stimulated with IGF-I.
RNA extraction and amplification
After aspirating the culture medium, the cell monolayer
was washed once with phosphate buffered saline. The
cells were lysed in a buffer containing guanidine isothio-
cyanate (RLT buffer, QIAGEN, CA, USA). The total
RNA was extracted with the RNeasy kit (QIAGEN, CA,
USA) according to the manufacturer’s instructions. The
RNA concentration was measured with a NanoDrop sys-
tem spectrophotometer (ND-1000 Spectrophotometer
Technologies, Wilmington, USA). The integrity of
extracted RNA was checked by electrophoresis in a 1%
agarose gel in MOPS buffer. For mRNA amplification,
the Amino Allyl MasageAmp™ II aRNA Amplification
Kit was used (Ambion, TX, USA). Amplification of
mRNA out of 500 ng total RNA, the purification of
cDNA, the in vitro transcription and the purification of
aRNA were performed according to the manufacturer’s
instructions. Integrity and quantity of the amplified
RNA was verified as described above.
Gene expression analysis using HEEBO microarrays
For global gene expression analysis, we used HEEBO.
The HEEBO microarrays consist of 44,544 70mer
probes, which include: (a) constitutive exonic probes
(30,718); (b) alternatively spliced/skipped exonic probes
(8,441); (c) non-coding RNA probes (196); (d) BCR/TCR
genic/regional probes (372); (e) other probes (843); and
(f) controls. HEEBO microarrays were produced at the
Stanford Functional Genomic Facility (Stanford, USA).
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Complete details regarding the clones on the arrays may
be found at Stanford functional genomics facility website
[73]. For microarray experiments, 8 μg amplified RNA
(aRNA) were mixed with doping controls. Samples were
vacuum dried, resolved in coupling buffer and labelled
with Cy5 dye. Labelled samples were pooled with equal
amounts of reverse coloured Cy3 labelled amplified
reference RNA from Stratagene (Stratagene, CA, USA).
The labelled aRNA was purified with AminoAllyl Masa-
geAmp™ II aRNA Amplification Kit (Ambion) according
tothe user manual and fragmented using fragmentation
reagents (Ambion). The fragmented probe was added to
a hybridization buffer containing Cot/PolyA/tRNA (0.05
μg/uL each), 0.3% SDS, 3.3 × SSC and supplemented
with HEPES buffer. Following a denaturing step at 100°
C, the probe was placed on the microarray for competi-
tive hybridization. After 18 h, slides with hybridized
probes were sequentially washed and immediately dried
in an ozone free environment and scanned using an
Axon Scanner 4100A (Axon Instruments, CA, USA).
The gene expression profiles of primary fibroblasts,
together with accompanying clinical data are available
on SMD database papers’ webpage [39]. In addition, the
raw data have been deposited in NCBI’s Gene Expres-
sion Omnibus [74] and are accessible through GEO Ser-
ies accession number GSE18955 http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE18955.
Data analysis and clustering
Microarray fluorescent image analysis was performed
using the software Genepix Pro version 5.0 3.0.6.89
(Axon Instruments). Spots with obvious array artifacts
or poor technical quality were manually removed from
any further analysis. Raw data files were stored in the
Stanford Microarray Database [39]. The data used for
the paper are available at the accompanying website at
Stanford Microarray Database [39]. Data were expressed
as the log2 ratio of fluorescence intensities of the sample
and the reference for each element on the array. A
sequential data filtering procedure was applied to
include only measurements fulfilling our quality require-
ments (data with regression correlation bigger than 0.6
and Cy3 channel or Cy5 channel mean intensity over
median background intensity bigger than 1.5). Genes
that did not meet these criteria for at least 60% of the
measurements across the experimental samples were
excluded from further analysis. We rejected elements
that did not have at least a 1.5-fold deviation from the
mean in at least two samples. Data were evaluated by
unsupervised hierarchical clustering [75] and displayed
using Treeview software [41]. For the stimulation
experiments, in order to emphasize the effect of IGF-I
treatment, the results for each gene were standardized
for each gene individually to the non-treated samples. In
order to standardize them, we subtracted an average
value of non-treated samples from each gene expression
value for each cell type separately. This was performed
in order to highlight those genes whose expression level
changed upon treatment. Extraction of fibroblast gene
signature and differentially expressed clusters was based
on the correlation within the cluster nodes and, there-
fore, not randomly selected or based on an arbitrary
cut- off.
In order to compare the gene expression profile of
CCL-171 and MCF-7 cells in response to IGF-I, we
merged the filtered, standardized gene expression pro-
files of both cell lines. We then manually excluded sam-
ples with a high standard deviation between the
biological replicates and those missing gene expression
data. Gene expression data for different clones repre-
senting one gene were averaged. A set of 566 unique
genes was hierarchically clustered in an unsupervised
manner [75] and displayed using Treeview software [41].
SAM
For primary fibroblasts, two-class SAM was applied [43].
One class was formed by normal and carcinoma asso-
ciated fibroblasts starved in low serum medium and the
other by the same cells treated with IGF-I. In order to
increase the sensitivity, we paired our samples.
Human cancer datasets
A dataset containing gene expression patterns from
advanced breast cancers was previously described by
Sorlie et al. as Norway/Stanford dataset [45,46]. Expres-
sion measurements for each gene and array were mean
centred. The list of 208 unique genes building breast
fibroblast derived IGF-I signature was extracted from
the Norway/Stanford dataset. In order to overcome pos-
sible overweighting of clones from Unigene clusters that
were matched to more than one probe on the Sorlie
array, expression values derived from probes matched to
the same Unigene cluster were averaged. Only genes
that had >80% data values present and tumour samples
from patients having complete clinical data were used.
The resulting dataset was subjected to average linkage
hierarchical clustering [75] and displayed with Treeview
[41].
Disease specific survival analysis was based on death
from the disease and patients were censored at the last
follow up. Patients who died from other causes were
considered alive and not censored. Kaplan-Meier survi-
val curves were compared using R package survival fit-
ting a Cox proportional hazards regression model [76].
The dataset for early stage breast cancer contained
295 breast cancer specimens analysed on a 25,000 spot
oligonucleotide array, as described previously [44]. In
brief, patients were diagnosed and treated at the Nether-
lands Cancer Institute (NKI) for early stage breast can-
cer (stage I and II) between 1984 and 1995. The clinical
data was updated in January 2005. The median follow-
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up for patients still alive is 12.3 years. Expression data
from the NKI dataset were extracted as described above
for the Norway/Stanford dataset. Distant metastases
were analysed as a first event only (distant metastasis-
free probability). Any patient who developed a local
recurrence, axillary recurrence, contralateral breast can-
cer or a second primary cancer (except for non-mela-
noma skin cancer), was censored at that time and
subsequent distant metastases were not analysed. This is
based on the theoretical possibility that the locally
recurrent or second primary cancers could be a source
for distant metastases. An ipsilateral supra-clavicular
recurrence was soon followed by a distant metastasis in
all but one patient. Thus, an ipsilateral supra-clavicular
recurrence was considered the first clinical evidence for
metastatic disease for this analysis and patients were not
censored at the time of ipsilateral supra-clavicular recur-
rence. Overall survival was analysed based on death
from any cause and patients were censored at last follow
up. Kaplan-Meier survival curves were fitted using a Cox
proportional hazards regression model (R survival pack-
age) [76].
The dataset published by Garber and colleagues [50]
contains global gene expression profiles for 67 human
lung cancers derived from 56 patients with survival data
for 24 patients. The dataset published by Bhattacharjee
[51] contains mRNA expression levels of 12,600 tran-
script sequences in 186 lung tumor samples, including
139 adenocarcinomas resected from the lung. Of these,
125 samples were associated with clinical data (some
patients in multiple runs). The Bhattacharjee dataset
was obtained from the Broad Institute website [77] and
Garber dataset from SMD publication webpage [39].
The list of 370 unique genes building fibroblast derived
IGF-I signature was extracted from the Garber and Bha-
tacharjee datasets as described above for breast cancer
datasets. Equally, the resulting dataset was subjected to
average linkage hierarchical clustering [75] and displayed
with Treeview [41]. Overall survival was analysed based
on death from any cause and patients were censored at
last follow up. Disease specific survival analysis was
based on death from the disease and patients were cen-
sored at last follow up. Patients who died from other
causes were considered alive and not censored. Kaplan-
Meier survival curves were fitted using a Cox propor-
tional hazards regression model (R package ‘survival’)
[76].
Centroid correlation
The method of calculating the centroid for each patient
was previously described by Sorlie [45]. Briefly, the cen-
troids for genes representing breast fibroblast derived
IGF-I signature and fibroblast derived IGF-I signature,
as well as other signatures, were calculated based on the
NKI dataset. To test for similarities between the
signatures, we checked the correlation between values of
different centroids for one patient. The correlation was
calculated using Pearson correlation coefficient with R
software [76].
Continuous scoring
The stratification of patients within the NKI and Bhatta-
charjee datasets was conducted according to the pre-
viously described methodology [60,61] based on a
continuous score derived from the signatures. Briefly,
the average expression level of each signature was calcu-
lated for each patient attributing a score. The patients
were then divided into two groups separating them by
the median value of the continuous scores. Kaplan-
Meier survival curves for the two groups were plotted
and the statistical significance was determined using a
Cox proportional hazards model (R package ‘survival’)
[76].
GO::TermFinder analysis
GO::TermFinder takes a list of genes as input, and
determines whether those genes have any gene ontology
(GO) terms overrepresented in their combined set of
annotations compared to what would be expected by
chance from a randomly selected group of genes from
the background population of all genes [39,40]. In our
analysis, we used the full gene lists from parental heat
maps as a file to calculate the frequency of particular
annotations in a background file and the gene lists from
specific clusters coming from same heat map to calcu-
late the frequency of particular annotations in the
defined cluster. For a SAM-derived signature, we used a
gene list that was an input file for SAM analysis.
General statistic methods
Normally distributed data were compared using a Stu-
dent’s t-test. When the multiple comparisons were
necessary, the data were analysed with ANOVA. Differ-
ences were considered as statistically significant when P
< 0.05. T-tests and ANOVA analysis were done using R
software (R package ‘stats’) [76].
Additional file 1: Table S1. List of genes building the fibroblast derived
insulin-like growth factor-1 (IGF-I) signature.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S1.PDF ]
Additional file 2: Figure S2. Graphical visualization of the output from
GO::Termfinder for biological process ontology. GOgraph layout that
includes the significant GO nodes up-regulated in CCL-171 cells, derived
from 325 clones compared to a background of 2133 clones. The colour
of the nodes is an indication of their Bonferroni corrected P-value
(orange <= 1e-10; yellow 1e-10 to 1e-8; green 1e-8 to 1e-6; cyan 1e-6 to
1e-4; blue 1e-4 to 1e-2; tan > 0.01).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S2.TIFF ]
Additional file 3: Figure S1. Distinct default gene expression profiles of
human lung fibroblasts and breast tumour cells. Genes are presented in
rows and experiments in columns. Both cell types demonstrate a clearly
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distinct default gene expression profile, typical for epithelial and
mesenchymal cells. Gene markers typical for mesenchymal (FN1, CDH2,
VIM) and epithelial/tumour cells (CDH1, TPD52, BMP-7) are marked.
Additionally, examples of proliferation associated genes up-regulated in
MCF-7 cells by default are shown.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S3.TIFF ]
Additional file 4: Figure S3. Box-and-whisker plot illustrating the
average expression level of fibronectin (FN1), N-cadherin (CDH2) and E-
cadherin (CDH1) in primary fibroblasts. Insulin-like growth factor (IGF-I)
does not affect the expression level of mesenchymal and epithelial
markers in primary breast fibroblasts (data not shown).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S4.TIFF ]
Additional file 5: Table S2. List of genes up-regulated (the breast
fibroblast derived insulin-like growth factor-1 [IGF-I] signature) and down-
regulated in primary breast fibroblasts upon IGF-I stimulation.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S5.PDF ]
Additional file 6: Figure S4. Graphical visualization of the output from
GO::Termfinder for biological process ontology. GOgraph layout that
includes the significant GO nodes up-regulated in primary breast
fibroblasts, derived from 186 clones compared to a background of 8918
clones. The colour of the nodes is an indication of their Bonferroni
corrected P-value (orange <= 1e-10; yellow 1e-10 to 1e-8; green 1e-8 to
1e-6; cyan 1e-6 to 1e-4; blue 1e-4 to 1e-2; tan > 0.01).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S6.TIFF ]
Additional file 7: Figure S6. Relationship of expression level of breast
fibroblast derived insulin-like growth factor-1 (IGF-I) signature with distant
metastasis free and overall survival applying continuous scoring. A.
Continuous score based on average expression level of the signature in
Netherlands Cancer Institute (NKI) patients. Colours correspond to score
below (yellow) or above (blue) the median (red line). Overall (B) and
metastasis free survival (C) analysis using a continuous score resulting
from breast fibroblast derived IGF-I signature in early stage breast cancer
patients from the NKI.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S7.PDF ]
Additional file 8: Table S3. The detailed list of correlation values of
breast fibroblast derived insulin-like growth factor-1 (IGF-I) signature to
the previously published signatures and fibroblast derived IGF-I signature.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S8.PDF ]
Additional file 9: Figure S7. Relationship of expression level of breast
fibroblast derived insulin-like growth factor-1 (IGF-I) signature with overall
survival and disease specific survival applying continuous scoring. A.
Continuous score based on average expression level of the signature in
Bhattacharjee dataset patients. Colours correspond to score below
(yellow) or above (blue) the median (red line). Overall (B) and disease
specific survival (C) analysis using a continuous score resulting from
breast fibroblast derived IGF-I signature in Bhattacharjee dataset patients.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S9.PDF ]
Additional file 10: Figure S5. Correlation of the fibroblast derived
insulin-like growth factor-1 (IGF-I) signature and the breast fibroblast IGF-I
induced signature centroids in the Netherlands Cancer Institute dataset.
Pearson correlations for the signature and the P value are shown in the
lower right part of the plot.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1741-7015-8-1-
S10.TIFF ]
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Conclusions and perspectives 
The results section deals with aspects of two biological phenomena having an 
impact on breast cancer; mutual interaction of breast cancer cells with endothelial 
cells and the influence of a growth factor on primary normal and tumor 
associated breast fibroblasts. The changes induced due to both aspects that we 
explored, might have an impact on the course of breast cancer. The observed 
gene expression changes allowed the formulation of gene expression signatures, 
which were evaluated within publically available gene expression databases, to 
validate the relevance of in vitro results in vivo. 
Fibroblast derived IGF–I signatures 
We showed that primary normal breast fibroblasts, carcinoma-associated breast 
fibroblasts and fibroblasts from the lung are sensitive to IGF–I stimulation, and 
that the fibroblasts of the different origins show a specific gene expression and 
phenotypical response to this stimulus. Moreover, genes up-regulated in primary 
breast and lung fibroblasts upon IGF-I stimulation have a prognostic significance 
in human breast cancer and lung adenocarcinomas. Gene expression patterns 
induced by IGF-I in primary breast fibroblasts have several advantages 
compared to the previously established “wound signature” [117] which is 
triggered by serum consisting of an unspecific mixture of potent stimuli on a mix 
of fibroblasts from different sites of the body. First, the gene expression pattern 
presented here was derived from a strictly controlled in vitro system with a 
defined concentration of recombinant IGF-I. Second, since it is known that 
carcinoma-associated fibroblasts vary from normal fibroblasts [28-29, 132] and 
that fibroblasts from different body sites have different default gene expression 
programs [134-135], site-specific breast primary fibroblasts were used to 
examine the subtle changes characteristic for these cells only. The signature 
from IGF-I stimulated primary breast fibroblasts was able to group breast cancer 
patients with similar clinical outcome together. Similarly, the signature derived 
from primary lung fibroblasts enabled the separation of lung cancer patients with 
distinct survival rates. Furthermore, the power of both signatures, derived from 
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 breast and lung fibroblasts, to cross-predict patient clinical performance in both 
types of solid tumors might suggest that gene expression programs represented 
in IGF-I stimulated fibroblasts is a general feature of solid tumors. In contrast to 
the “70-genes signature” [104] our gene expression patterns were derived from 
an unsupervised analysis. This approach assesses the correlation between the 
induced gene expression profile and clinical data in an independent way. Since, 
the gene expression signatures stratify the patients into groups with different 
overall survival, we speculate that the represented features are important for 
breast and lung cancer biology. Finak et al. [120] compared genes expressed in 
normal stroma to genes specifically induced in the whole LCM dissected tumor 
associated stroma. In contrast to Finak, the gene expression IGF-I-induced 
signatures are derived from a single cell type. As already suggested in the 
introduction, this gives an insight into actions taking place in the specific cell 
fraction. For example numerous soluble factors (POSTN, TNC, LOXL1) are 
induced in primary breast fibroblasts upon IGF-I stimulation. POSTN, TNC and a 
protein similar to LOXL1 were previously reported to be involved in tumor 
progression [140-143]. Moreover, the IGF-I-induced signatures from primary 
breast and lung fibroblasts are similar to each other and to other, significant, 
previously published signatures, like “wound” and “70-genes” and gene 
expression signature of “luminal B” group of breast cancer [88, 104, 117]. These 
signatures represent important aspects of tumor biology what imposes the role of 
processes induced by IGF-I in tumor stroma in cancer progression. The 
additional comparison of IGF-I actions on tumor cells and fibroblasts showed that 
these cell types have different changes in their gene expression patterns in 
response to the stimulus and therefore may behave differently. The IGF-I 
signaling pathway is important in the development of many tissues [144] and is 
closely related to insulin receptor signaling [145]. Both processes, development 
and insulin dependent metabolism, are vital in mammary gland homeostasis. 
Since IGF-I targeting affects both tumor and carcinoma associated fibroblasts, it 
was speculated that knowledge about the fibroblasts-characteristic response 
might be of importance to avoid targeting of these vital functions in non-
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carcinoma associated tissues [146]. Publicly available gene expression profiles 
(GEO: GSE3398) might help in future to address these issues involved in 
development of IGF-I blocking therapies. It can also be hypothesized that it may 
be of clinical significance to analyze the presented signatures as potential 
response predictors for these therapies.  
Tumor endothelium interaction derived signature 
The second part of the thesis is focused on the gene expression changes 
induced due to tumor-endothelial cell interaction. This work is an extension of 
experiments involving ex-vivo co-culture models, stimulating interaction of tumor 
cells with fibroblasts [12] and continues to systematically explore aspects of 
tumor-stroma interactions. Since some interactions require direct contact of the 
cells [12], a mixed co-culture, instead of transwell system in which cells contact 
only through the soluble signaling molecules, was used. A systematic overview of 
the heterotypic interactions effects of breast cancer and endothelial cells showed 
that interaction between breast cancer cells expressing CD44+/CD24- 
characteristics (e.g. Hs578T) and endothelial cells (HUVEC) induce genes with 
gene ontologies associated with increased proliferation and M-phase in the cell 
cycle. We demonstrated that genes induced due to the interaction of these cells 
include VEGF, FGF and other endothelial stimulatory factors. We managed to 
abrogate a large part of the stimulatory effect of Hs578T cells supernatant on 
HUVEC cells with bevacizumab. Since only a partial decrease of the stimulatory 
effect was observed, it may be suggested, that VEGF signaling is only one of 
many stimulatory loops between tumor and endothelial cells that might be 
targeted. It is probable, that genes present on our list are also responsible for 
drug resistance to anti-VEGF monotherapy as, presumably, they compensate the 
actions of blocked VEGF signaling. The signature was strongly correlated to 
other prognostic signatures, such as the “wound signature” and the “70-genes” 
signature and was able to stratify the breast cancer patients into two groups with 
different clinical outcomes. Since a predictive marker for anti-angiogenic 
therapies is missing, it can be speculated that the set of in vitro-designed 
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biomarkers, that already demonstrated prognostic power, is worth being checked 
in this context.  
The development of drugs targeting the stroma or tumor-stroma interaction raises 
a need to develop specific markers that would allow assessing the efficacy of 
such approaches. Tailoring the therapy to only susceptible patients would allow 
increase the drug/cost effectiveness and reduce any eventual side effects. 
Testing stroma derived signatures, such as those presented in this thesis, could 
also be vital in predicting effectiveness and eventual side effects of therapies 
affecting the stroma or both the tumor and stroma. 
Further perspectives 
Advantages of primary cell culture 
The direct tumor-stroma co-culture is a set-up mimicking the real tumor situation, 
which may be helpful in characterizing the signaling network between the cells. 
Based on our experience with the co-culture model that allowed direct cell-cell 
contact to mimic and simplify the situation of heterotypic interaction in a tumor, 
we think that this model would allow further exploration. The simple in vitro 
approach presented in this thesis allowed the description of stimulatory effects of 
tumor cells on endothelial cells and vice versa, analogically to mentioned co-
cultivation of fibroblasts with tumor cells [12]. Since stromal cells in breast cancer 
differ from their normal analogues, the use of site-matching primary tumor and 
stromal cells would be an important addition to the use of the cell lines which 
might allow the observation of additional specific interaction effects. Specifically, 
co-culturing of primary carcinoma-associated endothelial cells with primary 
cancer cells, derived from the same patient, would be informative, since the cells 
would have the same genetic background. Primary human breast cancer cells 
would be the most reliable source of information, as they would carry all of the 
genetic (e.g. SNPs) and epigenetic (such as methylation) imprints that might be 
crucial for cancer progression. Furthermore, since it is speculated that the stroma 
is involved in tumorigenesis [28] exploration of the paracrine circuits in the cells 
from a single patient in whom cancer developed, might reveal more of the 
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specific interactions that allowed the formation of that cancer. Despite extensive 
attempts using several different culture conditions in parallel, unfortunately, the 
primary breast cancer cells could not be expanded extensively enough and kept 
proliferating to conduct such an experiment. 
We speculated that, since gene expression changes accompanying tumor 
progression include the stromal compartment [28, 61], distinct differences 
between carcinoma-associated fibroblasts and normal fibroblasts only would 
allow building an effective prognosticator. In our laboratory we aimed to 
characterize the differences in gene expression changes between isolated 
primary breast fibroblasts and isolated carcinoma associated fibroblasts in paired 
specimens from the same patient and used the obtained gene expression 
signature as a prognosticator in the published datasets of early stage or 
advanced breast cancer. We managed to build up a collection of both tissues, 
however due to technical problems leading to subtle inconsistencies it was 
difficult to interpret the microarray gene expression profiling experiment and we 
were unable to formulate CAF-associated gene expression pattern which was 
significantly different from the primary normal breast fibroblasts associated gene 
expression pattern. We speculated that, since gene expression changes 
accompanying tumor progression include the stromal compartment [28, 61], 
distinct differences between carcinoma associated fibroblasts and normal 
fibroblasts would be enough to create a gene expression signature working as a 
valid prognostic marker in published gene expression datasets. The effectiveness 
of SDPP, published meanwhile by Finak et al. [120], which includes all types 
stromal cells, suggests that it is very likely as fibroblasts are significant fraction of 
tumor associated stroma and mediate most of paracrine signaling within tumor 
bulk [26]. Defining the hypothetical CAF specific signature and validating it as a 
predictor would allow estimating, if only all stroma features allow effective 
prognosis (like in SDPP) or if the signature coming from a single cell type (the 
hypothetical CAF signature) is enough to stratify patients with distinct clinical 
characteristics. Since carcinoma-associated fibroblasts retain their gene 
expression profiles when kept in cell culture [132], the use of single type of cells 
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(fibroblasts) in cell culture, in contrast to whole LCM dissected stroma, would be 
easier to monitor. It would also mean it would be easier to search for further 
aspects of stroma oriented therapies and stromal cells based prognosticators in 
breast cancer. 
The collection of primary breast fibroblasts and carcinoma-associated fibroblasts 
in purified cell cultures gives us the opportunity to further characterize heterotypic 
interactions between these fibroblasts and other cells. Extending the previously 
published results [12] it would be possible to test if interactions of primary breast 
fibroblasts from healthy tissue with tumor cells differ from the interaction with 
CAFs and if the prognostic power of gene expression signatures derived from 
primary carcinoma associated cells would be increased in comparison to the one 
from cell lines. 
Until now, all tested co-cultures and described interactions included tumor cells. It 
would also be interesting to check how the behavior of carcinoma-associated 
fibroblasts is modulated in the presence of other cells representing the tumor 
stroma. It is possible that the interaction between different tumor-associated 
stromal cells might affect cancer progression. Since all signaling loops existing 
between stromal cells affect the tumor associated stroma itself, the final resultant 
would affect the malignant epithelial cells. An easy to envision cascade of events 
is; secretion of growth factor in its non-mature form by one cell (e.g. endothelial) 
and cleavage of this factor to an active form by e.g. metaloproteinases secreted 
by CAFs, that are shown to express MMPs [47]. Active growth factors obtained 
this way would act on all cells present in the tumor milieu. For this purpose, it is 
possible to apply CAF cells and endothelial primary cells. Since it is already 
known that fibroblasts play an essential role in the angiogenic process through 
their production of extracellular matrix molecules and their release of essential 
growth factors [147], it would be interesting to test if tumor-associated fibroblasts 
act in a similar or even more potent manner on tumor associated endothelium. 
Unfortunately the volume of breast tissue that was obtained and the cell culture 
conditions, which were oriented towards fibroblast cell expansion, did not allow 
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the culture of primary carcinoma associated endothelial cells to verify this 
hypothesis.  
Impact of hormones and growth factors on tumor-stroma interaction 
Based on our experience with IGF-I we speculate that other growth factors have 
also a differential impact on tumor and tumor associated stromal cells. Their 
impact on carcinoma-associated fibroblasts could be systematically explored. An 
example of such an influence might be the recently demonstrated effect of 
Hedgehog (Hh) protein on cancer cells, as described by Yauch et al. [148]. 
Contradictory to the long accepted hypothesis, these authors showed that cancer 
cells per se do not respond to Hh and that Hh ligands fail to activate Hh signaling 
pathway in tumor epithelial cells. In contrast, they report the ligand-dependent 
activation of the Hh pathway in stromal cells. The Hh protein can affect the 
stroma by modulating the expression of different factors such as insulin-like 
growth factors and Wnt pathway components, which act on tumor cells and aid 
tumor progression. Some growth factors such as TGF-β, or hormones like 
estrogens, have been shown to have an indirect effect on tumor cells and act 
through fibroblasts. Since IGF-I stimulation causes fibroblasts to be in a more 
activated state, the effects of soluble factors secreted by primary fibroblasts in 
answer to IGF-I stimulation on tumor cells is definitely worth researching in the 
future. Defining similar loops in primary carcinoma-associated fibroblasts under 
the influence of other hormones and growth factors might aid the discovery of 
additional drug targets. 
Combining the exploration of the tumor-stroma interaction induced gene 
expression changes with exploration of the hormone/growth factor impact on 
cells building tumor stroma is also a worthwhile aim. It has been shown that 
estrogens act directly and indirectly on tumor cells [14] and fibroblasts modulate 
the bioavailability of estrogens [67] by active induction of local estrogen 
synthesis. Furthermore, tumor necrosis factor alpha (TNFα) inhibits the 
differentiation of breast fibroblasts, and aromatase, the key enzyme in the 
biosynthesis of estrogen, is over-expressed in these undifferentiated fibroblasts, 
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producing large quantities of estrogen, which in turn influences the growth and 
progression of malignant epithelial cells [149]. Furthermore, estrogen modulates 
the synthesis of receptors for TNF in human adipose fibroblasts from breast 
tissue in a paracrine fashion, which may serve as a mechanism for the inhibition 
of adipocyte differentiation in breast cancer [149]. Further research should 
include whether the action of other factors is modulated in tumor-stroma co-
culture. However, this would require the stimulation of tumor-stromal co-cultures 
cells with hormones/ growth factors in carefully chosen concentrations. Our 
preliminary data from the co-culture upon growth factor stimulation showed that 
the effects of stimuli are very potent compared to the effects of cell-cell 
interaction and can easily hide any effects of heterotypic interaction between the 
cells. In our first experiments, we treated the co-culture of equal numbers of 
human breast cancer cells MCF-7 with CCL-171 fibroblasts with 50 ng/ml of IGF-
I. The gene expression profile of the co-culture stimulated with IGF-I was distinct 
from the not stimulated co-culture. Genes induced in the co-culture stimulated 
with IGF-I mostly represented genes highly up-regulated in one or the other cell 
line stimulated with IGF-I. This suggests that the effect we observed was rather 
an averaged value of expression in both cell types separately than the effect of 
IGF-I stimulation of the co-culture. Even though, some genes that were 
specifically induced in the co-culture upon IGF-I stimulation were observed. 
These included neurotensin and anterior gradient 2 homolog (Xenopus laevis), 
both known to be important in breast cancer [150-151]. The purpose of the 
investigation would be to define the global gene interactions between the cells in 
patients with increased signaling of the examined hormone/growth factor. Those 
hormones or growth factors might act at cancer cells in a paracrine manner 
through carcinoma-associated fibroblasts, which would presumably define new 
drug targets or allow a decrease in resistance to currently existing therapies. 
Radioprotection or resistance to chemotherapy may involve paracrine signaling 
via stroma cells, for example including aforementioned hedgehog stimulation of 
the stromal fibroblasts. Hh action on fibroblasts results in the expression of 
components of the IGF pathway by these cells [152]. IGF-I is known to provide 
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 radioprotection and resistance to chemotherapeutic agents in tumor cells [153-
154].  
Differences in the stroma between different types of breast cancer  
Since breast cancer is a very heterogeneous disease one could speculate that 
this heterogeneity is also apparent in the stroma. [88]. Is every molecular type of 
breast cancer connected to a specific type of the stroma that accompanies it? 
Since the molecular taxonomy of cancers was developed with gene expression 
profiles coming from the whole tumor bulk containing the stroma with multiple 
different cell types, such a scenario is very likely. Ropeman [137] demonstrated 
that a significant part of the gene expression profile comes from the stromal cells, 
it seems likely that part of the current taxonomy is based on the stroma derived 
gene expression patterns. Gene-expression pattern-based taxonomy of tumor 
stroma might form heterogeneous groups that match or do not match 
heterogeneous cancer groups [88] or for example the parallel estrogen receptor 
status of cancer cells that it had accompanied. If that was true, one should 
immediately check if this stroma derived taxonomy is correlated with patient 
performance in terms of disease progression and survival.  
Furthermore, it would be possible to follow-up the patients who donated their 
tissue and compare their primary fibroblast gene expression profiles with clinical 
data. It would be of interest to see if unsupervised clustering of gene expression 
data of only carcinoma-associated fibroblasts was mirrored in clinical data 
ranging from receptor status of cancer cell up to patients survival. 
Genetic and epigenetic changes of tumor associated stroma 
We have shown the changes in gene expression on the mRNA level induced by 
tumor-stroma interaction and there is evidence that there are considerable 
differences between tumor-associated stroma and normal stroma of the breast. 
The mechanisms underlying these expression changes are not yet fully 
elucidated. Since there are tools to characterize small genetic changes, 
epigenetic modification and also micro RNAs which can significantly change the 
expression levels and bioavailability of factors influencing tumor and tumor-
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stroma interaction, investigation of these modifications seems to be a worthwhile 
aim. The first step was already done by Allinen et al. who showed, with array 
comparative genomic hybridization (aCGH), that genetic changes, such as 
chromosomal gains or losses, are restrained only to epithelial cells [28]. The lack 
of severe genetic modifications does not exclude the presence of the other mild 
modifications like SNPs that can also influence expression levels and the 
bioactivity of different factors. Knowing whether other modifications are present in 
a defined fraction of stromal cells would allow testing of, for example, whether 
any specific SNPs influencing expression levels and functionality of proteins 
crucial for cancer cells’s growth support. Since IGF-I, IGFBP1 and IGFBP3 gene 
polymorphisms have already been shown to be responsible for a change in 
circulating IGF-I levels [155], which is known to influence the course of breast 
cancer, one can speculate that other specific SNPs might also influence breast 
cancer progression. MicroRNAs (miRNAs) are a class of small noncoding RNAs 
that influence gene expression by targeting mRNAs and triggering either 
translation repression or RNA degradation. Aberrant expression of miRNAs 
contributes to carcinogenesis by promoting the expression of proto-oncogenes or 
by inhibiting the expression of tumor suppressor genes in different malignancies, 
including breast cancer [156]. Since miRNAs also play a role in the development 
of mouse mammary gland [156], it seems plausible that a changed profile of 
miRNA expression in the stroma would affect the behavior of the stromal cells 
and influence breast cancer progression. Presence of epigenetic changes in 
ductal carcinoma in situ and invasive breast carcinomas in the epithelial, in the 
myoepithelial cells and in the stromal fibroblasts in comparison to their analogues 
from normal breast tissue was already demonstrated by Hu et al. [157]. All of 
them, presumably, play a role in the maintenance of the abnormal cellular 
microenvironment in breast cancer [157]. It is likely that a more detailed study, 
involving more patients, would allow further characterization of epigenetic 
changes present in tumor-associated stroma. Defining the changes in stromal 
cells would allow, in future, analyzing how they are further modulated, or how 
they affect heterotypic interactions in the co-cultures of tumor and stromal cells. 
80
 
 
In sillico derived prognostic markers 
Since there are several stroma-derived gene expression patterns described it 
would be interesting the combine them and create a prognostic signature derived 
from stromal cells only. A similar analysis was already conducted for epithelial 
cells when Oncotype DX was created. I presume that combined signature 
created based on information extracted from the studies listed in the introduction 
would have a prognostic capacity for breast cancer patients as it covers gene 
expression alterations specific for all types of tumor associated stromal cells. 
Now much more detailed data (studies cited in the introduction) are available and 
the bioinformatics tools are more sophisticated. That could allow creating in 
silico, a better refined, only stroma-derived signature analogous to Oncotype DX, 
which could be an additional prognostic marker for breast cancer. 
The recent trend toward improvement in breast cancer mortality rate is largely 
due to increased diagnosis of early stage disease, while therapeutic options for 
advanced stage carcinomas are still fairly limited [28]. Increased knowledge 
about the influence of stroma on tumor cells and paracrine regulatory circuits 
among various cell types in normal and cancerous breast tissue will allow the 
discovery of new drug therapeutic options. Our work on tumor-endothelium 
interactions reveals additional aspects of the cooperation of these cells. The 
description of effects of IGF-I on fibroblasts, comprising a significant part of the 
tumor associated stroma, show that external stimuli also have an impact on 
tumor stroma, which may be distinct from the impact on tumor cells. The effects 
of those factors on tumor stroma might influence signaling within the tumor milieu 
and modulate tumor progression. Moreover, as the stroma serves not only as a 
supportive environment for tumor progression but it can also provoke 
tumorgenicity in adjacent cells in the absence of a tumor, leading to the 
acquisition of genomic changes [9], it is worth considering these cells (stroma) as 
potientially important targets in cancer prevention by ablation of genes or 
signaling loops that might make breast tissue more prone to develop breast 
cancer. Additionally, predictive markers are needed to assess the efficacy of the 
already established anti-angiogenic therapies, as well as for the currently 
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developed anti-IGF-I therapies. 
To summarize, our data highlights the importance of the tumor-endothelial cell 
interactions on global gene expression programs and shows that stromal cells 
also respond to external cues such as IGF-I. Genes induced in these systems 
have a prognostic capacity and might in addition be useful in deciding which is 
the most efficacious therapy for the individual concerned (personalized 
medicine). 
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Protocols 
Protocol 1. Preparation of primary cell cultures from biopsies 
1. Transport tumor tissue with some medium to the Petri dish. Aspirate the 
medium. 
2. Separate tumor from surrounding tissue, skin and fat. Cut the tumor in as 
small as possible parts. 
3. Transfer fragmentized tumor tissue into a sterile bottle and treat with 
collagenase / DRNase – mix for 1 hour (37C). 
4. Place the material on a sieve and mince the tumor material with light press 
of piston. Wash the sieve with PBS. 
5. Place the material in a tube and centrifuge 1300 r.p.m. / 10 min. 
6. Aspirate supernatant and wash the pellet with PBS. Centrifuge again and 
resuspend in PBS. 
7. Count the cells and set a cell culture in an appropriate dish. 
8. In parallel, proceed the normal tissue according to the same procedure. 
Protocol 2. Coating of the plates with Poly – L – Lysine 
1. Prepare stock solution of Poly-L-lysine hydrobromide (0.5 mg/mL) in 
water. 
2. Dilute the stock solution 1:30 (v/v) in sterile water. 
3. Cover the surfaces that are to be coated with the Poly-L-lysine solution 
and incubate for one hour (37ºC). 
4. Wash the surface twice with ice – cold sterile water and let it dry in a 
sterile environment.  
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 Protocol 3. Cell culture media preparation 
Cell culture media were prepared by admixing RPMI 1640 15% FCS 1:1 (v/v.) 
with F12 nutrient mix. 
RPMI 1640 15% FBS (v/v). F12 nutrient 10% FBS (v/v.) 
RPMI 1640 medium  - 400mL. 
FBS (heat inactivated) - 75mL. 
Penicillin/Streptomycin - 5mL. 
Puryvat   - 5mL. 
L-glutamin   -10mL. 
Non essential aminoacids - 5mL. 
Vitamines mix  - 5mL. 
2-mercapto-ethanol  - 0.5mL. 
F 12 medium   - 450mL. 
FBS (heat inactivated) - 50mL. 
Penicillin/Streptomycin - 5mL. 
Puryvat   - 5mL. 
  
 
Protocol 4. Microbeads separation protocols 
The procedure was conducted according to users’ manual protocol (Miltenyi 
Biotec; Anti-Fibroblast MicroBeads - Part Number 130-050-601). 
Protocol 5. WST -1 staining 
1. Set up the cell culture, that is to be measured, in a 96 well plate. 
2. At the day of measurement prepare 10% v/v solution of WST-1 in cell 
culture medium without additives (no FCS, no goodies, with antibiotics). 
3. Aspirate the cell culture medium from the wells of the 96 well plate with an 
automatic pipette. 
4. Wash the wells ones with PBS. Work gently not to scratch the cell 
monolayer. 
5. In the dark, add 70 µL of 10% WST-1 solution to every well of the 96 well 
plate. 
6. Incubate for 1h at 37ºC in a cell culture incubator. 
7. Measure the absorbance of formazan dye produced by metabolically 
active cells at wavelength 450 nm. 
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 Protocol 6. Amplification of RNA 
The procedure was conducted according to users’ manual protocol 
(MessageAmp™ Kit - Part Number AM1750) for both; sample RNA and 
reference RNA. 
Protocol 7. Microarrays 
Post processing of Oligo Arrays 
1. UV cross-link printed DNA onto glass substrate. 
2. Prehybridize microarrays with cross-linked DNA in 5 x SSC, 0.1 mg/mL 
BSA, 0.1 % SDS solution 1h at 42ºC. 
3. Rinse the microarrays twice in 0.1 x SSC solution for 5 minutes in a room 
temperature (RT). 
4. Rinse the microarrays in deionized water for 30 seconds at RT. 
5. Spin-dry the microarrays and them the same day. 
The aRNA/doping controls mix preparation 
1. Prepare 8µg sample amplified RNA (aRNA) and reference aRNA. 
2. Mix 8µg of sample aRNA with 5µl of Cy5 stained doping controls mix. 
3. Mix 8µg of reference aRNA with 5µl of Cy3 stained doping controls mix. 
4. Vacuum dry the samples and the references.  
5. Add 9µl of a coupling buffer to the dried aRNA/doping controls mix and 
reference aRNA/doping control mix. 
Staining the sample aRNA and the reference aRNA 
1. Prepare 11µl of Cy5 dye solution in DMSO for aRNA/doping controls mix. 
2. Prepare 11µl of Cy3 dye solution in DMSO for reference aRNA/doping 
controls mix 
3. Store in dark for maximum one hour. 
1. Add 11µl of prepared Cy5 dye to aRNA/doping controls mix. 
2. Add 11µl of prepared Cy3 dye to reference aRNA/doping controls mix. 
3. Incubate 30 minutes at RT in the dark. 
4. Quench the reaction by adding 4.5µl Hydroxylamine to aRNA/doping 
controls mix and reference aRNA/doping controls mix (15 minutes at RT in 
the dark). 
aRNA purification 
1. Add 105µl of aRNA Binding Buffer to aRNA/doping controls mix and 
reference aRNA/doping controls mix. 
2. Add 75µl of ACS grade 100% ethanol to aRNA/doping controls mix and 
reference aRNA/doping controls mix. 
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3. Pool sample aRNA/doping controls mix and reference aRNA/doping 
controls mix in a “Labeled aRNA filter cartridge”. Centrifuge for 1 minute at 
10,000x g. 
4. Wash with 500µl of aRNA Wash Buffer. 
5. Centrifuge for 1 minute at 10,000x g. 
6. Centrifuge for an additional 1 min at 10,000x g to remove trace amounts of 
ethanol. 
7. Transfer cartridge to a fresh “Labeled aRNA Elution Tube”. 
8. Incubate at RT for 2 minutes with 15µl of preheated water (50-60oC). 
9. Centrifuge for 1.5 min at 10,000x g and repeat the elution. 
Fragmentation of probe prior to hybridization 
1. Bring the labeled aRNA probe to 27 µl with Nuclease-free water. 
2. Fragmentize the probe with 3µl of 10xFragmentation buffer at 70ºC for 15 
minutes. 
3. Block the reaction with 3µl of Stop solution. 
4. Bring the probe to the volume of 38µl with 5µl of water. 
Probe preparation 
1. Mix the probe with 6 µl of PolyA/Cot1/tRNA mix (10 ug/µl each). 
2. Mix the probe with 9.35 µl of 20 x SSC solution. 
3. Add 1 µl of HEPES buffer (1M). 
4. Add 1.65 µl of 10% SDS.  
5. Denature the probe for 5 minutes at 70ºC and centrifuge at 10,000x g for 5 
minutes. 
6. Put warm probe on microarray slide and close them in a hybridization 
chamber. 
7. Incubate in the chamber at 65ºC for 16 hours. 
Microarrays washing 
1. Take out the hybridization chamber from the water bath. 
2. Dry the chamber exterior, unscrew chamber and take out the microarray 
and gently allow cover slip to fall off in 2xSSC, 0.1% SDS solution.  
3. Transfer array to a slide rack and wash in a fresh 2xSSC, 0.1% SDS 
solution.  
4. Transfer slide rack to 60ºC, 2xSSC, 0.1% SDS solution and agitate for 1.5 
minutes.  
5. Dip microarray in 2xSSC solution and swirl around to get rid of SDS 
6. Transfer microarrays to slide rack in the 1xSSC solution and agitate for 1.5 
minutes. 
7. Transfer the entire slide rack to the 0.2xSSC solution and agitate for 1.5 
minutes.  
87
8. Spin dry microarray at 600 RPM for 5 min. 
9. Scan the microarray immediately. 
Protocol 7. Microarray data retrieval 
1. The row data were retrieved and averaged by : BIOSEQUENCE_ID for 
Log(base2) of Cy5/Cy3 normalized ratio (Mean). 
2. Data were considered valid when spot was not flagged by experimenter as 
an artifact and regression correlation was bigger than 0.6 and channel 1 
normalized ratio (mean intensity over median background intensity) was 
bigger than 1.5 or channel 2 normalized ratio (mean intensity over median 
background intensity) was bigger than 1.5. 
3. Genes and arrays were centered by mean and in case of stimulation 
experiments gene wise centered by not stimulated sample. 
4. Only genes with more than 80% good data present were analyzed. 
Protocol 8. Chosen R-scripts 
Function – Extract selected genes from a dataset. 
This script was used to extract the gene expression values for the signature 
(prepared as a list of unique gene IDs) from the dataset containing gene 
expression data of the patients (like NKI dataset). Genes present as duplicates in 
the dataset were as well extracted in duplicates. 
match2 <- function(g1, x){ 
   st1 <- strsplit(g1, "\|", fixed=T) 
   l1 <- lapply(st1, function(z) lapply(as.list(z), function(zz) 
if(zz!=""){grep(paste("|",zz,"|", sep=""), rownames(x), extended=FALSE)})) 
   x[unique(unlist(l1)),] 
} 
Function – Average extracted genes. 
This script was used to average the gene expression data for the genes that had 
duplicates within dataset. The effect was that every gene ID present in the 
signature had only one (averaged) value for an each patient. 
averageGenes <- function(x){ 
 rn <- rownames(x) 
 rn2 <- strsplit(rn, "\|", fixed=T) 
 facrn3 <- as.factor(unlist(lapply(rn2, function(z) ifelse(z[1]=="", 
ifelse(z[2]=="", return(z[3]), return(z[2])), return(z[1]))))) 
 spx <- split(x, facrn3) 
 x2 <- t(sapply(spx, colMeans, na.rm = TRUE)) 
 return(x2) 
}
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 Function - Survival calculation. 
This script was used to conduct the survival analysis. It uses the package 
“survival” being a part of R library: “survival”. 
survival <- function(x){ 
library(survival)  
x1 <- survfit(Surv(SurvTime, Status)~Category, data=x)  
x2 <- coxph(Surv(SurvTime, Status)~Category, data=x) 
x3 <- survdiff(Surv(SurvTime, Status)~Category, data=x) plot(x1, col=1:2, lty=1, 
xlab="Time [Years]",ylab="Probability") 
legend("bottom",title = "Legend:", legend=c("left", "right"), col=1:2, lty=1, bty="n") 
print(summary(x2)$logtest["pvalue"]) 
print(x3) 
} 
Multivariable analysis of survival. 
This script was used to conduct the multivariable survival analysis. It uses the 
package “survival” being a part of R library: “survival”. 
 
multivariable <- function(x){ 
library(survival)  
fit1 <- survfit(Surv(SurvTime, Status) ~ Category + ER, data=x) 
plot(fit1, col=1:nlevels(x$Category:x$ER), lty=1, lwd = 3, mark.time=F) 
legend("bottomleft", legend=levels(x$Category:x$ER), lty=1, lwd=3, 
col=1:nlevels(x$Category:x$ER)) 
stat1 <- coxph(Surv(SurvTime, Status) ~ Category + ER, data=x) 
print(summary(stat1)$logtest["pvalue"]) 
} 
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Abbreviations
aCGH - array comparative genomic 
hybridization. 
BRCA1 - breast cancer 1, early 
onset 
BRCA2 - breast cancer type 2 
susceptibility protein. 
CAF – carcinoma associated 
fibroblasts. 
CCL5 (RANTES) - chemokine (C-C 
motif) ligand 5. 
CD – cluster of differentiation. 
CGH - comparative genomic 
hybridization. 
CSC – cancer stem cell. 
CXCL12 (SDF1) - stromall cell-
derived factor 1. 
CXCR4 - C-X-C chemokine receptor 
type 4. 
DCIS - ductal carcinoma in situ. 
DMFS - distant metastasis free 
survival. 
DNA - Deoxyribonucleic acid 
DTF - desmoid-type fibromatosis 
ECM - extracellular matrix. 
EMT - epithelial to mesenchymal 
transition. 
ER – estrogen receptor. 
ErbB2 (HER2/neu, ErbB-2, ERBB2) 
Human Epidermal growth factor 
Receptor 2. 
ESA - epithelial specific antigen. 
FAP - Fibroblast activation protein 
alpha. 
FGF - Fibroblast growth factor. 
FSP1 (mts1) - fibroblast secreted 
protein-1. 
HEEBO - Human Exonic Evidence 
Based Oligonucleotide microarrays. 
HEYL - hairy/enhancer-of-split. 
HGF - hepatocyte growth factor. 
Hh – Hedgehog. 
hMSCs - human mesenchymal stem 
cells. 
HNSCCS - head and neck 
squamous cell carcinoma. 
HUVEC - Human Umbilical Vein 
Endothelial Cells. 
IDC – invasive ductal carcinoma. 
IGFBP1 - insulin like growth factor 
binding protein one. 
IGFBP3 - insulin like growth factor 
binding protein three. 
IGF-I – insulin like growth factor one. 
IGFIR – insulin like growth factor 
receptor one. 
IL-8 – interleukin 8. 
IR – insulin receptor. 
IRG - interferon response genes. 
LCM - laser capture microdissected. 
LOXL2 - lysyl oxidase-like 2. 
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MAPK - mitogen-activated protein 
(MAP) kinases. 
MINDACT - Microarray In Node-
negative and 1 to 3 positive lymph 
node Disease may Avoid 
ChemoTherapy. 
MMP – metaloproteinases. 
MMP-1 – metalloproteinase 1. 
MMP-13 – metalloproteinase 13. 
MMP-2 – metalloproteinase 2. 
p53 - tumor protein 53. 
PI3K - Phosphoinositide 3-kinases 
POSTN – periostin. 
PRL – prolactin. 
PRL3 - Protein-tyrosine phosphatase 
type IVa, member 3. 
RNA - Ribonucleic acid. 
SAGE - serial analysis of gene 
expression. 
Sca1 - stem cell antigen one. 
SDPP - stroma derived prognostic 
predictor. 
SNAIL1 - Snail 1 Drosophila 
homolog. 
SNP - single nucleotide 
polymorphism. 
SPARC - secreted protein, acidic, 
cysteine-rich. 
STAT1 - signal transducer and 
activator of transcription 1. 
STF - solitary fibrous tumors  
TGF-β - transforming growth factor 
beta. 
TLL2 - tolloid-like 2. 
VEGF - vascular endothelial growth 
factor. 
VEGF-A - vascular endothelial 
growth factor-A. 
αSMA - alpha smooth muscle actin.
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